Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3410586,t 1/2,"In CHF patients t 1/2 of total epinine was significantly higher than in NS (4.1 +/- 0.2 h vs 3.1 +/- 0.2 h, mean +/- SE).",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),h,4.1,778,DB00988,Dopamine
,3410586,t 1/2,"In CHF patients t 1/2 of total epinine was significantly higher than in NS (4.1 +/- 0.2 h vs 3.1 +/- 0.2 h, mean +/- SE).",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),h,3.1,779,DB00988,Dopamine
,3410586,total urinary recoveries,"The mean +/- SE total urinary recoveries in the 24 h after dosing, expressed as percentages of the administered dose, were 60 +/- 3 in CHF patients and 69 +/- 4 in NS.",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),,60,780,DB00988,Dopamine
,3410586,total urinary recoveries,"The mean +/- SE total urinary recoveries in the 24 h after dosing, expressed as percentages of the administered dose, were 60 +/- 3 in CHF patients and 69 +/- 4 in NS.",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),,69,781,DB00988,Dopamine
,22219221,half-life,Plasma concentration of GSK598809 was maximal 2-3 hours postdose and decreased with a half-life of roughly 20 hours.,Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22219221/),h,20,1119,DB00988,Dopamine
,22881235,el,"The selected HME film formulation (DOM2) exhibited a tensile strength (0.72 Kg/mm(2)), elongation at break (28.4% mm(2)), in vivo residence time (120 min), peak detachment force (1.55 N), work of adhesion (1.49 mJ), swelling index (210.2%), erosion (10.5%) and in vitro drug release of 84.8% in 2 h.",Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881235/),%·mm(2),28.4,2027,DB00988,Dopamine
,22881235,residence time,"The selected HME film formulation (DOM2) exhibited a tensile strength (0.72 Kg/mm(2)), elongation at break (28.4% mm(2)), in vivo residence time (120 min), peak detachment force (1.55 N), work of adhesion (1.49 mJ), swelling index (210.2%), erosion (10.5%) and in vitro drug release of 84.8% in 2 h.",Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881235/),min,120,2028,DB00988,Dopamine
,22881235,peak detachment force,"The selected HME film formulation (DOM2) exhibited a tensile strength (0.72 Kg/mm(2)), elongation at break (28.4% mm(2)), in vivo residence time (120 min), peak detachment force (1.55 N), work of adhesion (1.49 mJ), swelling index (210.2%), erosion (10.5%) and in vitro drug release of 84.8% in 2 h.",Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881235/),n,1.55,2029,DB00988,Dopamine
,22881235,work of adhesion,"The selected HME film formulation (DOM2) exhibited a tensile strength (0.72 Kg/mm(2)), elongation at break (28.4% mm(2)), in vivo residence time (120 min), peak detachment force (1.55 N), work of adhesion (1.49 mJ), swelling index (210.2%), erosion (10.5%) and in vitro drug release of 84.8% in 2 h.",Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881235/),mj,1.49,2030,DB00988,Dopamine
,19101918,flow rate,"Chromatographic separation was operated with 0.2% ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a Hypurity C(18) column with a total run time of 3.2 min.",Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),[ml] / [min],0.50,2584,DB00988,Dopamine
,19101918,total run time,"Chromatographic separation was operated with 0.2% ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a Hypurity C(18) column with a total run time of 3.2 min.",Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),min,3.2,2585,DB00988,Dopamine
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,261.2,2586,DB00988,Dopamine
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,114.2,2587,DB00988,Dopamine
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,325.1,2588,DB00988,Dopamine
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,209.0,2589,DB00988,Dopamine
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB00988,Dopamine
,11069211,bioavailability,The bioavailability is approximately 50%.,Clinical pharmacokinetics of ropinirole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069211/),%,50,4089,DB00988,Dopamine
,11069211,half-life,"Ropinirole shows approximately linear pharmacokinetics when given as single or repeated doses, and is eliminated with a half-life of approximately 6 hours.",Clinical pharmacokinetics of ropinirole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069211/),h,6,4090,DB00988,Dopamine
,3803415,half-lives,"Following i.v. injection, the concentration of bromerguride declined biphasically, with half-lives of 7 min and 1.2 h.","Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803415/),min,7,6178,DB00988,Dopamine
,3803415,half-lives,"Following i.v. injection, the concentration of bromerguride declined biphasically, with half-lives of 7 min and 1.2 h.","Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803415/),h,1.2,6179,DB00988,Dopamine
,3803415,total clearance,The total clearance was 32 ml X min-1 X kg-1 and the apparent volume of distribution was 3.61/kg.,"Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803415/),[ml] / [kg·min],32,6180,DB00988,Dopamine
,3803415,apparent volume of distribution,The total clearance was 32 ml X min-1 X kg-1 and the apparent volume of distribution was 3.61/kg.,"Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803415/),1/[kg],3.61,6181,DB00988,Dopamine
,3803415,bioavailability,The bioavailability of oral bromerguride was 29% after 1 mg and 25% after 2 mg.,"Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803415/),%,29,6182,DB00988,Dopamine
,3803415,bioavailability,The bioavailability of oral bromerguride was 29% after 1 mg and 25% after 2 mg.,"Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803415/),%,25,6183,DB00988,Dopamine
,19571794,half-life,"Accordingly, to simulate the pharmacokinetic profile of a human METH binge exposure in rats, we used a computer-controlled, intravenous METH procedure (dynamic infusion, DI) to overcome species differences in METH pharmacokinetics and to replicate the human 12-h plasma METH half-life.",Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571794/),h,12,6679,DB00988,Dopamine
,10965414,Cmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),,1.97,7706,DB00988,Dopamine
,10965414,Cmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[ng] / [ml],2.05,7707,DB00988,Dopamine
,10965414,tmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),h,1,7708,DB00988,Dopamine
,10965414,tmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[ng] / [ml],2.05,7709,DB00988,Dopamine
,10965414,tmax,"The mean Cmax were 1.97 +/- 0.87 (after a median tmax of 1 h) and 2.05 +/- 0.95 ng/ml (after a median tmax of 0.83 h) after the administration of digoxin with (test) and without (reference) concomitant DHEC, respectively; the corresponding estimated treatment ratio for test: reference was 0.939, 95% CI: 0.781 to 1.129.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),h,0.83,7710,DB00988,Dopamine
,10965414,AUC(0-48),"The mean AUC(0-48) were 13.6 +/- 5.0 ng.h/ml and 13.3 +/- 4.7 ng.h/ml for the test and reference treatment, respectively; the corresponding estimated treatment ratio for test: reference was 1.011, 95% CI: 0.866 to 1.142.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[h·ng] / [ml],13.6,7711,DB00988,Dopamine
,10965414,AUC(0-48),"The mean AUC(0-48) were 13.6 +/- 5.0 ng.h/ml and 13.3 +/- 4.7 ng.h/ml for the test and reference treatment, respectively; the corresponding estimated treatment ratio for test: reference was 1.011, 95% CI: 0.866 to 1.142.",Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965414/),[h·ng] / [ml],13.3,7712,DB00988,Dopamine
,26834462,Terminal half-lives,"Terminal half-lives of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine ranged from 31.6 to 68.4, 29.7 to 37.5, and 314 to 446 hours, respectively.",Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),h,31.6 to 68.4,8037,DB00988,Dopamine
,26834462,Terminal half-lives,"Terminal half-lives of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine ranged from 31.6 to 68.4, 29.7 to 37.5, and 314 to 446 hours, respectively.",Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),h,29.7 to 37.5,8038,DB00988,Dopamine
,26834462,Terminal half-lives,"Terminal half-lives of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine ranged from 31.6 to 68.4, 29.7 to 37.5, and 314 to 446 hours, respectively.",Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),h,314 to 446,8039,DB00988,Dopamine
,26834462,half-life,Effective half-life (calculated from time to steady state) of total active moieties was ~1 week.,Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),week,1,8040,DB00988,Dopamine
,7687709,Peak plasma concentrations,"The interindividual pharmacokinetics of ibopamine varied considerably: Peak plasma concentrations of ibopamine in the three subjects were 2.8, 4.5, and 35.4 ng/ml, respectively.",Effects of ibopamine on postural hypotension in pure autonomic failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7687709/),[ng] / [ml],2.8,8616,DB00988,Dopamine
,7687709,Peak plasma concentrations,"The interindividual pharmacokinetics of ibopamine varied considerably: Peak plasma concentrations of ibopamine in the three subjects were 2.8, 4.5, and 35.4 ng/ml, respectively.",Effects of ibopamine on postural hypotension in pure autonomic failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7687709/),[ng] / [ml],4.5,8617,DB00988,Dopamine
,7687709,Peak plasma concentrations,"The interindividual pharmacokinetics of ibopamine varied considerably: Peak plasma concentrations of ibopamine in the three subjects were 2.8, 4.5, and 35.4 ng/ml, respectively.",Effects of ibopamine on postural hypotension in pure autonomic failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7687709/),[ng] / [ml],35.4,8618,DB00988,Dopamine
,8400092,clearance rates,"Children with TOF had significantly faster clearance rates of morphine (1.39 +/- 0.37 L/kg/h) than children following the Fontan procedure (0.86 +/- 0.31 L/kg/h, P < 0.01).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],1.39,10254,DB00988,Dopamine
,8400092,clearance rates,"Children with TOF had significantly faster clearance rates of morphine (1.39 +/- 0.37 L/kg/h) than children following the Fontan procedure (0.86 +/- 0.31 L/kg/h, P < 0.01).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],0.86,10255,DB00988,Dopamine
,8400092,clearance rates,"When stratifying children by their postsurgical needs for inotropic support, those needing epinephrine, dopamine, or dobutamine at more than 10 micrograms/kg/min had significantly slower clearance rates (0.73 +/- 0.3 L/kg/h) when compared to the rest of the patients (1.5 +/- 0.41 L/kg/h, P < 0.05).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],0.73,10256,DB00988,Dopamine
,8400092,clearance rates,"When stratifying children by their postsurgical needs for inotropic support, those needing epinephrine, dopamine, or dobutamine at more than 10 micrograms/kg/min had significantly slower clearance rates (0.73 +/- 0.3 L/kg/h) when compared to the rest of the patients (1.5 +/- 0.41 L/kg/h, P < 0.05).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],1.5,10257,DB00988,Dopamine
,24337079,T max,BMS-820836 had a median T max of 5.0-7.2 h and a mean apparent terminal T 1/2 of 34-57 h.,"Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337079/),h,5.0-7.2,10443,DB00988,Dopamine
,24337079,apparent terminal T 1/2,BMS-820836 had a median T max of 5.0-7.2 h and a mean apparent terminal T 1/2 of 34-57 h.,"Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337079/),h,34-57,10444,DB00988,Dopamine
,24337079,occupancies,"Mean striatal SERT occupancies were 19 ± 9 % and 82 ± 8 % after single doses of 0.5 and 3 mg BMS-820836, respectively.","Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337079/),%,19,10445,DB00988,Dopamine
,24337079,occupancies,"Mean striatal SERT occupancies were 19 ± 9 % and 82 ± 8 % after single doses of 0.5 and 3 mg BMS-820836, respectively.","Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337079/),%,82,10446,DB00988,Dopamine
,24337079,occupancy,The mean striatal DAT occupancy was 19 ± 9 % after a single 3 mg BMS-820836 dose.,"Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337079/),%,19,10447,DB00988,Dopamine
,16439127,oral bioavailability (F,"Thus, 1H-pyridin-2-one 7b displays oral bioavailability (F=37%) as well as brain penetration (brain plasma ratio 3.7) in rat.",Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16439127/),%,37,11986,DB00988,Dopamine
,16439127,brain plasma ratio,"Thus, 1H-pyridin-2-one 7b displays oral bioavailability (F=37%) as well as brain penetration (brain plasma ratio 3.7) in rat.",Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16439127/),,3.7,11987,DB00988,Dopamine
<,16439127,F,"Within the urea series, an excellent D(3) versus D(2) selectivity (>100-fold) could be achieved by removal of one NH group (compound 6), although bioavailability (rat) was suboptimal (F<10%).",Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16439127/),%,10,11988,DB00988,Dopamine
,27749254,Maximal plasma concentration (cmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),[μg] / [ml],15.2,12226,DB00988,Dopamine
,27749254,Maximal plasma concentration (cmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),min,5,12227,DB00988,Dopamine
,27749254,Maximal plasma concentration (cmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),[μg] / [ml],3.6,12228,DB00988,Dopamine
,27749254,time to reach cmax (tmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),min,5,12229,DB00988,Dopamine
,27749254,time to reach cmax (tmax),"Maximal plasma concentration (cmax) and the time to reach cmax (tmax) were 15.2 μg mL-1 and 5 min for the nasal gel, 3.6 μg mL-1 and 30 min for the oral drug suspension, respectively.",Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),min,30,12230,DB00988,Dopamine
up to,27749254,Relative bioavailability,Relative bioavailability of the drug nasal preparation to the oral suspension was up to 1600.0 %.,Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749254/),%,1600.0,12231,DB00988,Dopamine
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,2.3,12397,DB00988,Dopamine
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.2,12398,DB00988,Dopamine
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.4,12399,DB00988,Dopamine
,21926602,half-time,"Dopamine half-time was 5.4 ± 0.7 min at normothermia, increased to 11.6 ± 0.8 min at 25 °C, but returned to control during rewarming at 34-35 °C.",Changes in cardiovascular effects of dopamine in response to graded hypothermia in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21926602/),min,5.4,14962,DB00988,Dopamine
,21926602,half-time,"Dopamine half-time was 5.4 ± 0.7 min at normothermia, increased to 11.6 ± 0.8 min at 25 °C, but returned to control during rewarming at 34-35 °C.",Changes in cardiovascular effects of dopamine in response to graded hypothermia in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21926602/),min,11.6,14963,DB00988,Dopamine
,30042675,half-lives,"PK analyses demonstrated good absorption with peak plasma maximum concentrations (Cmax) occurring around 4 h post-dose and consistent half-lives of around 17 h for the 6, 12, and 20 mg doses.","A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30042675/),h,17,15057,DB00988,Dopamine
,32952674,PDI,"The obtained RES-NCs displayed the particle size of 222.54 ± 1.66 nm, the PDI of 0.125 ± 0.035, the zeta potential of -9.41 ± 0.37 mV, and a rapid in vitro dissolution rate.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),,0.125,15517,DB00988,Dopamine
,32952674,zeta potential,"The obtained RES-NCs displayed the particle size of 222.54 ± 1.66 nm, the PDI of 0.125 ± 0.035, the zeta potential of -9.41 ± 0.37 mV, and a rapid in vitro dissolution rate.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),mv,-,15518,DB00988,Dopamine
,32952674,zeta potential,"The obtained RES-NCs displayed the particle size of 222.54 ± 1.66 nm, the PDI of 0.125 ± 0.035, the zeta potential of -9.41 ± 0.37 mV, and a rapid in vitro dissolution rate.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),mv,9.41,15519,DB00988,Dopamine
,32952674,interaction energy,"Molecular dynamics simulation of RES and HPMC revealed an interaction energy of -68.09 kJ/mol and a binding energy of -30.98 ± 0.388 kJ/mol, indicating that the spontaneous binding between the two molecules is through van der Waals forces.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),[kj] / [mol],68.09,15520,DB00988,Dopamine
,32952674,binding energy,"Molecular dynamics simulation of RES and HPMC revealed an interaction energy of -68.09 kJ/mol and a binding energy of -30.98 ± 0.388 kJ/mol, indicating that the spontaneous binding between the two molecules is through van der Waals forces.",Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952674/),[kj] / [mol],30.98,15521,DB00988,Dopamine
,30918068,plasma C max,"In a pharmacokinetic study, we determined that efficacy was associated with plasma C max of 8900 ng/ml and area under the curve from time 0 to infinity (AUC0-inf) of 11,136 hour⋅ng/ml.",Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918068/),[ng] / [ml],8900,16208,DB00988,Dopamine
,30918068,area under the curve from time 0 to infinity (AUC0-inf),"In a pharmacokinetic study, we determined that efficacy was associated with plasma C max of 8900 ng/ml and area under the curve from time 0 to infinity (AUC0-inf) of 11,136 hour⋅ng/ml.",Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918068/),[h·ng] / [ml],"11,136",16209,DB00988,Dopamine
,30918068,plasma C max,"We then showed, in macaques, that oral administration of trehalose (2.67 g/kg per day) produced plasma exposures of similar magnitude, with plasma C max of 10,918 ng/ml and AUC0-inf of 27,445 hour⋅ng/ml.",Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918068/),[ng] / [ml],"10,918",16210,DB00988,Dopamine
,30918068,AUC0-inf,"We then showed, in macaques, that oral administration of trehalose (2.67 g/kg per day) produced plasma exposures of similar magnitude, with plasma C max of 10,918 ng/ml and AUC0-inf of 27,445 hour⋅ng/ml.",Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918068/),[h·ng] / [ml],"27,445",16211,DB00988,Dopamine
<,19608695,Renal elimination,Renal elimination of the parent compound was <1%.,"Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608695/),%,1,17255,DB00988,Dopamine
,19608695,Absolute bioavailability,Absolute bioavailability of transdermally applied rotigotine was 37%.,"Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608695/),%,37,17256,DB00988,Dopamine
,1762075,clearance,"Dose-dependent disposition of dopamine was observed in both plasma concentration-time profiles and in clearance (20.3 +/- 9.6 ml/min/kg at 5 micrograms/kg/min vs. 41.6 +/- 19.1 ml/min/kg at 1 micrograms/kg/min, P = 0.038).",Use of an isolated in situ canine lung perfusion model to evaluate dopamine clearance by the lung. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762075/),[ml] / [kg·min],20.3,17361,DB00988,Dopamine
,1762075,clearance,"Dose-dependent disposition of dopamine was observed in both plasma concentration-time profiles and in clearance (20.3 +/- 9.6 ml/min/kg at 5 micrograms/kg/min vs. 41.6 +/- 19.1 ml/min/kg at 1 micrograms/kg/min, P = 0.038).",Use of an isolated in situ canine lung perfusion model to evaluate dopamine clearance by the lung. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762075/),[ml] / [kg·min],41.6,17362,DB00988,Dopamine
,20590604,K(i),"WAY-318068 is a potent and effective inhibitor of the NET with a K(i) of 8.7 nM in a binding assay, and an IC(50) of 6.8 nM in an assay of transporter function, without significant binding to the dopamine transporter.","WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590604/),nM,8.7,17447,DB00988,Dopamine
,20590604,IC(50),"WAY-318068 is a potent and effective inhibitor of the NET with a K(i) of 8.7 nM in a binding assay, and an IC(50) of 6.8 nM in an assay of transporter function, without significant binding to the dopamine transporter.","WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590604/),nM,6.8,17448,DB00988,Dopamine
,27572830,T max,Median T max was reached 3 to 4 h postdose.,"A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572830/),h,3 to 4,18042,DB00988,Dopamine
,27572830,T max,Fed conditions slowed absorption (T max = 6 h) and increased oral bioavailability.,"A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572830/),h,6,18043,DB00988,Dopamine
,20129511,total body clearance,Amantadine total body clearance was 0.17 L/h/kg with a half-life of 13.9 hours.,Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129511/),[l] / [h·kg],0.17,18414,DB00988,Dopamine
,20129511,half-life,Amantadine total body clearance was 0.17 L/h/kg with a half-life of 13.9 hours.,Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20129511/),h,13.9,18415,DB00988,Dopamine
,32032570,IC50,IC50 values for rutin suspension and rutin NE were found to be 36.7 and 25.4 μg/ml respectively.,Role of Rutin Nanoemulsion in Ameliorating Oxidative Stress: Pharmacokinetic and Pharmacodynamics Studies. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32032570/),[μg] / [ml],36.7,19183,DB00988,Dopamine
,32032570,IC50,IC50 values for rutin suspension and rutin NE were found to be 36.7 and 25.4 μg/ml respectively.,Role of Rutin Nanoemulsion in Ameliorating Oxidative Stress: Pharmacokinetic and Pharmacodynamics Studies. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32032570/),[μg] / [ml],25.4,19184,DB00988,Dopamine
,24938850,clearance (CL),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),[l] / [h],0.089,19891,DB00988,Dopamine
,24938850,central volume of distribution (Vc ),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),l,0.908,19892,DB00988,Dopamine
,24938850,intercompartmental clearance (Q),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),[l] / [h],0.157,19893,DB00988,Dopamine
,24938850,peripheral volume of distribution (Vp ),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),l,0.560,19894,DB00988,Dopamine
,17879975,Vd,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),[l] / [kg],8.69-34.3,20311,DB00988,Dopamine
,17879975,Vd,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),[l] / [kg],0.9,20312,DB00988,Dopamine
,17879975,elimination (t l/2,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),h,4.1-5.4,20313,DB00988,Dopamine
,17879975,elimination (t l/2,The BZT analogs displayed a higher distribution (Vd = 8.69-34.3 vs. 0.9 L/kg) along with longer elimination (t l/2: 4.1-5.4 vs. 0.5 h) than previously reported for cocaine.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),h,0.5,20314,DB00988,Dopamine
,17879975,Brain-to-plasma partition coefficients,Brain-to-plasma partition coefficients were 1.3-2.5 vs.,"Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879975/),,1.3-2.5,20315,DB00988,Dopamine
,25791613,AUC0-24h,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of unconjugated rotigotine were 5.88 ng·h/mL and 0.347 ng/mL, respectively; at the 4 mg/24 h dose, the corresponding values were 13.74 ng·h/mL and 0.838 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[h·ng] / [ml],5.88,21036,DB00988,Dopamine
,25791613,AUC0-24h,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of unconjugated rotigotine were 5.88 ng·h/mL and 0.347 ng/mL, respectively; at the 4 mg/24 h dose, the corresponding values were 13.74 ng·h/mL and 0.838 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[h·ng] / [ml],13.74,21037,DB00988,Dopamine
,25791613,AUC0-24h,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of unconjugated rotigotine were 5.88 ng·h/mL and 0.347 ng/mL, respectively; at the 4 mg/24 h dose, the corresponding values were 13.74 ng·h/mL and 0.838 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[ng] / [ml],0.838,21038,DB00988,Dopamine
,25791613,Cmax,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of unconjugated rotigotine were 5.88 ng·h/mL and 0.347 ng/mL, respectively; at the 4 mg/24 h dose, the corresponding values were 13.74 ng·h/mL and 0.838 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[ng] / [ml],0.347,21039,DB00988,Dopamine
,25791613,Cmax,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of unconjugated rotigotine were 5.88 ng·h/mL and 0.347 ng/mL, respectively; at the 4 mg/24 h dose, the corresponding values were 13.74 ng·h/mL and 0.838 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[h·ng] / [ml],13.74,21040,DB00988,Dopamine
,25791613,Cmax,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of unconjugated rotigotine were 5.88 ng·h/mL and 0.347 ng/mL, respectively; at the 4 mg/24 h dose, the corresponding values were 13.74 ng·h/mL and 0.838 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[ng] / [ml],0.838,21041,DB00988,Dopamine
,25791613,t½,The mean t½ of rotigotine was 4.96 hours.,Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),h,4.96,21042,DB00988,Dopamine
,25791613,AUC0-24h,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of total rotigotine were 14.02 ng·h/mL and 0.776 ng/mL; at the 4-mg/24 h dose, 32.38 ng·h/mL and 1.867 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[h·ng] / [ml],14.02,21043,DB00988,Dopamine
,25791613,AUC0-24h,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of total rotigotine were 14.02 ng·h/mL and 0.776 ng/mL; at the 4-mg/24 h dose, 32.38 ng·h/mL and 1.867 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[h·ng] / [ml],32.38,21044,DB00988,Dopamine
,25791613,Cmax,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of total rotigotine were 14.02 ng·h/mL and 0.776 ng/mL; at the 4-mg/24 h dose, 32.38 ng·h/mL and 1.867 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[ng] / [ml],0.776,21045,DB00988,Dopamine
,25791613,Cmax,"At the 2 mg/24 h dose at steady state, the geometric mean AUC0-24h and Cmax values of total rotigotine were 14.02 ng·h/mL and 0.776 ng/mL; at the 4-mg/24 h dose, 32.38 ng·h/mL and 1.867 ng/mL.",Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791613/),[ng] / [ml],1.867,21046,DB00988,Dopamine
greater,12954808,time to peak DAT occupancy,The time to peak DAT occupancy for the cocaine analogs was greater than 30 min.,The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954808/),min,30,21077,DB00988,Dopamine
,25629913,clearance,"After IV administration of pergolide, mean ± SD clearance, elimination half-life, and initial volume of distribution were 959 ± 492 mL/h/kg, 5.64 ± 2.36 hours, and 0.79 ± 0.32 L/kg, respectively.",Pharmacokinetics of pergolide after intravenous administration to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25629913/),[ml] / [h·kg],959,21128,DB00988,Dopamine
,25629913,elimination half-life,"After IV administration of pergolide, mean ± SD clearance, elimination half-life, and initial volume of distribution were 959 ± 492 mL/h/kg, 5.64 ± 2.36 hours, and 0.79 ± 0.32 L/kg, respectively.",Pharmacokinetics of pergolide after intravenous administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25629913/),h,5.64,21129,DB00988,Dopamine
,25629913,initial volume of distribution,"After IV administration of pergolide, mean ± SD clearance, elimination half-life, and initial volume of distribution were 959 ± 492 mL/h/kg, 5.64 ± 2.36 hours, and 0.79 ± 0.32 L/kg, respectively.",Pharmacokinetics of pergolide after intravenous administration to horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25629913/),[l] / [kg],0.79,21130,DB00988,Dopamine
,25629913,elimination half-life,"With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation in pergolide concentrations.",Pharmacokinetics of pergolide after intravenous administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25629913/),h,6,21131,DB00988,Dopamine
,8278896,koff,"The measured and model predicted dissociation rate (measured koff = 0.065 min-1, model prediction koff = 0.007 min-1) and the equilibrium dissociation constant (measured KD = 0.14 nM, model prediction KD = 2.2 nM) differ by an order of magnitude.",Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8278896/),1/[min],0.065,21844,DB00988,Dopamine
,8278896,koff,"The measured and model predicted dissociation rate (measured koff = 0.065 min-1, model prediction koff = 0.007 min-1) and the equilibrium dissociation constant (measured KD = 0.14 nM, model prediction KD = 2.2 nM) differ by an order of magnitude.",Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8278896/),1/[min],0.007,21845,DB00988,Dopamine
,8278896,KD,"The measured and model predicted dissociation rate (measured koff = 0.065 min-1, model prediction koff = 0.007 min-1) and the equilibrium dissociation constant (measured KD = 0.14 nM, model prediction KD = 2.2 nM) differ by an order of magnitude.",Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8278896/),nM,0.14,21846,DB00988,Dopamine
,8278896,KD,"The measured and model predicted dissociation rate (measured koff = 0.065 min-1, model prediction koff = 0.007 min-1) and the equilibrium dissociation constant (measured KD = 0.14 nM, model prediction KD = 2.2 nM) differ by an order of magnitude.",Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8278896/),nM,2.2,21847,DB00988,Dopamine
,3240764,bioavailability,The bioavailability of terguride was 79% in the rat and 15% in the monkey.,"Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240764/),%,79,22133,DB00988,Dopamine
,3240764,bioavailability,The bioavailability of terguride was 79% in the rat and 15% in the monkey.,"Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240764/),%,15,22134,DB00988,Dopamine
,3240764,half-life,Plasma levels of the unchanged drug declined with a half-life of 50 min (rat) or 20 min (monkey).,"Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240764/),min,50,22135,DB00988,Dopamine
,3240764,half-life,Plasma levels of the unchanged drug declined with a half-life of 50 min (rat) or 20 min (monkey).,"Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240764/),min,20,22136,DB00988,Dopamine
,18381901,E(max) (EC(50)),The values for serum concentration predicted to provide 50% of E(max) (EC(50)) were in the range of 5-10 ng/ml in all brain regions.,Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381901/),[ng] / [ml],5-10,22652,DB00988,Dopamine
,9651106,constant flow rate,The liver was perfused with a recirculating system at a constant flow rate of 20 ml/min.,The pharmacokinetic change of lidocaine by catecholamines using isolated perfused rat liver (IPRL). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9651106/),[ml] / [min],20,22690,DB00988,Dopamine
>,27731639,specific activities,[18F]5 was synthesized in reproducibly high radiochemical yields and purity (>98%) as well as high specific activities (>20 GBq/μmol).,Radiofluorinated N-Octanoyl Dopamine ([18F]F-NOD) as a Tool To Study Tissue Distribution and Elimination of NOD in Vitro and in Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27731639/),[gbq] / [μM],20,23172,DB00988,Dopamine
,8798925,flow-rate,"The HPLC assay comprised a 25 cm-long Techopak C18 column and a mobile phase of (0.25 M sodium dihydrogen phosphate plus 0.25% heptane sulphonic acid, to pH 3.3 with orthophosphoric acid) containing 30% (v/v) methanol and 0.003% (w/v) EDTA, run at a flow-rate of 1.5 ml/min.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[ml] / [min],1.5,23681,DB00988,Dopamine
,8798925,initial half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,8.2,23682,DB00988,Dopamine
,8798925,initial half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,46.6,23683,DB00988,Dopamine
,8798925,elimination half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,76.4,23684,DB00988,Dopamine
,8798925,elimination half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,166.5,23685,DB00988,Dopamine
,8798925,area under the plasma concentration-time curve (AUC),"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[h·ng] / [ml],236,23686,DB00988,Dopamine
,8798925,area under the plasma concentration-time curve (AUC),"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[h·ng] / [ml],405,23687,DB00988,Dopamine
,9763403,systemic plasma CL,Values for systemic plasma CL (28-40 ml/min/kg) suggested hepatic plasma flow-limited CL.,"Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763403/),[ml] / [kg·min],28-40,24017,DB00988,Dopamine
,9763403,Fecal excretion,"Fecal excretion (64%) was the major route of 14C elimination in monkeys, followed by urine (14%).","Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763403/),%,64,24018,DB00988,Dopamine
,9763403,Fecal excretion,"Fecal excretion (64%) was the major route of 14C elimination in monkeys, followed by urine (14%).","Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763403/),%,14,24019,DB00988,Dopamine
,1840323,half lives,"The half lives of the alpha, beta and gamma phases were 1.3, 8.1 and 27 min, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,1.3,24789,DB00988,Dopamine
,1840323,half lives,"The half lives of the alpha, beta and gamma phases were 1.3, 8.1 and 27 min, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,8.1,24790,DB00988,Dopamine
,1840323,half lives,"The half lives of the alpha, beta and gamma phases were 1.3, 8.1 and 27 min, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,27,24791,DB00988,Dopamine
,1840323,mean residence time (MRT),"The mean residence time (MRT) and total clearance were 14.5 min and 78 ml/min/kg, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),min,14.5,24792,DB00988,Dopamine
,1840323,total clearance,"The mean residence time (MRT) and total clearance were 14.5 min and 78 ml/min/kg, respectively.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),[ml] / [kg·min],78,24793,DB00988,Dopamine
,1840323,Cmax,"When 3 mg/kg of E4101 were administered orally under fasting, E4101 in plasma reached the peak (Cmax: 22.4 ng/ml) 45 min after administration.","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),[ng] / [ml],22.4,24794,DB00988,Dopamine
,1840323,bioavailability,The bioavailability was 3.6%.,"Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),%,3.6,24795,DB00988,Dopamine
,1840323,duration of effective plasma concentration,"When 10 mg/kg of E4101 in combination with 25 mg/kg of ascorbic acid as a sustained-release dosage form using oily somisolid matrix orally administered to non-fasted beagles, the duration of effective plasma concentration (2 ng/ml plasma in i.d. administration) was 8.4 +/- 1.0 hr (mean +/- SE, n-4).","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),h,2,24796,DB00988,Dopamine
,1840323,duration of effective plasma concentration,"When 10 mg/kg of E4101 in combination with 25 mg/kg of ascorbic acid as a sustained-release dosage form using oily somisolid matrix orally administered to non-fasted beagles, the duration of effective plasma concentration (2 ng/ml plasma in i.d. administration) was 8.4 +/- 1.0 hr (mean +/- SE, n-4).","Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),h,8.4,24797,DB00988,Dopamine
,1840323,Cmax,The Cmax was 16.2 +/- 2.5 ng/ml.,"Pharmacokinetics of a novel dopamine DA1 receptor agonist, E4101, and an improvement of its bioavailability in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840323/),[ng] / [ml],16.2,24798,DB00988,Dopamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,2.6,25394,DB00988,Dopamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,68,25395,DB00988,Dopamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,40,25396,DB00988,Dopamine
,28499878,Km,"From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM).","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,60,25397,DB00988,Dopamine
,28499878,Km,"Moreover, the uptake of sulpiride by human hepatocytes was diminished by tetraethylammonium, and saturable with Km of 18 μM.","Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499878/),μM,18,25398,DB00988,Dopamine
,2373136,half-lives,"Following the i.v. injection, plasma terguride levels declined biphasically, with half-lives of 0.2 and 1.5 h; total clearance was 17 ml.min-1.kg-1.",Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),h,0.2,25680,DB00988,Dopamine
,2373136,half-lives,"Following the i.v. injection, plasma terguride levels declined biphasically, with half-lives of 0.2 and 1.5 h; total clearance was 17 ml.min-1.kg-1.",Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),h,1.5,25681,DB00988,Dopamine
,2373136,total clearance,"Following the i.v. injection, plasma terguride levels declined biphasically, with half-lives of 0.2 and 1.5 h; total clearance was 17 ml.min-1.kg-1.",Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),[ml] / [kg·min],17,25682,DB00988,Dopamine
,2373136,oral bioavailability,The oral bioavailability of terguride over all doses was about 20%.,Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),%,20,25683,DB00988,Dopamine
,12793843,Area under the concentration-time curve (AUC(tau)),Area under the concentration-time curve (AUC(tau)) over the 12-hour dosage interval was about 30-40% lower than in healthy volunteers (33.90 vs 49.60 mg.,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),mg,33.90,25881,DB00988,Dopamine
,12793843,Area under the concentration-time curve (AUC(tau)),Area under the concentration-time curve (AUC(tau)) over the 12-hour dosage interval was about 30-40% lower than in healthy volunteers (33.90 vs 49.60 mg.,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),mg,49.60,25882,DB00988,Dopamine
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[l] / [h·kg],0.204,25883,DB00988,Dopamine
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[l] / [h·kg],0.145,25884,DB00988,Dopamine
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[ml] / [kg·min],3.40,25885,DB00988,Dopamine
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[ml] / [kg·min],2.42,25886,DB00988,Dopamine
,12793843,elimination half-life,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),h,5.2,25887,DB00988,Dopamine
,12793843,elimination half-life,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),h,7.6,25888,DB00988,Dopamine
,12793843,C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),,102,25889,DB00988,Dopamine
,12793843,24-hour,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),1/[sit],930,25890,DB00988,Dopamine
,12793843,AUC/MIC ratio,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),1/[sit],930,25891,DB00988,Dopamine
,8735509,duration,"The mean (SD) duration of anaesthesia was 64.8 (3.1) minutes for group 1 and 60 (0) minutes for group 2; the mean total dose of propofol given to the sheep in group 1 was 801 (84) mg, and the sheep in group 2 received 470 (46) mg of propofol and 267 (30) mg of ketamine.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,64.8,26609,DB00988,Dopamine
,8735509,duration,"The mean (SD) duration of anaesthesia was 64.8 (3.1) minutes for group 1 and 60 (0) minutes for group 2; the mean total dose of propofol given to the sheep in group 1 was 801 (84) mg, and the sheep in group 2 received 470 (46) mg of propofol and 267 (30) mg of ketamine.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,60,26610,DB00988,Dopamine
,8735509,elimination half-life,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,56.6,26611,DB00988,Dopamine
,8735509,elimination half-life,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,50.3,26612,DB00988,Dopamine
,8735509,volume of distribution at steady state,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[l] / [kg],1.037,26613,DB00988,Dopamine
,8735509,volume of distribution at steady state,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[l] / [kg],1.515,26614,DB00988,Dopamine
,8735509,body clearance,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[ml] / [kg·min],85.4,26615,DB00988,Dopamine
,8735509,body clearance,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[ml] / [kg·min],128.0,26616,DB00988,Dopamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,12.1,26617,DB00988,Dopamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,11.9,26618,DB00988,Dopamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,72.1,26619,DB00988,Dopamine
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,69.9,26620,DB00988,Dopamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,2.8,26621,DB00988,Dopamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,6.3,26622,DB00988,Dopamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,10.9,26623,DB00988,Dopamine
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,5.3,26624,DB00988,Dopamine
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,5.3,26625,DB00988,Dopamine
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,11.2,26626,DB00988,Dopamine
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,15.1,26627,DB00988,Dopamine
,26536022,half-life,"It was quickly eliminated with a half-life of 0.520 to 0.793 hour, suggesting no accumulation during multiple-dose phase.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),h,0.520 to 0.793,27119,DB00988,Dopamine
,26536022,Cmax,The Cmax of apomorphine at effective dose was presumed to be approximately 20 ng/mL.,A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27120,DB00988,Dopamine
,26536022,effective blood concentration,"Two-hour interval injections did not cause reduced responses, and effective blood concentration was presumed to be approximately 20 ng/mL similar, to the previous study conducted at North America.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27121,DB00988,Dopamine
,20110012,"AUC(0-24h,ss)","Among the ER prototypes tested at 0.75 mg once daily in study 1, a matrix tablet had the optimal pharmacokinetic resemblance to IR pramipexole 0.25 mg TID, with a geometric mean AUC(0-24h,ss) of 17.4 ng.h/mL (vs 16.0 ng.h/mL for the IR formulation), C(max,ss) of 0.967 ng/mL (vs 1.09 ng/mL), and C(min,ss) of 0.455 ng/mL (vs 0.383 ng/mL).",Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110012/),[h·ng] / [ml],17.4,28601,DB00988,Dopamine
,20110012,"AUC(0-24h,ss)","Among the ER prototypes tested at 0.75 mg once daily in study 1, a matrix tablet had the optimal pharmacokinetic resemblance to IR pramipexole 0.25 mg TID, with a geometric mean AUC(0-24h,ss) of 17.4 ng.h/mL (vs 16.0 ng.h/mL for the IR formulation), C(max,ss) of 0.967 ng/mL (vs 1.09 ng/mL), and C(min,ss) of 0.455 ng/mL (vs 0.383 ng/mL).",Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110012/),[h·ng] / [ml],16.0,28602,DB00988,Dopamine
,20110012,"C(max,ss)","Among the ER prototypes tested at 0.75 mg once daily in study 1, a matrix tablet had the optimal pharmacokinetic resemblance to IR pramipexole 0.25 mg TID, with a geometric mean AUC(0-24h,ss) of 17.4 ng.h/mL (vs 16.0 ng.h/mL for the IR formulation), C(max,ss) of 0.967 ng/mL (vs 1.09 ng/mL), and C(min,ss) of 0.455 ng/mL (vs 0.383 ng/mL).",Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110012/),[ng] / [ml],0.967,28603,DB00988,Dopamine
,20110012,"C(max,ss)","Among the ER prototypes tested at 0.75 mg once daily in study 1, a matrix tablet had the optimal pharmacokinetic resemblance to IR pramipexole 0.25 mg TID, with a geometric mean AUC(0-24h,ss) of 17.4 ng.h/mL (vs 16.0 ng.h/mL for the IR formulation), C(max,ss) of 0.967 ng/mL (vs 1.09 ng/mL), and C(min,ss) of 0.455 ng/mL (vs 0.383 ng/mL).",Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110012/),[ng] / [ml],1.09,28604,DB00988,Dopamine
,20110012,"C(min,ss)","Among the ER prototypes tested at 0.75 mg once daily in study 1, a matrix tablet had the optimal pharmacokinetic resemblance to IR pramipexole 0.25 mg TID, with a geometric mean AUC(0-24h,ss) of 17.4 ng.h/mL (vs 16.0 ng.h/mL for the IR formulation), C(max,ss) of 0.967 ng/mL (vs 1.09 ng/mL), and C(min,ss) of 0.455 ng/mL (vs 0.383 ng/mL).",Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110012/),[ng] / [ml],0.455,28605,DB00988,Dopamine
,20110012,"C(min,ss)","Among the ER prototypes tested at 0.75 mg once daily in study 1, a matrix tablet had the optimal pharmacokinetic resemblance to IR pramipexole 0.25 mg TID, with a geometric mean AUC(0-24h,ss) of 17.4 ng.h/mL (vs 16.0 ng.h/mL for the IR formulation), C(max,ss) of 0.967 ng/mL (vs 1.09 ng/mL), and C(min,ss) of 0.455 ng/mL (vs 0.383 ng/mL).",Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110012/),[ng] / [ml],0.383,28606,DB00988,Dopamine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,379,29341,DB00988,Dopamine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,32.9,29342,DB00988,Dopamine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,37.2,29343,DB00988,Dopamine
,1884740,Total body clearance,Total body clearance averaged 115 ml.kg-1.min-1.,Dopamine pharmacokinetics in critically ill newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884740/),[ml] / [kg·min],115,29691,DB00988,Dopamine
,1884740,apparent volume of distribution,"The apparent volume of distribution and elimination half life averaged 1.8 l.kg-1 and 6.9 min, respectively.",Dopamine pharmacokinetics in critically ill newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884740/),[l] / [kg],1.8,29692,DB00988,Dopamine
,1884740,elimination half life,"The apparent volume of distribution and elimination half life averaged 1.8 l.kg-1 and 6.9 min, respectively.",Dopamine pharmacokinetics in critically ill newborn infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884740/),min,6.9,29693,DB00988,Dopamine
,9208359,total oral clearance,The total oral clearance for all participants was 419 mL/min.,Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208359/),[ml] / [min],419,29702,DB00988,Dopamine
,9208359,volume of distribution,The mean volume of distribution and elimination half-life for all participants was 486 +/- 93.2 L and 12.9 +/- 3.27 hours.,Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208359/),l,486,29703,DB00988,Dopamine
,9208359,elimination half-life,The mean volume of distribution and elimination half-life for all participants was 486 +/- 93.2 L and 12.9 +/- 3.27 hours.,Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9208359/),h,12.9,29704,DB00988,Dopamine
,1686693,maximal plasma concentrations,200 mg ibopamine lead to maximal plasma concentrations of 60 to 100 nmol/l.,[Ibopamine--pharmacologic principles]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),[nM] / [l],60 to 100,29805,DB00988,Dopamine
,1686693,plasma half-life,The plasma half-life of epinine amounts to about 45 min.,[Ibopamine--pharmacologic principles]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),min,45,29806,DB00988,Dopamine
,1686693,affinity,"Investigations in isolated organs have shown that the action on DA1, DA2-receptors occurs in the range of 100-700 nmol/l), whereas stimulation of beta 1- and beta 2-receptors affords significantly higher levels (affinity to human cardiac beta 1- and beta 2-receptors 5-10 mumol/l).",[Ibopamine--pharmacologic principles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),[μM] / [l],5-10,29807,DB00988,Dopamine
<,11569533,intrinsic clearance (CLi),"2. In the presence of NADPH, SB-277011 was relatively stable in the presence of liver microsomes from rat, dog, cynomolgus monkey and human with an intrinsic clearance (CLi) of < 2 ml min(-1) g(-1) liver for all species.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[liver·ml] / [g·min],2,30109,DB00988,Dopamine
<,11569533,CLi,"In total liver homogenates, SB-277011 was metabolized at a similar rate in rat and dog (CLi < 2 ml min(-1) g(-1) liver) to that in liver microsomes but in cynomolgus monkey and human (CLi = 9.9 and 45 ml min(-1) g(-1) liver, respectively) the intrinsic clearance was approximately 6- and 35-fold higher, respectively, than that in liver microsomes.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[liver·ml] / [g·min],2,30110,DB00988,Dopamine
,11569533,CLi,"In total liver homogenates, SB-277011 was metabolized at a similar rate in rat and dog (CLi < 2 ml min(-1) g(-1) liver) to that in liver microsomes but in cynomolgus monkey and human (CLi = 9.9 and 45 ml min(-1) g(-1) liver, respectively) the intrinsic clearance was approximately 6- and 35-fold higher, respectively, than that in liver microsomes.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[liver·ml] / [g·min],9.9,30111,DB00988,Dopamine
,11569533,CLi,"In total liver homogenates, SB-277011 was metabolized at a similar rate in rat and dog (CLi < 2 ml min(-1) g(-1) liver) to that in liver microsomes but in cynomolgus monkey and human (CLi = 9.9 and 45 ml min(-1) g(-1) liver, respectively) the intrinsic clearance was approximately 6- and 35-fold higher, respectively, than that in liver microsomes.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[liver·ml] / [g·min],45,30112,DB00988,Dopamine
,11569533,CLi,"3. In the absence of NADPH, SR-277011 was rapidly cleared in liver homogenates from cynomolgus monkey and human (CLi = 7.4 and 27 ml min(-1) g(-1) liver, respectively) demonstrating that a significant pathway of metabolism of this compound was via an NADPH-independent non-microsomal oxidative route.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[liver·ml] / [g·min],7.4,30113,DB00988,Dopamine
,11569533,CLi,"3. In the absence of NADPH, SR-277011 was rapidly cleared in liver homogenates from cynomolgus monkey and human (CLi = 7.4 and 27 ml min(-1) g(-1) liver, respectively) demonstrating that a significant pathway of metabolism of this compound was via an NADPH-independent non-microsomal oxidative route.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[liver·ml] / [g·min],27,30114,DB00988,Dopamine
,11569533,plasma clearance,"4. The in vivo pharmacokinetics showed that the plasma clearance of SB-277011 was low in rat (20 ml min(-1) kg(-1)), moderate in dog (14 ml min(-1) kg(-1)) and high in cynomolgus monkey (58 ml min(-1)kg(-1)), which is consistent with the in vitro findings and demonstrated a greater capacity for the monkey to metabolize this compound.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[ml] / [kg·min],20,30115,DB00988,Dopamine
,11569533,plasma clearance,"4. The in vivo pharmacokinetics showed that the plasma clearance of SB-277011 was low in rat (20 ml min(-1) kg(-1)), moderate in dog (14 ml min(-1) kg(-1)) and high in cynomolgus monkey (58 ml min(-1)kg(-1)), which is consistent with the in vitro findings and demonstrated a greater capacity for the monkey to metabolize this compound.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[ml] / [kg·min],14,30116,DB00988,Dopamine
,11569533,plasma clearance,"4. The in vivo pharmacokinetics showed that the plasma clearance of SB-277011 was low in rat (20 ml min(-1) kg(-1)), moderate in dog (14 ml min(-1) kg(-1)) and high in cynomolgus monkey (58 ml min(-1)kg(-1)), which is consistent with the in vitro findings and demonstrated a greater capacity for the monkey to metabolize this compound.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),[ml] / [min],58,30117,DB00988,Dopamine
,11569533,oral bioavailability,"The oral bioavailability of SB-277011 in rat, dog and cynomolgus monkey was 35, 43 and 2%, respectively.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),%,35,30118,DB00988,Dopamine
,11569533,oral bioavailability,"The oral bioavailability of SB-277011 in rat, dog and cynomolgus monkey was 35, 43 and 2%, respectively.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),%,43,30119,DB00988,Dopamine
,11569533,oral bioavailability,"The oral bioavailability of SB-277011 in rat, dog and cynomolgus monkey was 35, 43 and 2%, respectively.","Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569533/),%,2,30120,DB00988,Dopamine
,33462988,IC50,"Preclinical studies in rat and dog have shown trazpiroben to have minimal brain penetration and low affinity for the human ether-à-go-go-related gene (hERG) potassium channel (IC50 , 15.6 µM), thereby reducing the risk of the CNS and cardiovascular adverse effects seen with other dopamine D2 /D3 receptor antagonists.","Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33462988/),μM,15.6,30201,DB00988,Dopamine
,33462988,Tmax,"Trazpiroben was rapidly absorbed and eliminated (Tmax , ∼1.1 hours; t1/2 , 4-11 hours) after administration of single (5-300 mg) and multiple (50 or 100 mg) doses.","Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33462988/),h,∼1.1,30202,DB00988,Dopamine
,33462988,t1/2,"Trazpiroben was rapidly absorbed and eliminated (Tmax , ∼1.1 hours; t1/2 , 4-11 hours) after administration of single (5-300 mg) and multiple (50 or 100 mg) doses.","Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33462988/),h,4-11,30203,DB00988,Dopamine
,33462988,Cmax,"Receptor target engagement was confirmed for all doses, as indicated by an increase in serum prolactin levels compared with placebo (mean prolactin Cmax , 134.3 ng/mL after administration of trazpiroben 10 mg vs 16.1 ng/mL with placebo).","Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33462988/),[ng] / [ml],134.3,30204,DB00988,Dopamine
,33462988,Cmax,"Receptor target engagement was confirmed for all doses, as indicated by an increase in serum prolactin levels compared with placebo (mean prolactin Cmax , 134.3 ng/mL after administration of trazpiroben 10 mg vs 16.1 ng/mL with placebo).","Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33462988/),[ng] / [ml],16.1,30205,DB00988,Dopamine
,11981235,plasma levodopa concentration,Mean plasma levodopa concentration ranged between 0.45 to 7.07 microg/mL and peak concentrations between 0.95 to 13.75 microg/mL.,Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981235/),[μg] / [ml],0.45 to 7.07,31667,DB00988,Dopamine
,11981235,peak concentrations,Mean plasma levodopa concentration ranged between 0.45 to 7.07 microg/mL and peak concentrations between 0.95 to 13.75 microg/mL.,Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981235/),[μg] / [ml],0.95 to 13.75,31668,DB00988,Dopamine
,11457653,bioavailability,The bioavailability of the total radioactivity was 68+/-30%.,Levels of dopamine in blood and brain following nasal administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11457653/),%,68,33428,DB00988,Dopamine
>,23649882,occupancy,"In healthy volunteers, single doses of lurasidone 40-80 mg resulted in D₂ receptor occupancy levels of >60%, a level of receptor occupancy previously associated with clinical response for atypical antipsychotics.",Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649882/),%,60,33910,DB00988,Dopamine
,10430537,AU,"The ratios of the area under the cocaine concentration-time curve (AUC) between the olfactory bulb and plasma at early times following in administration were significantly higher than those obtained after the iv dose (13.4 +/- 5.56 vs 6.16 +/- 0.94, p < 0.05, for AUC ratio up to 2 min post dose; 9.39 +/- 1.47 vs 7.34 +/- 0.59, p < 0.05, for AUC ratio up to 4 min post dose).",Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430537/),,9,35344,DB00988,Dopamine
,9617506,clearance,The mean clearance of apomorphine was 4.5 L/min (2.2 to 6.6 L/min).,Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617506/),[l] / [min],4.5,36245,DB00988,Dopamine
,9617506,minimal effective concentration (MEC),Clinical efficacy occurred at a mean minimal effective concentration (MEC) of 4.7 ng/mL (range 1.4 to 10.7 ng/mL).,Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617506/),[ng] / [ml],4.7,36246,DB00988,Dopamine
,9617506,minimal toxic concentration,The mean minimal toxic concentration was 16.7 ng/mL (8.5 to 24.5 ng/mL) and was significantly different from the mean MEC.,Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617506/),[ng] / [ml],16.7,36247,DB00988,Dopamine
,24469600,half-life,"At fasting state, amisulpride reached the first peak (37.1 ± 13.3 ng/ml) at ~2.3 h, and decreased down to 19.4 ± 4.3 ng/ml until 3.5 h, and then again went up to the second peak (25.3 ± 5.8 ng/ml) at 5 h followed by a slow decay with 10.6 h of half-life.",Prandial effect on the systemic exposure of amisulpride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),h,10.6,37200,DB00988,Dopamine
,24469600,maximum concentration,"The maximum concentration of amisulpride (56.0 ± 12.7 ng/ml) was increased by a 1.5-fold compared with that under fasting (p > 0.05), and the time to peak shortened a little (1.7 ± 0.6 h).",Prandial effect on the systemic exposure of amisulpride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),[ng] / [ml],56.0,37201,DB00988,Dopamine
,24469600,time to peak,"The maximum concentration of amisulpride (56.0 ± 12.7 ng/ml) was increased by a 1.5-fold compared with that under fasting (p > 0.05), and the time to peak shortened a little (1.7 ± 0.6 h).",Prandial effect on the systemic exposure of amisulpride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),h,1.7,37202,DB00988,Dopamine
,18165446,Cmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],14.12,37687,DB00988,Dopamine
,18165446,Cmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],9.28,37688,DB00988,Dopamine
,18165446,C(60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],9.62,37689,DB00988,Dopamine
,18165446,C(60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],6.08,37690,DB00988,Dopamine
,18165446,AUC(0-60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],10.01,37691,DB00988,Dopamine
,18165446,AUC(0-60),"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],3.93,37692,DB00988,Dopamine
,18165446,Tmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,0.81,37693,DB00988,Dopamine
,18165446,Tmax,"Tolerant patients had significantly greater Cmax (14.12 +/- 7.25 vs 9.28 +/- 5.22 mg/L; p < .05), C(60) (9.62 +/- 4.65 vs 6.08 +/- 4.00 mg/L; p < .001), and AUC(0-60) (10.01 +/- 5.97 vs 3.93 +/- 2.84 mg/h/L; p < .01) and shortened Tmax (0.81 +/- 0.61 vs 1.98 +/- 1.26 hours; p < .001) compared with intolerant patients.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,1.98,37694,DB00988,Dopamine
,18165446,Cmax,"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],15.26,37695,DB00988,Dopamine
,18165446,C(60),"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [l],11.96,37696,DB00988,Dopamine
,18165446,AUC(0-60),"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),[mg] / [h·l],10.90,37697,DB00988,Dopamine
,18165446,Tmax,"After prokinetic therapy, Cmax (15.26 +/- 8.85 mg/L), C(60) (11.96 +/- 5.99 mg/L), and AUC(0-60) (10.90 +/- 6.57 mg/h/L) increased and Tmax (1.07 +/- 1.01 hours) decreased in the intolerant group to values similar to the tolerant group.",Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18165446/),h,1.07,37698,DB00988,Dopamine
,26704630,flow rate,"Chromatography was performed on Hibar C18 column with mobile phase of ammonium acetate (10mM, pH 8.0 adjusted with ammonia) and ACN at a flow rate of 1mL/min.","Pharmacokinetic and tissue distribution studies of 1,9-pyrazoloanthrone, a c-Jun-N-terminal kinase inhibitor in Wistar rats by a simple and sensitive HPLC method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26704630/),[ml] / [min],1,38101,DB00988,Dopamine
,27722855,elimination half-life,"In adult healthy subjects and patients, a 40 mg dose results in peak plasma concentrations in 1-3 h, a mean elimination half-life of 18 h (mostly eliminated in the feces), and apparent volume of distribution of 6173 L; it is approximately 99 % bound to serum plasma proteins.","Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27722855/),h,18,38435,DB00988,Dopamine
,27722855,apparent volume of distribution,"In adult healthy subjects and patients, a 40 mg dose results in peak plasma concentrations in 1-3 h, a mean elimination half-life of 18 h (mostly eliminated in the feces), and apparent volume of distribution of 6173 L; it is approximately 99 % bound to serum plasma proteins.","Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27722855/),l,6173,38436,DB00988,Dopamine
,29119704,half-life,"RP5063 displayed a dose-dependent Cmax at 4 to 6 h, linear dose proportionality for both Cmax and AUC, and a half-life between 40 and 71 h.",Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29119704/),h,40 and 71,38658,DB00988,Dopamine
,4014356,initial half-life,"In both, the dopamine clearance was biphasic with an initial half-life of 1.5 minutes in fetal blood and 1.0 minute in maternal blood.",3H-dopamine clearance from the intravascular compartment of the maternal and fetal rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014356/),min,1.5,38925,DB00988,Dopamine
,4014356,initial half-life,"In both, the dopamine clearance was biphasic with an initial half-life of 1.5 minutes in fetal blood and 1.0 minute in maternal blood.",3H-dopamine clearance from the intravascular compartment of the maternal and fetal rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014356/),min,1.0,38926,DB00988,Dopamine
>,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39088,DB00988,Dopamine
<,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39089,DB00988,Dopamine
,15319342,elimination half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,4.8,39090,DB00988,Dopamine
,15319342,half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,14.8,39091,DB00988,Dopamine
,30211770,half-life,"Ketamine's half-life of ∼2 h cannot explain antidepressant effects that last for 1 week, suggesting the triggering of long-lasting neuroplasticity.","(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30211770/),h,∼2,39737,DB00988,Dopamine
,7871095,elimination half-life (t 1/2),Its disappearance from brain and plasma was almost parallel with a comparable elimination half-life (t 1/2) of about 2 h.,"Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7871095/),h,2,39743,DB00988,Dopamine
,7871095,Cmax,"Metabolite II entered the brain and equilibrated with plasma more slowly than the parent compound, achieving mean Cmax (0.2 microM) within 3 h of dosing.","Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7871095/),μM,0.2,39744,DB00988,Dopamine
,7871095,Cmax,Metabolite IV was rapidly detected in rat brain but hardly amounted to 10% (0.1 microM) of the parent compound Cmax (1 microM).,"Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7871095/),μM,1,39745,DB00988,Dopamine
,30362146,half-life,Ropinirole concentrations peaked at 4.4 ± 2.7 h and exhibited a half-life of 5.8 ± 1.7 h.,Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30362146/),h,5.8,39759,DB00988,Dopamine
,16320098,V1,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],11.4,40352,DB00988,Dopamine
,16320098,CL,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],30.9,40353,DB00988,Dopamine
,16320098,V2,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],27.3,40354,DB00988,Dopamine
,16320098,CL(ic),"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],34.6,40355,DB00988,Dopamine
,11888059,Plasma,"Plasma and brain recoveries of AHN-1055 were 95 and 79%, respectively.","Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888059/),%,95,41532,DB00988,Dopamine
,11888059,brain recoveries,"Plasma and brain recoveries of AHN-1055 were 95 and 79%, respectively.","Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888059/),%,79,41533,DB00988,Dopamine
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,31.5,42114,DB00988,Dopamine
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,29.1,42115,DB00988,Dopamine
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,21.4,42116,DB00988,Dopamine
,18455783,time to maximum concentration,The time to maximum concentration for METH and AMP following i.m. administration was 0.3 h.,Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18455783/),h,0.3,43633,DB00988,Dopamine
,3609071,half-lives,Bromerguride plasma levels declined with half-lives of 0.7 h and 9 h (R) and 0.2 h and 2.7 h (D) after i.v. treatment.,"Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609071/),h,0.7,44134,DB00988,Dopamine
,3609071,half-lives,Bromerguride plasma levels declined with half-lives of 0.7 h and 9 h (R) and 0.2 h and 2.7 h (D) after i.v. treatment.,"Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609071/),h,9,44135,DB00988,Dopamine
,3609071,half-lives,Bromerguride plasma levels declined with half-lives of 0.7 h and 9 h (R) and 0.2 h and 2.7 h (D) after i.v. treatment.,"Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609071/),h,0.2,44136,DB00988,Dopamine
,3609071,half-lives,Bromerguride plasma levels declined with half-lives of 0.7 h and 9 h (R) and 0.2 h and 2.7 h (D) after i.v. treatment.,"Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609071/),h,2.7,44137,DB00988,Dopamine
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],1.0,44209,DB00988,Dopamine
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],2.5,44210,DB00988,Dopamine
> or =,18089653,overall extraction efficiencies,"At 3 concentrations spanning the linear dynamic range of the assay, mean overall extraction efficiencies from plasma were > or =85% for all compounds of interest.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85,44211,DB00988,Dopamine
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85.6,44212,DB00988,Dopamine
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,107.2,44213,DB00988,Dopamine
,1358119,Drug half life,Drug half life is 2-2.5 hrs.,Pharmacologic properties of (-)-3PPP (preclamol) in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358119/),h,2-2.5,44514,DB00988,Dopamine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,2.58,44913,DB00988,Dopamine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,0.94,44914,DB00988,Dopamine
,25475011,Cmax,"MDPV exhibited the highest Cmax at all doses (74.2-271.3 μg/l) and 4-OH-3-MeOH-PV the highest AUC (11 366-47 724 minutes per μg/l), being the predominant metabolite.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),[μg] / [l],74.2-271.3,45214,DB00988,Dopamine
,25475011,AUC,"MDPV exhibited the highest Cmax at all doses (74.2-271.3 μg/l) and 4-OH-3-MeOH-PV the highest AUC (11 366-47 724 minutes per μg/l), being the predominant metabolite.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),[min] / [l·μg],11 366-47 724,45215,DB00988,Dopamine
,25475011,time to Cmax (Tmax ),"MDPV time to Cmax (Tmax ) was 12.9-18.6 minutes, while 3,4-catechol-PV and 4-OH-3-MeO-PV peaked later with Tmax 188.6-240 minutes after s.c. dosing.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),min,12.9-18.6,45216,DB00988,Dopamine
,25475011,Tmax,"MDPV time to Cmax (Tmax ) was 12.9-18.6 minutes, while 3,4-catechol-PV and 4-OH-3-MeO-PV peaked later with Tmax 188.6-240 minutes after s.c. dosing.","Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475011/),min,188.6-240,45217,DB00988,Dopamine
,9617507,clearance,"The values of relevant pharmacokinetic parameters were as follows: clearance 40 +/- 15 ml.min-1.kg-1, volume of distribution at steady state 1.6 +/- 0.5 l.kg-1, and terminal half-life 41 +/- 13 min.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),[ml] / [kg·min],40,46396,DB00988,Dopamine
,9617507,volume of distribution at steady state,"The values of relevant pharmacokinetic parameters were as follows: clearance 40 +/- 15 ml.min-1.kg-1, volume of distribution at steady state 1.6 +/- 0.5 l.kg-1, and terminal half-life 41 +/- 13 min.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),[l] / [kg],1.6,46397,DB00988,Dopamine
,9617507,terminal half-life,"The values of relevant pharmacokinetic parameters were as follows: clearance 40 +/- 15 ml.min-1.kg-1, volume of distribution at steady state 1.6 +/- 0.5 l.kg-1, and terminal half-life 41 +/- 13 min.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),min,41,46398,DB00988,Dopamine
less,9617507,total excretion,"The total excretion of unconjugated S-apomorphine, apocodeine, and isoapocodeine was less than 0.1% of the administered dose.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,0.1,46399,DB00988,Dopamine
,9617507,total excretion,"The total excretion of unchanged apomorphine, apomorphine sulfate, and apomorphine glucuronide amounted to 0.3 +/- 0.4%, 3.8 +/- 1% and 6.0 +/- 2.2% of the administered dose, respectively.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,0.3,46400,DB00988,Dopamine
,9617507,total excretion,"The total excretion of unchanged apomorphine, apomorphine sulfate, and apomorphine glucuronide amounted to 0.3 +/- 0.4%, 3.8 +/- 1% and 6.0 +/- 2.2% of the administered dose, respectively.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,3.8,46401,DB00988,Dopamine
,9617507,total excretion,"The total excretion of unchanged apomorphine, apomorphine sulfate, and apomorphine glucuronide amounted to 0.3 +/- 0.4%, 3.8 +/- 1% and 6.0 +/- 2.2% of the administered dose, respectively.","Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9617507/),%,6.0,46402,DB00988,Dopamine
,15082032,peak plasma concentrations,The absorption of safinamide was rapid with peak plasma concentrations ranging from 2 to 4 h.,"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),h,2 to 4,49953,DB00988,Dopamine
,15082032,accumulation factor,"In repeat dose regimen once daily, the steady state was reached on the 5th study day with a marginal accumulation factor of 1.5-1.7.","Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),,1.5-1.7,49954,DB00988,Dopamine
,15082032,t(1/2),The drug was cleared with a t(1/2) of about 22 h.,"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),h,22,49955,DB00988,Dopamine
,15082032,t(1/2),"The drug is cleared from the body with a t(1/2) of approximately equal to 22 h, without producing any clinically relevant accumulation at steady state.","Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),h,22,49956,DB00988,Dopamine
,12180532,mass,The mass median aerodynamic diameter of the aerosol was 2.9 +/- 0.1 microm with a geometric standard deviation of 1.3 +/- 0.1 (n = 15).,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),μm,2.9,51570,DB00988,Dopamine
,12180532,aerodynamic diameter,The mass median aerodynamic diameter of the aerosol was 2.9 +/- 0.1 microm with a geometric standard deviation of 1.3 +/- 0.1 (n = 15).,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),μm,2.9,51571,DB00988,Dopamine
,12180532,Tmax,Tmax (mean +/- SD) after inhalation ranged from 0.9 +/- 0.6 to 11.5 +/- 2.5.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),,0.9,51572,DB00988,Dopamine
,12180532,Tmax,Tmax (mean +/- SD) after inhalation ranged from 0.9 +/- 0.6 to 11.5 +/- 2.5.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),,11.5,51573,DB00988,Dopamine
,12180532,absolute pulmonary bioavailibility,The mean absolute pulmonary bioavailibility (as A-86929) based on emitted dose ranged from 81.9% to 107.4%.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),%,81.9,51574,DB00988,Dopamine
,12180532,absolute pulmonary bioavailibility,The mean absolute pulmonary bioavailibility (as A-86929) based on emitted dose ranged from 81.9% to 107.4%.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),%,107.4,51575,DB00988,Dopamine
,28008717,flow rate,"The biological samples were extracted by liquid-liquid extraction and separated on a Bonshell ASB C18 column (2.1 × 100 mm, 2.7 μm, Agela) with gradient mobile phase at the flow rate of 0.2 mL/min.","Pharmacokinetics, tissue distribution, and excretion studies of l-isocorypalmine using ultra high performance liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008717/),[ml] / [min],0.2,51746,DB00988,Dopamine
,31964449,Tmax,"For d- and l-amphetamine when the tablet is swallowed whole, Tmax was 5.00 hours (with a range of 2.00-9.00 hours).",Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31964449/),h,5.00,54649,DB00988,Dopamine
,31964449,Tmax,"For d- and l-amphetamine when the tablet has been chewed, Tmax was 5.00 hours (with a range of 3.00-7.00 hours).",Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31964449/),h,5.00,54650,DB00988,Dopamine
,9512065,t1/2,"Specifically, we observed that at 5 min onward, B6 mice cleared cocaine from the brain with a t1/2 estimated at 22.3 min, while distribution in D2 mice appeared to be incomplete until 15 min with a subsequent t1/2 estimated at 11.2 min.",Distribution and clearance of cocaine in brain is influenced by genetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512065/),min,22.3,55432,DB00988,Dopamine
,9512065,t1/2,"Specifically, we observed that at 5 min onward, B6 mice cleared cocaine from the brain with a t1/2 estimated at 22.3 min, while distribution in D2 mice appeared to be incomplete until 15 min with a subsequent t1/2 estimated at 11.2 min.",Distribution and clearance of cocaine in brain is influenced by genetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512065/),min,11.2,55433,DB00988,Dopamine
,19722525,IC(50),"Numerous compounds (e.g., 19-22) had low nonamolar hNET potency with IC(50) values of 7-10 nM and excellent selectivity (>500 fold) at hNET over hSERT and hDAT.","1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19722525/),nM,7-10,56724,DB00988,Dopamine
,12464717,maximum plasma concentration (C(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[mg] / [l],1.99,57497,DB00988,Dopamine
,12464717,maximum plasma concentration (C(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[mg] / [l],0.82,57498,DB00988,Dopamine
,12464717,time to reach maximum concentration (t(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,0.7,57499,DB00988,Dopamine
,12464717,area under the plasma concentration-time curve (AUC(0- infinity ),2.6 h) and area under the plasma concentration-time curve (AUC(0- infinity ) 4.52 vs. 3.18 mg x h x l-1).,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[h·mg] / [l],4.52,57500,DB00988,Dopamine
,12464717,area under the plasma concentration-time curve (AUC(0- infinity ),2.6 h) and area under the plasma concentration-time curve (AUC(0- infinity ) 4.52 vs. 3.18 mg x h x l-1).,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[h·mg] / [l],3.18,57501,DB00988,Dopamine
,12464717,C(max),The respective values after multiple doses (day 8) were: C(max) 1.98 vs.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.98,57502,DB00988,Dopamine
,12464717,t(max),"0.93 mg x l-1, t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,0.7,57503,DB00988,Dopamine
,12464717,AUC(0-infinity ),2.3 h and AUC(0-infinity ) 4.84 vs.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,4.84,57504,DB00988,Dopamine
,12464717,relative bioavailability,The relative bioavailability (Madopar DR vs. Madopar HBS) was 1.73 on day 1 and 1.32 on day 8.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.73,57505,DB00988,Dopamine
,12464717,relative bioavailability,The relative bioavailability (Madopar DR vs. Madopar HBS) was 1.73 on day 1 and 1.32 on day 8.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.32,57506,DB00988,Dopamine
,20043136,occupancy,"At 10 h, plasma d-MPH levels were lower (3.8+/-1.2 vs. 5.2+/-2.0) and brain DAT occupancy was lower (34.8+/-12.9 vs. 44.3+/-11.8) for DBDS-MPH than OROS-MPH.",A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20043136/),,34.8,58697,DB00988,Dopamine
,20043136,occupancy,"At 10 h, plasma d-MPH levels were lower (3.8+/-1.2 vs. 5.2+/-2.0) and brain DAT occupancy was lower (34.8+/-12.9 vs. 44.3+/-11.8) for DBDS-MPH than OROS-MPH.",A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20043136/),,44.3,58698,DB00988,Dopamine
,27063714,retention time,The retention time of dopamine was about 11.32 min.,Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),min,11.32,59607,DB00988,Dopamine
,27063714,limit of detection (LOD),"The limit of detection (LOD) and the limit of qualification (LOQ) were 5 and 20 pg/mL, respectively.",Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),[pg] / [ml],5,59608,DB00988,Dopamine
,27063714,limit of qualification (LOQ),"The limit of detection (LOD) and the limit of qualification (LOQ) were 5 and 20 pg/mL, respectively.",Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),[pg] / [ml],20,59609,DB00988,Dopamine
,27063714,recovery,"The recovery ranged from 98.2 to 109.0%, and both the intra-RSD and inter-RSD were below <9%, respectively.",Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),%,98.2 to 109.0,59610,DB00988,Dopamine
,27063714,probe recovery,The probe recovery for dopamine in this brain microdialysis experiment was about 25%.,Quantification of Dopamine in Brain Microdialysates with High-Performance Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063714/),%,25,59611,DB00988,Dopamine
,2531146,IC50,FESP in vitro binding properties to the dopamine receptor (IC50 = 1.5 nM) are similar to those of spiperone.,"3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2531146/),nM,1.5,59801,DB00988,Dopamine
,2531146,specific activity,"Specific dopamine D2-receptor binding was saturated with increasing concentrations of radioligand (specific activity range: 1-10,000 Ci/mmol), was stereospecifically blocked with (+)butaclamol (0.5 mg/kg), and showed only partial displacement with spiperone (200 micrograms/kg, i.v. administration 90 min after FESP injection).","3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2531146/),[ci] / [mM],"1-10,000",59802,DB00988,Dopamine
,34366380,steady-state exposure,Foslevodopa/foscarbidopa infusion provides stable LD and CD exposures compared to oral LD/CD dosing with the average steady-state exposure ranging from 747-4660 ng/mL for the different groups.,Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34366380/),[ng] / [ml],747-4660,60341,DB00988,Dopamine
,33141308,time to 90% of steady state,The median time to 90% of steady state was approximately 1 week for cariprazine and DCAR and 3 weeks for DDCAR.,Population Pharmacokinetics of Cariprazine and its Major Metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141308/),week,1,60910,DB00988,Dopamine
,33141308,time to 90% of steady state,The median time to 90% of steady state was approximately 1 week for cariprazine and DCAR and 3 weeks for DDCAR.,Population Pharmacokinetics of Cariprazine and its Major Metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141308/),weeks,3,60911,DB00988,Dopamine
,16446602,clearance,"Amikacin clearance was 0.46 (range, 0.09-2.33) mL/kg/min and distribution volume was 0.54 (range, 0.17-2.31) L/kg.",Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446602/),[ml] / [kg·min],0.46,61445,DB00988,Dopamine
,16446602,distribution volume,"Amikacin clearance was 0.46 (range, 0.09-2.33) mL/kg/min and distribution volume was 0.54 (range, 0.17-2.31) L/kg.",Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16446602/),[l] / [kg],0.54,61446,DB00988,Dopamine
,22264200,half-life,Pharmacokinetic studies showed that Albu-CocH (5 mg/kg) had a half-life of 56.6 hours in squirrel monkeys.,Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264200/),h,56.6,61494,DB00988,Dopamine
,16485914,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses.,Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485914/),h,1.5,61864,DB00988,Dopamine
,7542676,absolute oral bioavailability,"The absolute oral bioavailability of risperidone is nearly 70%, and after oral administration, it is rapidly absorbed with the plasma level reaching a peak at about 1 h.","A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7542676/),%,70,63037,DB00988,Dopamine
,1680627,steady-state plasma concentration,The steady-state plasma concentration of dobutamine (infusion rate corrected to 5.0 micrograms/kg/min) was 105 +/- 19 ng/ml (range: 3.79-400; median: 76).,The pharmacokinetics of dobutamine in pediatric intensive care unit patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680627/),[ng] / [ml],105,63500,DB00988,Dopamine
,1680627,clearance rate,The clearance rate was 151.1 +/- 47.5 ml/kg/min (range: 12.5-1319; median: 66).,The pharmacokinetics of dobutamine in pediatric intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680627/),[ml] / [kg·min],151.1,63501,DB00988,Dopamine
,1680627,t1/2 alpha,The t1/2 alpha was 1.65 +/- 0.20 min (range: 0.64-3.01; median: 1.52) while the t1/2 beta was 25.8 +/- 11.5 min (range: 4.6-68.6; median: 16.9).,The pharmacokinetics of dobutamine in pediatric intensive care unit patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680627/),min,1.65,63502,DB00988,Dopamine
,1680627,t1/2 beta,The t1/2 alpha was 1.65 +/- 0.20 min (range: 0.64-3.01; median: 1.52) while the t1/2 beta was 25.8 +/- 11.5 min (range: 4.6-68.6; median: 16.9).,The pharmacokinetics of dobutamine in pediatric intensive care unit patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680627/),min,25.8,63503,DB00988,Dopamine
,15740795,K(i),"BMS-505130 is a potent and selective serotonin transport inhibitor; K(i) for binding to the serotonin transporter = 0.18 nM (K(i) values for binding to the norepinephrine and dopamine transporters = 4.6 and 2.1 microM, respectively).","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),nM,0.18,63515,DB00988,Dopamine
,15740795,K(i),"BMS-505130 is a potent and selective serotonin transport inhibitor; K(i) for binding to the serotonin transporter = 0.18 nM (K(i) values for binding to the norepinephrine and dopamine transporters = 4.6 and 2.1 microM, respectively).","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),μM,4.6,63516,DB00988,Dopamine
,15740795,K(i),"BMS-505130 is a potent and selective serotonin transport inhibitor; K(i) for binding to the serotonin transporter = 0.18 nM (K(i) values for binding to the norepinephrine and dopamine transporters = 4.6 and 2.1 microM, respectively).","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),μM,2.1,63517,DB00988,Dopamine
,15740795,plasma half-life,"Following oral administration, peak plasma concentrations of BMS-505130 reached Tmax at 1.6 +/- 0.7 h and then declined to concentrations <10% of Cmax within the following 6 h; plasma half-life following i.v. dosing was 0.46 +/- 0.02 h.","Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740795/),h,0.46,63518,DB00988,Dopamine
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.7,63805,DB00988,Dopamine
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.9,63806,DB00988,Dopamine
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.8,63807,DB00988,Dopamine
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.4,63808,DB00988,Dopamine
,19879867,pA(2),"In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA(2)=7.2) at cloned human tachykinin NK(3) receptor whereas GSK256471 diminished the neurokinin B-induced E(max) response, indicative of non-surmountable antagonist pharmacology (pA(2)=9.2).",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.2,63809,DB00988,Dopamine
,19879867,pA(2),"In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA(2)=7.2) at cloned human tachykinin NK(3) receptor whereas GSK256471 diminished the neurokinin B-induced E(max) response, indicative of non-surmountable antagonist pharmacology (pA(2)=9.2).",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,9.2,63810,DB00988,Dopamine
,19879867,apparent pK(B),"GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pK(B)=8.1), whilst GSK256471 abolished the agonist-induced response.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.1,63811,DB00988,Dopamine
,19879867,ED(50),"Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK(3) receptor occupancy in medial prefrontal cortex (ED(50) values of 0.8 and 0.9 mg/kg, i.p., respectively) and the dose-dependent attenuation of agonist-induced ""wet dog shake"" behaviours in guinea pigs.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),[mg] / [kg],0.8,63812,DB00988,Dopamine
,19879867,ED(50),"Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK(3) receptor occupancy in medial prefrontal cortex (ED(50) values of 0.8 and 0.9 mg/kg, i.p., respectively) and the dose-dependent attenuation of agonist-induced ""wet dog shake"" behaviours in guinea pigs.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),[mg] / [kg],0.9,63813,DB00988,Dopamine
,18814193,total chromatographic run time,"The total chromatographic run time was 3.0 min and the elution of PPX and IS occurred at approximately 2.32 and 2.52, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),min,3.0,63947,DB00988,Dopamine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,212.10,63948,DB00988,Dopamine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,153.10,63949,DB00988,Dopamine
,18814193,ion transitions,The MS/MS ion transitions monitored were 212.10 --> 153.10 for PPX and 180.20 --> 107.30 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18814193/),,180.20,63950,DB00988,Dopamine
,12742115,total time,"The peak was detected using a fluorescence detector set at Ex 315 nm and Em 405 nm, and the total time for a chromatographic separation was approximately 30 min.",Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742115/),min,30,63978,DB00988,Dopamine
,12742115,recoveries,Mean recoveries were 97% for perospirone and 96% for ID-15036.,Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742115/),%,97,63979,DB00988,Dopamine
,12742115,recoveries,Mean recoveries were 97% for perospirone and 96% for ID-15036.,Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742115/),%,96,63980,DB00988,Dopamine
,31206720,bioavailability,The IM mean bioavailability was 66.97%.,Pharmacokinetics of levosulpiride after single-dose administration in goats (Capra hircus) by different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31206720/),%,66.97,64419,DB00988,Dopamine
,31206720,bioavailability,"After PO administration, the drug plasma concentrations were detectable only in the time range 1.5-4 hr, and the bioavailability (4.73%) was low.",Pharmacokinetics of levosulpiride after single-dose administration in goats (Capra hircus) by different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31206720/),%,4.73,64420,DB00988,Dopamine
,8471409,tmax,The mean tmax value increased from 0.82 h after fasting to 1.44 h after a low-fat meal and to 2.46 h after a high-fat meal.,Food intake increases the relative oral bioavailability of vanoxerine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h,0.82,64745,DB00988,Dopamine
,8471409,tmax,The mean tmax value increased from 0.82 h after fasting to 1.44 h after a low-fat meal and to 2.46 h after a high-fat meal.,Food intake increases the relative oral bioavailability of vanoxerine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h,1.44,64746,DB00988,Dopamine
,8471409,tmax,The mean tmax value increased from 0.82 h after fasting to 1.44 h after a low-fat meal and to 2.46 h after a high-fat meal.,Food intake increases the relative oral bioavailability of vanoxerine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h,2.46,64747,DB00988,Dopamine
,8471409,Cmax,"Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),nM,55,64748,DB00988,Dopamine
,8471409,Cmax,"Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),nM,52,64749,DB00988,Dopamine
,8471409,Cmax,"Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),nM,84,64750,DB00988,Dopamine
,8471409,"AUC up to the last measurable concentration (AUC(0,t))","Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h·nM,110 to 194,64751,DB00988,Dopamine
,8471409,"AUC up to the last measurable concentration (AUC(0,t))","Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h·nM,110 to 391,64752,DB00988,Dopamine
,22818206,analysis time,The analysis time was about 5.5 min.,Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22818206/),min,5.5,64874,DB00988,Dopamine
,11669473,Kd,Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),nM,3.2,65070,DB00988,Dopamine
,11669473,K(on),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[M·min],2.8 x 10(7),65071,DB00988,Dopamine
,11669473,K(off),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[min],0.099,65072,DB00988,Dopamine
,11669473,Kd,Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),nM,1.5,65073,DB00988,Dopamine
,11669473,Kd,Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),nM,1.35,65074,DB00988,Dopamine
,11669473,K(on),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[M·min],2 x 10(7),65075,DB00988,Dopamine
,11669473,K(off),Both the affinity of [3H]TBZOH to its binding site in platelets (Kd = 3.2+/-0.5 nM) and the kinetic rate constants (K(on) = 2.8 x 10(7) M(-1) min(-1); K(off) = 0.099 min(-1)) were similar to that in rat brain (Kd(striatum) = 1.5 nM; Kd(cerebral cortex) = 1.35 nM; K(on) = 2 x 10(7) M(-1) min(-1); K(off) = 0.069 min(-1)).,Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11669473/),1/[min],0.069,65076,DB00988,Dopamine
,9298924,LD50,"Pharmacokinetic parameters of unbound HI 6 in blood and brain were calculated after administration of HI 6 (50, 75 or 100 mg/kg i.m.) in control rats and rats injected with soman (90 microg/kg s.c., 0.9 LD50) 1 min before HI 6 treatment.",Pharmacokinetics and effects of HI 6 in blood and brain of soman-intoxicated rats: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9298924/),,0.,65944,DB00988,Dopamine
,3480904,elimination half-life,Mean elimination half-life of pimozide in children was 66 hours compared with 111 hours in adults with Tourette's syndrome.,Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480904/),h,66,66141,DB00988,Dopamine
,3480904,elimination half-life,Mean elimination half-life of pimozide in children was 66 hours compared with 111 hours in adults with Tourette's syndrome.,Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480904/),h,111,66142,DB00988,Dopamine
,34062113,elimination half-life (t1/2),PK values in control rats showed dose-dependent increases in maximum serum concentrations (Cmax) and area under the curve (AUCinf) values with an elimination half-life (t1/2) of approximately 2.1 h.,Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34062113/),h,2.1,66826,DB00988,Dopamine
,19713555,terminal half-life,Paliperidone is eliminated with a terminal half-life of approximately 24 hours.,Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19713555/),h,24,67441,DB00988,Dopamine
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,1.76,67810,DB00988,Dopamine
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,0.50,67811,DB00988,Dopamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,2,67906,DB00988,Dopamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,6.8,67907,DB00988,Dopamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,15,67908,DB00988,Dopamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,58,67909,DB00988,Dopamine
,8321085,half-life of washout,[123I]Epidepride was displaced by haloperidol (0.1 and 1 mg/kg) with a half-life of washout of 55 min.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,55,67910,DB00988,Dopamine
,8321085,KD,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),pM,46,67911,DB00988,Dopamine
,8321085,Bmax,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),[pM] / [g·tissue],33,67912,DB00988,Dopamine
,8321085,KD,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),pM,25,67913,DB00988,Dopamine
,8321085,Bmax,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),[pM] / [g·tissue],32,67914,DB00988,Dopamine
,8321085,half-life,In vitro kinetic analysis of association and dissociation curves revealed a half-life for receptor dissociation at 37 degrees C of 15 min and 79-90 min at 25 degrees C.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,15,67915,DB00988,Dopamine
,8321085,half-life,In vitro kinetic analysis of association and dissociation curves revealed a half-life for receptor dissociation at 37 degrees C of 15 min and 79-90 min at 25 degrees C.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,79-90,67916,DB00988,Dopamine
,1423772,bioavailability,"The effects of the addition of hydroxypropyl cellulose (HPC), sodium deoxycholate, POE (6) hydrogenated caster oil (HCO-60) and Azone on the nasal absorption increased bioavailability from 11.7% (control) to about 20%, 35%, 25% and 68%, respectively.",Enhancement of bioavailability of dopamine via nasal route in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423772/),%,11.7,68146,DB00988,Dopamine
,1423772,bioavailability,"The effects of the addition of hydroxypropyl cellulose (HPC), sodium deoxycholate, POE (6) hydrogenated caster oil (HCO-60) and Azone on the nasal absorption increased bioavailability from 11.7% (control) to about 20%, 35%, 25% and 68%, respectively.",Enhancement of bioavailability of dopamine via nasal route in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423772/),%,20,68147,DB00988,Dopamine
,1423772,bioavailability,"The effects of the addition of hydroxypropyl cellulose (HPC), sodium deoxycholate, POE (6) hydrogenated caster oil (HCO-60) and Azone on the nasal absorption increased bioavailability from 11.7% (control) to about 20%, 35%, 25% and 68%, respectively.",Enhancement of bioavailability of dopamine via nasal route in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423772/),%,35,68148,DB00988,Dopamine
,1423772,bioavailability,"The effects of the addition of hydroxypropyl cellulose (HPC), sodium deoxycholate, POE (6) hydrogenated caster oil (HCO-60) and Azone on the nasal absorption increased bioavailability from 11.7% (control) to about 20%, 35%, 25% and 68%, respectively.",Enhancement of bioavailability of dopamine via nasal route in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423772/),%,25,68149,DB00988,Dopamine
,1423772,bioavailability,"The effects of the addition of hydroxypropyl cellulose (HPC), sodium deoxycholate, POE (6) hydrogenated caster oil (HCO-60) and Azone on the nasal absorption increased bioavailability from 11.7% (control) to about 20%, 35%, 25% and 68%, respectively.",Enhancement of bioavailability of dopamine via nasal route in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1423772/),%,68,68150,DB00988,Dopamine
,2968911,receptor density,Estimation of Bmax yielded a D2 receptor density of only 6 pmol per cm3 in baboon striatum.,PET measurement of D2 and S2 receptor binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in baboon brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968911/),[pM] / [cm3],6,69157,DB00988,Dopamine
,7735206,total clearance,The total clearance of exogenous L-dopa in plasma was 3.13(l/h)/kg.,Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735206/),[l] / [h)·kg],3.13,69856,DB00988,Dopamine
,7735206,production rate constant,The production rate constant of endogenous L-dopa in plasma was 6.59(mg/h)/kg.,Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735206/),[mg] / [h)·kg],6.59,69857,DB00988,Dopamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.69,69883,DB00988,Dopamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.76,69884,DB00988,Dopamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.98,69885,DB00988,Dopamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.96,69886,DB00988,Dopamine
,24884590,pEC50,3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide 7m showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties.,Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24884590/),,7.53,70033,DB00988,Dopamine
,8739811,halflife,"Despite the long halflife of 3-O-methyltolcapone (39 h), only minor accumulation occurred due to suppression of its formation by tolcapone.",Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739811/),h,39,70334,DB00988,Dopamine
,12694152,Distribution volume at steady-state,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,180,70900,DB00988,Dopamine
,12694152,Distribution volume at steady-state,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,0.92,70901,DB00988,Dopamine
,12694152,Distribution volume at steady-state,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,127,70902,DB00988,Dopamine
,12694152,clearance,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,0.92,70903,DB00988,Dopamine
,12694152,clearance,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,127,70904,DB00988,Dopamine
,12694152,clearance,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,0.74,70905,DB00988,Dopamine
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),[ng] / [ml],9.53,71178,DB00988,Dopamine
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),[ng] / [ml],18.00,71179,DB00988,Dopamine
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),ms,1.,71180,DB00988,Dopamine
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),ms,1.54,71181,DB00988,Dopamine
,33685346,total body clearance,"The total body clearance of brexpiprazole in rat and monkey was 2.32 and 0.326 L/h/kg, respectively, after intravenous administration, and oral availability was 13.6% and 31.0%, respectively.","Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685346/),[l] / [h·kg],2.32,71866,DB00988,Dopamine
,33685346,total body clearance,"The total body clearance of brexpiprazole in rat and monkey was 2.32 and 0.326 L/h/kg, respectively, after intravenous administration, and oral availability was 13.6% and 31.0%, respectively.","Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685346/),[l] / [h·kg],0.326,71867,DB00988,Dopamine
,33685346,oral availability,"The total body clearance of brexpiprazole in rat and monkey was 2.32 and 0.326 L/h/kg, respectively, after intravenous administration, and oral availability was 13.6% and 31.0%, respectively.","Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685346/),%,13.6,71868,DB00988,Dopamine
,33685346,oral availability,"The total body clearance of brexpiprazole in rat and monkey was 2.32 and 0.326 L/h/kg, respectively, after intravenous administration, and oral availability was 13.6% and 31.0%, respectively.","Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685346/),%,31.0,71869,DB00988,Dopamine
,33685346,"Vd,z","Brexpiprazole distributed widely to body tissues, and Vd,z were 2.81 and 1.82 L/kg in rat and monkey, respectively.","Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685346/),[l] / [kg],2.81,71870,DB00988,Dopamine
,33685346,"Vd,z","Brexpiprazole distributed widely to body tissues, and Vd,z were 2.81 and 1.82 L/kg in rat and monkey, respectively.","Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685346/),[l] / [kg],1.82,71871,DB00988,Dopamine
,33685346,serum protein binding,The serum protein binding of brexpiprazole was 99% or more in animals and human.,"Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685346/),%,99,71872,DB00988,Dopamine
,15039453,C(max),"Pulmonary administration of L-dopa (2 mg) to rats resulted in a rapid elevation of plasma levels (C(max) = 4.8 +/- 1.10 microg/ml at 2 min), whereas oral administration of L-dopa produced a much delayed and lower C(max) (1.8 +/- 0.40 microg/ml at 30 min).",A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039453/),[μg] / [ml],4.8,72290,DB00988,Dopamine
,15039453,C(max),"Pulmonary administration of L-dopa (2 mg) to rats resulted in a rapid elevation of plasma levels (C(max) = 4.8 +/- 1.10 microg/ml at 2 min), whereas oral administration of L-dopa produced a much delayed and lower C(max) (1.8 +/- 0.40 microg/ml at 30 min).",A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039453/),[μg] / [ml],1.8,72291,DB00988,Dopamine
,10684503,clearance,"The clearance of dopamine by the hemofilter was 0.078 +/- 0.011 mL/kg/min, and for dobutamine it was 0.036 +/- 0.008 mL/kg/min.",Pharmacokinetics of Catecholamines During Hemofiltration in Pediatric Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684503/),[ml] / [kg·min],0.078,72475,DB00988,Dopamine
,10684503,clearance,"The clearance of dopamine by the hemofilter was 0.078 +/- 0.011 mL/kg/min, and for dobutamine it was 0.036 +/- 0.008 mL/kg/min.",Pharmacokinetics of Catecholamines During Hemofiltration in Pediatric Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684503/),[ml] / [kg·min],0.036,72476,DB00988,Dopamine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,85.8,73658,DB00988,Dopamine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,80.0,73659,DB00988,Dopamine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,66.4,73660,DB00988,Dopamine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,57.1,73661,DB00988,Dopamine
>,30865315,half-life,"Geometric mean area under the plasma concentration-time curve from time zero to time of last quantifiable concentration increased 357% and 518% vs normal in ESRD with and without hemodialysis, respectively, with half-life >100 hours in both groups.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),h,100,73662,DB00988,Dopamine
,26000388,zeta potential,"In the present investigation, soft nanocarriers, viz., microemulsion of ropinirole with the globule size of 160.2 ± 3.87 nm and zeta potential of -4.24 mV was explored for transdermal application.",Colloidal soft nanocarrier for transdermal delivery of dopamine agonist: ex vivo and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26000388/),mv,-4.24,74306,DB00988,Dopamine
,2897206,elimination half-life,3 The mean elimination half-life (+/- s. e. mean) was 9.8 +/- 1.0 min.,"Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897206/),min,9.8,74663,DB00988,Dopamine
,2897206,total body clearance,The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1.,"Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897206/),[ml] / [kg·min],30.3,74664,DB00988,Dopamine
,2897206,volume of distribution,The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1.,"Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897206/),[ml] / [kg],582,74665,DB00988,Dopamine
,9756144,elimination half-life,The short elimination half-life of N-0923 (90 min) would allow for the rapid initiation of drug effect when necessary and at the same time permit the effect to be terminated quickly if necessary.,"N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9756144/),min,90,76131,DB00988,Dopamine
,23350812,Peak plasma concentration,"Peak plasma concentration was 1-3 min post-dose, and plasma level dose proportionality was observed.","Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23350812/),min,1-3,76486,DB00988,Dopamine
,9483165,plasma elimination half-life,"It has an appropriate receptor affinity profile, with potent and long-lasting dopaminergic stimulatory effects in 6-hydroxydopamine-lesioned rats and in MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine)-lesioned primates; it has a consistent pharmacokinetic profile, with a very long mean plasma elimination half-life of 65 to 110 hours, and its absorption and excretion are unaffected by food, age or renal or hepatic disease; moreover, when given concomitantly, cabergoline does not influence levodopa pharmacokinetics.",Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483165/),h,65 to 110,77725,DB00988,Dopamine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],140,79102,DB00988,Dopamine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],14.7,79103,DB00988,Dopamine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],130,79104,DB00988,Dopamine
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],111,79105,DB00988,Dopamine
,15015904,time to maximum,"Both the plasma concentrations and behavioural effects of methylphenidate demonstrate a time to maximum of between 1 and 3 hours, with the maximum behavioural effects occurring when the plasma concentrations are increasing.",Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15015904/),h,1 and 3,80800,DB00988,Dopamine
,7731017,bioavailability,"The bioavailability of R-(+)-6 (7.6 +/- 1.1%) appeared to be slightly lower than that of 2 (11.2 +/- 5.2%), although the in vitro metabolism of R-(+)-6 appeared to be slower than that of 2.","Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7731017/),%,7.6,81842,DB00988,Dopamine
,7731017,bioavailability,"The bioavailability of R-(+)-6 (7.6 +/- 1.1%) appeared to be slightly lower than that of 2 (11.2 +/- 5.2%), although the in vitro metabolism of R-(+)-6 appeared to be slower than that of 2.","Synthesis and evaluation of pharmacological and pharmacokinetic properties of monopropyl analogs of 5-, 7-, and 8-[[(trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: central dopamine and serotonin receptor activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7731017/),%,11.2,81843,DB00988,Dopamine
,1356782,plasma half-life,The plasma half-life of the parent compound was 5.5 h.,Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356782/),h,5.5,81876,DB00988,Dopamine
,33484916,relative bioavailability,The relative bioavailability of 3D tablet formulation was calculated as 107.6% compared with the marketed tablet.,3D printed extended release tablets for once daily use: An in vitro and in vivo evaluation study for a personalized solid dosage form. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33484916/),%,107.6,82079,DB00988,Dopamine
,15037665,latency of onset to clinical effect,Studies have shown the latency of onset to clinical effect after s.c. injection ranged from 7.3 to 14 minutes.,Subcutaneously administered apomorphine: pharmacokinetics and metabolism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15037665/),min,7.3 to 14,82736,DB00988,Dopamine
,11266169,oral bioavailability,"In rat studies 19 was brain penetrant with an excellent pharmacokinetic profile (oral bioavailability 77%, t1/2 5.2h).","Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11266169/),%,77,82742,DB00988,Dopamine
,11266169,t1/2,"In rat studies 19 was brain penetrant with an excellent pharmacokinetic profile (oral bioavailability 77%, t1/2 5.2h).","Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11266169/),h,5.2,82743,DB00988,Dopamine
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.0,84478,DB00988,Dopamine
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,5,84479,DB00988,Dopamine
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.1,84480,DB00988,Dopamine
,16770757,peak plasma concentrations (Cmax),"In the two periods of treatment, the mean peak plasma concentrations (Cmax) were 44.02 ng/ml (metoclopramide alone) and 62.72 ng/ml (metoclopramide after pre-treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[ng] / [ml],44.02,84654,DB00988,Dopamine
,16770757,peak plasma concentrations (Cmax),"In the two periods of treatment, the mean peak plasma concentrations (Cmax) were 44.02 ng/ml (metoclopramide alone) and 62.72 ng/ml (metoclopramide after pre-treatment with fluoxetine).",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[ng] / [ml],62.72,84655,DB00988,Dopamine
,16770757,Cmax,"The times taken to reach Cmax and tmax, were 1.15 h and 1.06 h, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,1.15,84656,DB00988,Dopamine
,16770757,tmax,"The times taken to reach Cmax and tmax, were 1.15 h and 1.06 h, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,1.06,84657,DB00988,Dopamine
,16770757,areas under the curve (AUC(0-infinity)),"The total areas under the curve (AUC(0-infinity)) were 312.61 ng.h/ml and 590.62 ng.h/ml, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[h·ng] / [ml],312.61,84658,DB00988,Dopamine
,16770757,areas under the curve (AUC(0-infinity)),"The total areas under the curve (AUC(0-infinity)) were 312.61 ng.h/ml and 590.62 ng.h/ml, respectively.",Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),[h·ng] / [ml],590.62,84659,DB00988,Dopamine
,16770757,half-life values (t1/2),The half-life values (t1/2) were 5.52 h and 8.47 h.,Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,5.52,84660,DB00988,Dopamine
,16770757,half-life values (t1/2),The half-life values (t1/2) were 5.52 h and 8.47 h.,Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770757/),h,8.47,84661,DB00988,Dopamine
,6151170,serum half-life,It achieves peak serum concentrations within one hour and has a serum half-life of 2 to 5 hours.,"Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151170/),h,2 to 5,86750,DB00988,Dopamine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pg] / [ml],670 to 9430,87284,DB00988,Dopamine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pM] / [l],"3660 to 51,490",87285,DB00988,Dopamine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pg] / [ml],4360,87286,DB00988,Dopamine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pM] / [l],"23,810",87287,DB00988,Dopamine
,8420716,clearance rates,Epinephrine clearance rates ranged from 15.6 to 79.2 mL/kg/min (mean 29.3 +/- 16.1) and were not dependent on steady-state plasma concentrations.,Pharmacokinetics of exogenous epinephrine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[ml] / [kg·min],29.3,87288,DB00988,Dopamine
,8420716,clearance rates,Epinephrine clearance rate was in the same range as the clearance rates of dopamine (34.1 +/- 16.6) and dobutamine (35.9 +/- 27.8) and was linearly related to them (p < .005).,Pharmacokinetics of exogenous epinephrine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),,34.1,87289,DB00988,Dopamine
,8420716,clearance rates,Epinephrine clearance rate was in the same range as the clearance rates of dopamine (34.1 +/- 16.6) and dobutamine (35.9 +/- 27.8) and was linearly related to them (p < .005).,Pharmacokinetics of exogenous epinephrine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),,35.9,87290,DB00988,Dopamine
,6717507,cardiac index,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[l] / [meter·min·square],1.8,87296,DB00988,Dopamine
,6717507,cardiac index,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[l] / [meter·min·square],2.4,87297,DB00988,Dopamine
,6717507,systemic vascular resistance,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[dyn·s] / [(cm)^5],1905,87298,DB00988,Dopamine
,6717507,systemic vascular resistance,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[dyn·s] / [(cm)^5],1513,87299,DB00988,Dopamine
,6717507,peak level,Plasma concentrations of dopamine rose to a peak level of 34 +/- 5 ng per milliliter one hour after drug ingestion and decreased toward base line over the ensuing five hours.,Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[ng] / [milliliter],34,87300,DB00988,Dopamine
,17765221,K(i),"JNJ-28583867 (2-Methyl-4-(4-methylsulfanyl-phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline) is a selective and potent histamine H(3) receptor antagonist (K(i)=10.6 nM) and inhibitor of the serotonin transporter (SERT) (K(i)=3.7 nM), with 30-fold selectivity for SERT over the dopamine and norepinephrine transporters.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),nM,10.6,87547,DB00988,Dopamine
,17765221,K(i),"JNJ-28583867 (2-Methyl-4-(4-methylsulfanyl-phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline) is a selective and potent histamine H(3) receptor antagonist (K(i)=10.6 nM) and inhibitor of the serotonin transporter (SERT) (K(i)=3.7 nM), with 30-fold selectivity for SERT over the dopamine and norepinephrine transporters.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),nM,3.7,87548,DB00988,Dopamine
,17765221,oral bioavailability,"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),%,32,87549,DB00988,Dopamine
,17765221,half-life,"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),h,6.9,87550,DB00988,Dopamine
,17765221,C(max),"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),[ng] / [ml],260,87551,DB00988,Dopamine
,19915181,t(max),"Following inhalation, the t(max) median (25%, 75%) was 2 (1, 3) minutes.",Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915181/),min,2,87833,DB00988,Dopamine
,8584609,tmax,The plasma drug concentration curves indicated a fast absorption with tmax at 0.5-1 h and an apparent elimination half-life of 3-4 h.,"Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584609/),h,0.5-1,88118,DB00988,Dopamine
,8584609,apparent elimination half-life,The plasma drug concentration curves indicated a fast absorption with tmax at 0.5-1 h and an apparent elimination half-life of 3-4 h.,"Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584609/),h,3-4,88119,DB00988,Dopamine
,8584609,tmax,"When administered just after lunch, the Cmax was reduced by 50-60% and the tmax increased to 3 h, but without change of AUC.","Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584609/),h,3,88120,DB00988,Dopamine
,11559034,C(max),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],154.5,88271,DB00988,Dopamine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1990.9,88272,DB00988,Dopamine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],181.6,88273,DB00988,Dopamine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1465.9,88274,DB00988,Dopamine
,17625500,peak plasma METH concentrations,"METH doses were escalated over 33 weeks, with final dosages resulting in estimated peak plasma METH concentrations of 1-3 microM, a range measured in human abusers.",Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17625500/),μM,1-3,88339,DB00988,Dopamine
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,71.7,88871,DB00988,Dopamine
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,64.3,88872,DB00988,Dopamine
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,75.4,88873,DB00988,Dopamine
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,72.1,88874,DB00988,Dopamine
,31082785,Maximum plasma concentrations,Maximum plasma concentrations after the first oral dose of pergolide (0.104-0.684 ng/mL; median 0.261 ng/mL; interquartile range [IQR] 0.184-0.416 ng/mL) were not significantly different to the maximum steady-state concentration at day 18 (0.197-0.628 ng/mL; median 0.274; IQR 0.232-0.458 ng/mL).,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),[ng] / [ml],0.104-0.684,91667,DB00988,Dopamine
,31082785,Maximum plasma concentrations,Maximum plasma concentrations after the first oral dose of pergolide (0.104-0.684 ng/mL; median 0.261 ng/mL; interquartile range [IQR] 0.184-0.416 ng/mL) were not significantly different to the maximum steady-state concentration at day 18 (0.197-0.628 ng/mL; median 0.274; IQR 0.232-0.458 ng/mL).,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),[ng] / [ml],0.261,91668,DB00988,Dopamine
,31082785,maximum steady-state concentration,Maximum plasma concentrations after the first oral dose of pergolide (0.104-0.684 ng/mL; median 0.261 ng/mL; interquartile range [IQR] 0.184-0.416 ng/mL) were not significantly different to the maximum steady-state concentration at day 18 (0.197-0.628 ng/mL; median 0.274; IQR 0.232-0.458 ng/mL).,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),[ng] / [ml],0.274,91669,DB00988,Dopamine
less,31082785,terminal elimination half-life,Fluctuations in pergolide concentration were consistent with a terminal elimination half-life of less than 12 h.,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),h,12,91670,DB00988,Dopamine
>,33663326,IC50,"Brexpiprazole exhibited weak inhibitory effects (IC50 >13 μmol/L) on CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activities, but had moderate inhibitor activity on CYP2B6 (IC50 8.19 μmol/L).","In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33663326/),[μM] / [l],13,91874,DB00988,Dopamine
,33663326,IC50,"Brexpiprazole exhibited weak inhibitory effects (IC50 >13 μmol/L) on CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activities, but had moderate inhibitor activity on CYP2B6 (IC50 8.19 μmol/L).","In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33663326/),[μM] / [l],8.19,91875,DB00988,Dopamine
,33663326,ratio of systemic unbound concentration,The ratio of systemic unbound concentration (3.8 nmol/L) to the Ki value was sufficiently low.,"In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33663326/),[nM] / [l],3.8,91876,DB00988,Dopamine
,33663326,ratio to systemic unbound concentration,"Brexpiprazole and DM-3411 exhibited weak or no inhibitory effects for hepatic and renal transporters (OATPs, OATs, OCTs, MATE1, and BSEP), except for MATE-2K (0.156 μmol/L of DM-3411), even for which the ratio to systemic unbound concentration (5.3 nmol/L) was sufficiently low.","In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33663326/),[nM] / [l],5.3,91877,DB00988,Dopamine
,33663326,IC50,"Brexpiprazole effected the functions of P-gp and BCRP with IC50 values of 6.31 and 1.16 μmol/L, respectively, however, the pharmacokinetic alteration was not observed in the clinical concomitant study on P-gp and BCRP substrates.","In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33663326/),[μM] / [l],6.31,91878,DB00988,Dopamine
,33663326,IC50,"Brexpiprazole effected the functions of P-gp and BCRP with IC50 values of 6.31 and 1.16 μmol/L, respectively, however, the pharmacokinetic alteration was not observed in the clinical concomitant study on P-gp and BCRP substrates.","In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33663326/),[μM] / [l],1.16,91879,DB00988,Dopamine
,2150527,Elimination half-life,Elimination half-life was estimated at 1-2 days.,A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150527/),d,1-2,92188,DB00988,Dopamine
,7545821,receptor,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,50,92569,DB00988,Dopamine
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,50,92570,DB00988,Dopamine
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,54,92571,DB00988,Dopamine
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,40,92572,DB00988,Dopamine
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,43,92573,DB00988,Dopamine
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,55,92574,DB00988,Dopamine
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,63,92575,DB00988,Dopamine
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,73,92576,DB00988,Dopamine
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,45,92577,DB00988,Dopamine
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,56,92578,DB00988,Dopamine
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,68,92579,DB00988,Dopamine
,10435404,F,The value of F was 4.66% which was significantly lower than the values of Fsrr (13.67%) and Frr (32.63%).,Cocaine pharmacodynamics after intravenous and oral administration in rats: relation to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435404/),%,4.66,93096,DB00988,Dopamine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,4.4,93210,DB00988,Dopamine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,7.5,93211,DB00988,Dopamine
,9596142,bioavailability,The pharmacokinetic results showed that the average cocaine bioavailability after i.p. administration was 71% and after oral administration was only 19.2%.,An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),%,71,94195,DB00988,Dopamine
,9596142,bioavailability,The pharmacokinetic results showed that the average cocaine bioavailability after i.p. administration was 71% and after oral administration was only 19.2%.,An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),%,19.2,94196,DB00988,Dopamine
,9596142,brain,"Cocaine was rapidly distributed into the brain, and the brain ECF/plasma distribution ratio measured as the ratio of the brain ECF AUC to the plasma AUC was 2.02 +/- 0.59.",An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),,2.02,94197,DB00988,Dopamine
,9596142,/plasma distribution ratio,"Cocaine was rapidly distributed into the brain, and the brain ECF/plasma distribution ratio measured as the ratio of the brain ECF AUC to the plasma AUC was 2.02 +/- 0.59.",An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596142/),,2.02,94198,DB00988,Dopamine
,33315105,Cerebrospinal fluid/serum ratio,Cerebrospinal fluid/serum ratio of nilotinib concentration was 0.2% to 0.3%.,Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33315105/),,0.2,95017,DB00988,Dopamine
,33315105,Cerebrospinal fluid/serum ratio,Cerebrospinal fluid/serum ratio of nilotinib concentration was 0.2% to 0.3%.,Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33315105/),%,0.3,95018,DB00988,Dopamine
,6510462,half-life,"Following i.v. injection, the concentration of TDHL declined with a half-life of 37 +/- 19 min.","Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510462/),min,37,95824,DB00988,Dopamine
,6510462,total clearance,The total clearance was 38 +/- 27 ml/min/kg and the apparent volume of distribution was 1.3 +/- 0.41/kg.,"Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510462/),[ml] / [kg·min],38,95825,DB00988,Dopamine
,6510462,apparent volume of distribution,The total clearance was 38 +/- 27 ml/min/kg and the apparent volume of distribution was 1.3 +/- 0.41/kg.,"Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510462/),1/[kg],1.3,95826,DB00988,Dopamine
,6510462,bioavailability,"The bioavailability of oral TDHL was proportional to the dose; after 200, 400 and 800 micrograms the bioavailability was 20 +/- 25%, 31 +/- 24% and 48 +/- 26%.","Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510462/),%,20,95827,DB00988,Dopamine
,6510462,bioavailability,"The bioavailability of oral TDHL was proportional to the dose; after 200, 400 and 800 micrograms the bioavailability was 20 +/- 25%, 31 +/- 24% and 48 +/- 26%.","Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510462/),%,31,95828,DB00988,Dopamine
,6510462,bioavailability,"The bioavailability of oral TDHL was proportional to the dose; after 200, 400 and 800 micrograms the bioavailability was 20 +/- 25%, 31 +/- 24% and 48 +/- 26%.","Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510462/),%,48,95829,DB00988,Dopamine
,12083775,half-life,"The effectiveness of PET as a diagnostic tool, the convenient half-life of (18)F (110 min) and the favorable pharmacokinetics of 6-[(18)F]FDOPA have combined to make this an extremely valuable reagent to study dopaminergic activity.","Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083775/),min,110,95910,DB00988,Dopamine
,9918556,T1/2beta,Cocaine was rapidly distributed (T1/2beta = 1.09 min) and eliminated (T1/2alpha = 14.93 min).,Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),min,1.09,96364,DB00988,Dopamine
,9918556,T1/2alpha,Cocaine was rapidly distributed (T1/2beta = 1.09 min) and eliminated (T1/2alpha = 14.93 min).,Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),min,14.93,96365,DB00988,Dopamine
,9918556,free fraction,The free fraction of cocaine was 31.3-33.1% for serum cocaine concentrations of 0.5 to 1 microg/ml.,Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),%,31.3-33.1,96366,DB00988,Dopamine
,9918556,EC50,"Because the concentration at half of Emax for the shorter-response rate (EC50 = 0.467 microg/ml) was greater than that for density of reinforcement (IC50 = 0.070 microg/ml), the former began to return toward baseline sooner than the latter.",Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),[μg] / [ml],0.467,96367,DB00988,Dopamine
,9918556,IC50,"Because the concentration at half of Emax for the shorter-response rate (EC50 = 0.467 microg/ml) was greater than that for density of reinforcement (IC50 = 0.070 microg/ml), the former began to return toward baseline sooner than the latter.",Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918556/),[μg] / [ml],0.070,96368,DB00988,Dopamine
,16764833,apparent terminal half-lives,"The apparent terminal half-lives of desvenlafaxine in plasma, brain and hypothalamus were 3.0, 2.1 and 2.5 h, respectively.",Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764833/),h,3.0,96660,DB00988,Dopamine
,16764833,apparent terminal half-lives,"The apparent terminal half-lives of desvenlafaxine in plasma, brain and hypothalamus were 3.0, 2.1 and 2.5 h, respectively.",Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764833/),h,2.1,96661,DB00988,Dopamine
,16764833,apparent terminal half-lives,"The apparent terminal half-lives of desvenlafaxine in plasma, brain and hypothalamus were 3.0, 2.1 and 2.5 h, respectively.",Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764833/),h,2.5,96662,DB00988,Dopamine
,22541755,AUC0- t,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),[h·ng] / [ml],184.4,98215,DB00988,Dopamine
,22541755,AUC0- t,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),[h·ng] / [ml],179.6,98216,DB00988,Dopamine
,22541755,AUC0-∞,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),[h·ng] / [ml],192.8,98217,DB00988,Dopamine
,22541755,AUC0-∞,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),[h·ng] / [ml],186.6,98218,DB00988,Dopamine
,22541755,Cmax,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),[ng] / [ml],98.9,98219,DB00988,Dopamine
,22541755,Cmax,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),[ng] / [ml],84.4,98220,DB00988,Dopamine
,22541755,tmax,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),h,0.8,98221,DB00988,Dopamine
,22541755,tmax,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),h,0.7,98222,DB00988,Dopamine
,22541755,half-life,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),h,2.4,98223,DB00988,Dopamine
,22541755,half-life,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),h,2.3,98224,DB00988,Dopamine
,22541755,Ke,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),,0.289,98225,DB00988,Dopamine
,22541755,Ke,"Several PK characteristics were determined from the plasma samples, and data from reference and test formulations in the plasma were represented such as AUC0- t (184.4 vs. 179.6 ng×h/ml), AUC0-∞ (192.8 vs. 186.6 ng×h/ml), Cmax (98.9 vs. 84.4 ng/ ml), tmax (0.8 vs. 0.7 h), half-life (2.4 vs. 2.3 h), Ke (0.289 vs. 0.301), respectively.",Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541755/),,0.301,98226,DB00988,Dopamine
,8012555,recoveries,"The intra- and inter-assay precision varied in the 2.4-6.9% and 3.2-9.1% ranges respectively, whereas the recoveries were close to 85% for L-DOPA and 3-OMD and 70% for DA and LDME.","Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012555/),%,85,98555,DB00988,Dopamine
,8012555,recoveries,"The intra- and inter-assay precision varied in the 2.4-6.9% and 3.2-9.1% ranges respectively, whereas the recoveries were close to 85% for L-DOPA and 3-OMD and 70% for DA and LDME.","Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012555/),%,70,98556,DB00988,Dopamine
,3050344,KD,"The binding of 125I-SCH 38840 to rat striatal membranes, in vitro, was saturable and exhibited a KD of 1.47 nM.",Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3050344/),nM,1.47,98613,DB00988,Dopamine
,3050344,KI,"Further studies with the unlabeled SCH 38840 demonstrated that it inhibited dopamine-stimulated adenylate cyclase with a KI of 66.1 nM, indicating that SCH 38840 was acting as a D-1 antagonist.",Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3050344/),nM,66.1,98614,DB00988,Dopamine
,3050344,half-life,"The half-life of the in vivo binding of 125I-SCH 38840 was approximately 1.25 h, and was nearly equivalent to the half-life of the anti-CAR activity of unlabeled SCH 38840.",Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3050344/),h,1.25,98615,DB00988,Dopamine
,18248312,transit time,"Levodopa is only absorbed in the small intestine, where transit time is approximately 3 h and the plasma elimination half-life is short.",Irregular gastrointestinal drug absorption in Parkinson's disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18248312/),h,3,98632,DB00988,Dopamine
,2898533,Ki,"Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM).",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,1-1.3,99033,DB00988,Dopamine
,2898533,AB50,"Compound 34, 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]hexahydro-4,7-etheno-1H- cyclobut[f]isoindole-1,3(2H)-dione, demonstrated 3 times the activity of buspirone, blocking CAR in rats with an AB50 of 13 mg/kg.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),[mg] / [kg],13,99034,DB00988,Dopamine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,16,99035,DB00988,Dopamine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,345,99036,DB00988,Dopamine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,458,99037,DB00988,Dopamine
,18810393,blood serum concentration,"After administration via drinking water in saline-injected control animals, the hal blood serum concentration was 2.6 +/- 0.45 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],2.6,99177,DB00988,Dopamine
,18810393,serum concentration,"In ket-injected animals, the mean serum concentration of hal amounted to 1.2 +/- 0.44 ng/ml.",Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810393/),[ng] / [ml],1.2,99178,DB00988,Dopamine
,25795100,Absolute bioavailability,Absolute bioavailability after 24 h transdermal delivery is 37 % of the applied rotigotine dose.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),%,37,99596,DB00988,Dopamine
>,25795100,apparent volume of distribution,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),l,2500,99597,DB00988,Dopamine
,25795100,total body clearance,The drug shows a high apparent volume of distribution (>2500 L) and a total body clearance of 300-600 L/h.,"An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795100/),[l] / [h],300-600,99598,DB00988,Dopamine
,12562141,terminal half-life,"In humans, quetiapine exhibits linear pharmacokinetics with a mean terminal half-life of 7 hours.","Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562141/),h,7,99732,DB00988,Dopamine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],63,100616,DB00988,Dopamine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],127,100617,DB00988,Dopamine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],8,100618,DB00988,Dopamine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],31,100619,DB00988,Dopamine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,40-66,100620,DB00988,Dopamine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,0.5,100621,DB00988,Dopamine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,0.6-0.9,100622,DB00988,Dopamine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,5.0-6.2,100623,DB00988,Dopamine
,33291402,hardness,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),kp,4.58,101330,DB00988,Dopamine
,33291402,friability,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),%,0.73,101331,DB00988,Dopamine
,33291402,disintegration time,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),s,37.5,101332,DB00988,Dopamine
,33291402,drug release,"The optimized formulation has hardness of 4.58 ± 0.52 KP, friability of 0.73 ± 0.158%, disintegration time of 37.5 ± 1.87 s and drug release of 100.51 ± 1.34% after 30 min.","Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33291402/),%,100.51,101333,DB00988,Dopamine
,16000280,total study time,"Accurate and precise determination of BP1 (binding potential times the free fraction in the metabolite-corrected plasma compartment) and BP2 (binding potential times the free fraction in the intracerebral nonspecifically bound compartment) was achieved using Logan analysis and kinetic analysis, with a total study time of 90 min.",Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16000280/),min,90,101504,DB00988,Dopamine
,21802143,Drug Interaction Probability Score,"The calculated Drug Interaction Probability Score between TAC and LAN was 6, indicating a probable interaction.",Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21802143/),,6,101788,DB00988,Dopamine
,9876986,clearance,"Dopamine clearance for the whole group was 46.4 +/- 35.9 ml/kg per min (mean +/- SD), which is significantly lower than 70 +/- 15.2 ml/kg per min reported for elective surgical patients (p = 0.01).",Dopamine clearance in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876986/),[ml] / [kg·min],46.4,101969,DB00988,Dopamine
,9876986,clearance,"Dopamine clearance for the whole group was 46.4 +/- 35.9 ml/kg per min (mean +/- SD), which is significantly lower than 70 +/- 15.2 ml/kg per min reported for elective surgical patients (p = 0.01).",Dopamine clearance in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876986/),[ml] / [kg·min],70,101970,DB00988,Dopamine
,9876986,clearances,"Twelve patients with renal dysfunction had significantly lower dopamine clearances (36 +/- 16.6 ml/kg per min) than the remaining 36 patients (61 +/- 38.5 ml/kg per min, p = 0.022).",Dopamine clearance in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876986/),[ml] / [kg·min],36,101971,DB00988,Dopamine
,9876986,clearances,"Twelve patients with renal dysfunction had significantly lower dopamine clearances (36 +/- 16.6 ml/kg per min) than the remaining 36 patients (61 +/- 38.5 ml/kg per min, p = 0.022).",Dopamine clearance in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876986/),[ml] / [kg·min],61,101972,DB00988,Dopamine
,28366342,CL/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,676.86,102201,DB00988,Dopamine
,28366342,CL/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,671.72,102202,DB00988,Dopamine
,28366342,CL/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,937.56,102203,DB00988,Dopamine
,28366342,CL/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,1088.77,102204,DB00988,Dopamine
,28366342,VSS/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,5403.16,102205,DB00988,Dopamine
,28366342,VSS/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,6220.79,102206,DB00988,Dopamine
,28366342,VSS/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,7114.01,102207,DB00988,Dopamine
,28366342,VSS/f,"Least-squares mean (95% confidence interval) CL/f and VSS/f values were broadly similar across all dose steps (CL/f: 0.5 mg/24 h: 676.86 [408.50-1121.51]; 1 mg/24 h: 671.72 [459.11-982.80]; 2 mg/24 h: 937.56 [658.50-1334.89]; 3 mg/24 h: 1088.77 [723.47-1638.53]; VSS/f: 5403.16 [2850.67-10,241.17]; 6220.79 [3842.05-10,072.28]; 7114.01 [4547.88-11,128.07]; 6037.92 [3598.36-10,131.41]).",Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28366342/),,6037.92,102208,DB00988,Dopamine
,10509549,half-life,Tolerance to the blood pressure lowering effects of the drug developed slowly during the 48 h of drug infusion; the half-life for this effect was 60 h.,Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509549/),h,60,103374,DB00988,Dopamine
,22722022,maximal plasma concentration of L-DOPA (C(max)),The maximal plasma concentration of L-DOPA (C(max)) was 18.2 ± 3.8 nmol/ml and was achieved 1.6 ± 0.3 h after administration (t(max)).,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),[nM] / [ml],18.2,103432,DB00988,Dopamine
,22722022,t(max),The maximal plasma concentration of L-DOPA (C(max)) was 18.2 ± 3.8 nmol/ml and was achieved 1.6 ± 0.3 h after administration (t(max)).,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),h,1.6,103433,DB00988,Dopamine
,22722022,Half-life,Half-life was 58.8 ± 22.7 min.,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),min,58.8,103434,DB00988,Dopamine
,3597709,steady state serum PRL levels,"In five normal men whose endogenous PRL secretion was suppressed by dopamine, a loading dose of hPRL (70-90 micrograms) followed by a constant infusion (1.39-2.9 ng/min) produced steady state serum PRL levels of 15.2-25.4 ng/mL by 30-60 min.",Pharmacokinetic studies of highly purified human prolactin in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3597709/),[ng] / [ml],15.2-25.4,103971,DB00988,Dopamine
,3597709,volume of distribution,The calculated mean volume of distribution was 7.3 +/- 2.9 (+/- SD) L.,Pharmacokinetic studies of highly purified human prolactin in normal human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3597709/),l,7.3,103972,DB00988,Dopamine
,3597709,MCR,"The calculated MCR was 71 +/- 19 mL/min X m2, and the calculated production rate was 802 +/- 377 micrograms/24 h X m2.",Pharmacokinetic studies of highly purified human prolactin in normal human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3597709/),[ml] / [m2·min],71,103973,DB00988,Dopamine
,3597709,production rate,"The calculated MCR was 71 +/- 19 mL/min X m2, and the calculated production rate was 802 +/- 377 micrograms/24 h X m2.",Pharmacokinetic studies of highly purified human prolactin in normal human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3597709/),[μg] / [24·h·m2],802,103974,DB00988,Dopamine
,3597709,plasma disappearance half-life,The plasma disappearance half-life following discontinuation of the infusion was 37 +/- 10 min.,Pharmacokinetic studies of highly purified human prolactin in normal human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3597709/),min,37,103975,DB00988,Dopamine
,3597709,peak levels,"After the 4 micrograms/kg dose (n = 8), mean serum PRL levels rose from 10.0 +/- 1.8 (+/- SEM) ng/mL to peak levels of 13.1 +/- 1.8 ng/mL (P less than 0.01).",Pharmacokinetic studies of highly purified human prolactin in normal human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3597709/),[ng] / [ml],13.1,103976,DB00988,Dopamine
,29971461,Cmax,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l],16.4,104026,DB00988,Dopamine
,29971461,Cmax,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l],62.2,104027,DB00988,Dopamine
,29971461,AUC0 → ∞,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l·min],708,104028,DB00988,Dopamine
,29971461,AUC0 → ∞,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l·min],3316,104029,DB00988,Dopamine
,29971461,V/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg],582.6,104030,DB00988,Dopamine
,29971461,V/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg],115.9,104031,DB00988,Dopamine
,29971461,Cl/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg·min],4.6,104032,DB00988,Dopamine
,29971461,Cl/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg·min],1.2,104033,DB00988,Dopamine
,29971461,EC50,"The sigmoidal Emax model fitted the observed data well; MDPV being markedly more potent than 4-MMC (EC50, 0.043 versus 0.7 μmol/L).","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μM] / [l],0.043,104034,DB00988,Dopamine
,29971461,EC50,"The sigmoidal Emax model fitted the observed data well; MDPV being markedly more potent than 4-MMC (EC50, 0.043 versus 0.7 μmol/L).","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μM] / [l],0.7,104035,DB00988,Dopamine
,1607003,AUC(o-t),The plasma 5-ISMN concentration-time profile was the same whether 5-ISMN was administered concomitantly with ibopamine or alone [AUC(o-t): 2.24 micrograms.,Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607003/),μg,2.24,104283,DB00988,Dopamine
,12973468,terminal elimination half-life,Absorption is rapid and the terminal elimination half-life (13 h) allows twice-daily administration.,"Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973468/),h,13,104744,DB00988,Dopamine
,10564839,lung bioavailability,"Following intratracheal instillation of the drug solution, the lung bioavailability was found to be approximately 75% in dogs.","Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),%,75,105157,DB00988,Dopamine
,10564839,C(max),"Using tracheostomized beagle dogs, the C(max) following tracheal administration of 5 mg aerosolized ABT-431 was found to be 13.3+/-0.9 ng ml(-1) and the AUC(0-24) was estimated at 33.2+/-10.6 h ng ml(-1).","Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),[ng] / [ml],13.3,105158,DB00988,Dopamine
,10564839,AUC(0-24),"Using tracheostomized beagle dogs, the C(max) following tracheal administration of 5 mg aerosolized ABT-431 was found to be 13.3+/-0.9 ng ml(-1) and the AUC(0-24) was estimated at 33.2+/-10.6 h ng ml(-1).","Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),[h·ng] / [ml],33.2,105159,DB00988,Dopamine
,10564839,lung bioavailability,The lung bioavailability of the aerosolized drug was 34% compared to intravenous injection in dogs.,"Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),%,34,105160,DB00988,Dopamine
,25830369,Cmax,"Cmax, tmax, mean residence time (MRT), and area under the curve from 0 to 24 h (AUC0-24) were 3.97 ± 0.53 ng/mL, 3.58 ± 0.49 h, 8.29 ± 0.93 h, and 35.20 ± 8.11 ng/mL ċ h for ropinirole osmotic pump tablets (ROPT) and 4.15 ± 1.07 ng/mL, 2.92 ± 0.49 h, 7.84 ± 1.09 h, and 34.34 ± 10.06 ng/mL ċ h for REQUIP XL.",Development and uniform evaluation of ropinirole osmotic pump tablets with REQUIP XL both in vitro and in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25830369/),[ng] / [ml],3.97,105564,DB00988,Dopamine
,25830369,area under the curve from 0 to 24 h (AUC0-24),"Cmax, tmax, mean residence time (MRT), and area under the curve from 0 to 24 h (AUC0-24) were 3.97 ± 0.53 ng/mL, 3.58 ± 0.49 h, 8.29 ± 0.93 h, and 35.20 ± 8.11 ng/mL ċ h for ropinirole osmotic pump tablets (ROPT) and 4.15 ± 1.07 ng/mL, 2.92 ± 0.49 h, 7.84 ± 1.09 h, and 34.34 ± 10.06 ng/mL ċ h for REQUIP XL.",Development and uniform evaluation of ropinirole osmotic pump tablets with REQUIP XL both in vitro and in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25830369/),[ng] / [h·ml·ċ],35.20,105565,DB00988,Dopamine
,25830369,area under the curve from 0 to 24 h (AUC0-24),"Cmax, tmax, mean residence time (MRT), and area under the curve from 0 to 24 h (AUC0-24) were 3.97 ± 0.53 ng/mL, 3.58 ± 0.49 h, 8.29 ± 0.93 h, and 35.20 ± 8.11 ng/mL ċ h for ropinirole osmotic pump tablets (ROPT) and 4.15 ± 1.07 ng/mL, 2.92 ± 0.49 h, 7.84 ± 1.09 h, and 34.34 ± 10.06 ng/mL ċ h for REQUIP XL.",Development and uniform evaluation of ropinirole osmotic pump tablets with REQUIP XL both in vitro and in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25830369/),h,2.92,105566,DB00988,Dopamine
,25830369,area under the curve from 0 to 24 h (AUC0-24),"Cmax, tmax, mean residence time (MRT), and area under the curve from 0 to 24 h (AUC0-24) were 3.97 ± 0.53 ng/mL, 3.58 ± 0.49 h, 8.29 ± 0.93 h, and 35.20 ± 8.11 ng/mL ċ h for ropinirole osmotic pump tablets (ROPT) and 4.15 ± 1.07 ng/mL, 2.92 ± 0.49 h, 7.84 ± 1.09 h, and 34.34 ± 10.06 ng/mL ċ h for REQUIP XL.",Development and uniform evaluation of ropinirole osmotic pump tablets with REQUIP XL both in vitro and in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25830369/),[ng] / [h·ml·ċ],34.34,105567,DB00988,Dopamine
,2014157,plasma t1/2,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),min,21,106641,DB00988,Dopamine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],1682,106642,DB00988,Dopamine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],486,106643,DB00988,Dopamine
,31150569,Cmax,The median Cmax for COC in plasma was 379.7 ng/mL (347.5-517.7) and 344.24 ng/mL (271.6-583.2) in whole blood.,"Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],379.7,106762,DB00988,Dopamine
,31150569,Cmax,The median Cmax for COC in plasma was 379.7 ng/mL (347.5-517.7) and 344.24 ng/mL (271.6-583.2) in whole blood.,"Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],344.24,106763,DB00988,Dopamine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],441.2,106764,DB00988,Dopamine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],371.18,106765,DB00988,Dopamine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],105.5,106766,DB00988,Dopamine
,31150569,Cmax,"The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),[ng] / [ml],135.5,106767,DB00988,Dopamine
,31150569,whole blood to plasma ratio,"Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),,0.76,106768,DB00988,Dopamine
,31150569,whole blood to plasma ratio,"Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),,0,106769,DB00988,Dopamine
,31150569,whole blood to plasma ratio,"Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites.","Detection of cocaine and its metabolites in whole blood and plasma following a single dose, controlled administration of intranasal cocaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150569/),,1,106770,DB00988,Dopamine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],14138,107137,DB00988,Dopamine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],12680,107138,DB00988,Dopamine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],11850,107139,DB00988,Dopamine
,15040458,AUC,"The AUC of apomorphine in rabbits were: for subcutaneous injection, 14138 +/- 502 ng/ml/min and 12680 +/- 855 ng/ml/min, n=10 and 6, respectively; for intravenous injection, 11850 +/- 718 ng/ml/min and 9147 +/- 671 ng/ml/min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),[ng] / [min·ml],9147,107140,DB00988,Dopamine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,17.1,107141,DB00988,Dopamine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,18.7,107142,DB00988,Dopamine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,15.3,107143,DB00988,Dopamine
,15040458,"T1/2,elim","The T1/2,elim values were: for subcutaneous injection, 17.1 +/- 1.70 min and 18.7 +/- 1.68 min, n=10 and 6, respectively; for intravenous injection, 15.3 +/- 1.20 min and 15.0 +/- 2.24 min, n=10 and 6, respectively.",Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040458/),min,15.0,107144,DB00988,Dopamine
,7531352,apparent elimination half-life,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.0,108472,DB00988,Dopamine
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,1.5,108473,DB00988,Dopamine
,7531352,mean residence times,"In plasma, the apparent elimination half-life of risperidone was 1.0 h, and mean residence times were 1.5 h for risperidone and 2.5 h for its 9-hydroxy metabolite.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,2.5,108474,DB00988,Dopamine
,7531352,half-lives,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,3-4,108475,DB00988,Dopamine
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,4-6,108476,DB00988,Dopamine
,7531352,mean residence times,"After a subcutaneous dose of 0.02 mg/kg, the ED50 for central 5-HT2 antagonism in male rats, half-lives in frontal cortex and striatum were 3-4 h for risperidone, whereas mean residence times were 4-6 h for risperidone and about 12 h for 9-hydroxy-risperidone.",Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531352/),h,12,108477,DB00988,Dopamine
,16220330,half-life,"The ultra-short-acting mu opioid agonist analgesic/anesthetic remifentanil (RMF) is extremely rapidly eliminated from blood (half-life in rats, 0.3-0.7 min).",Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,0.3-0.7,109075,DB00988,Dopamine
,16220330,t(1/2),"Regardless of the mode of administration (i.e., contingent or noncontingent), intra-accumbens RMF peaked in the first 10-min sample and decreased exponentially with a t(1/2) of 10.0+/-1.2 min (N=31).",Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,10.0,109076,DB00988,Dopamine
,16220330,half-life,Noncontingent single-dose RMF was eliminated from the whole brain with a half-life of 1.1+/-0.2 min and from blood with a half-life of 0.3 min or less.,Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,1.1,109077,DB00988,Dopamine
,16220330,half-life,Noncontingent single-dose RMF was eliminated from the whole brain with a half-life of 1.1+/-0.2 min and from blood with a half-life of 0.3 min or less.,Simultaneous intra-accumbens remifentanil and dopamine kinetics suggest that neither determines within-session operant responding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16220330/),min,0.3,109078,DB00988,Dopamine
<,19788498,oral bioavailability,"Due to extensive pre-systemic metabolism, the oral bioavailability of (-)-stepholidine was poor (<2%).","Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788498/),%,2,109920,DB00988,Dopamine
,19788498,AUC (area under concentration-time curve) ratio,"However, the compound was extensively transported across the blood-brain barrier, demonstrating an AUC (area under concentration-time curve) ratio of brain : plasma of approximately 0.7.","Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788498/),,0.7,109921,DB00988,Dopamine
≥,33785525,Brain-to-plasma ratios,"Brain-to-plasma ratios for methylone and MDC were ≥ 3 (range 3-12), whereas those for HHMC and HMMC were ≤ 0.2 (range 0.01-0.2).",Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33785525/),,3,110402,DB00988,Dopamine
≤,33785525,Brain-to-plasma ratios,"Brain-to-plasma ratios for methylone and MDC were ≥ 3 (range 3-12), whereas those for HHMC and HMMC were ≤ 0.2 (range 0.01-0.2).",Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33785525/),,0.2,110403,DB00988,Dopamine
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),[ng] / [ml],71,112312,DB00988,Dopamine
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,65,112313,DB00988,Dopamine
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,67,112314,DB00988,Dopamine
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,52,112315,DB00988,Dopamine
,28334978,D2/3,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,43,112316,DB00988,Dopamine
,28334978,occupancies,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,43,112317,DB00988,Dopamine
,28334978,occupancies,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,25,112318,DB00988,Dopamine
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,61,112319,DB00988,Dopamine
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,49,112320,DB00988,Dopamine
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,69,112321,DB00988,Dopamine
,7767316,half-life,"The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7% ID/g) at 5 min, followed by clearance with a half-life of 16.1 min.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),min,16.1,112974,DB00988,Dopamine
,7767316,ratio,"As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),,7.4,112975,DB00988,Dopamine
,7767316,ED50,[11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum.,[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),[mg] / [kg],0.3,112976,DB00988,Dopamine
,10187758,systemic bioavailability,Intragastric alcohol administration significantly increased cocaine systemic bioavailability after ip administration from 0.550 +/- 0.044 to 0. 754 +/- 0.071.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,0.550,114230,DB00988,Dopamine
,10187758,systemic bioavailability,Intragastric alcohol administration significantly increased cocaine systemic bioavailability after ip administration from 0.550 +/- 0.044 to 0. 754 +/- 0.071.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,0. 754,114231,DB00988,Dopamine
,10187758,absorption rate constant,"Also, the absorption rate constant increased from 0. 199 +/- 0.045 to 0.276 +/- 0.059 min-1 due to alcohol coadministration; however, this increase was not significant.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),1/[min],0. 199,114232,DB00988,Dopamine
,10187758,absorption rate constant,"Also, the absorption rate constant increased from 0. 199 +/- 0.045 to 0.276 +/- 0.059 min-1 due to alcohol coadministration; however, this increase was not significant.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),1/[min],0.276,114233,DB00988,Dopamine
,10187758,elimination half-life,Alcohol inhibition of cocaine metabolism caused an increase in cocaine elimination half-life from 26.3 +/- 3.6 to 40.0 +/- 8.1 min.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),min,26.3,114234,DB00988,Dopamine
,10187758,elimination half-life,Alcohol inhibition of cocaine metabolism caused an increase in cocaine elimination half-life from 26.3 +/- 3.6 to 40.0 +/- 8.1 min.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),min,40.0,114235,DB00988,Dopamine
,10187758,Emax,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,850,114236,DB00988,Dopamine
,10187758,Emax,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,1550,114237,DB00988,Dopamine
,10187758,EC50,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),[ng] / [ml],3400,114238,DB00988,Dopamine
,10187758,EC50,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),[ng] / [ml],2000,114239,DB00988,Dopamine
,9497016,plasma half-life,Quetiapine (Seroquel) is a novel antipsychotic with an atypical profile in animal models and a relatively short plasma half-life of 2.5 5 h.,Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,2.5,114312,DB00988,Dopamine
,9497016,t[max],"Quetiapine was shown to bind to dopamine D2 receptors in striatum and 2 h (t[max]) after the last dose, 44% receptor occupancy was calculated.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,2,114313,DB00988,Dopamine
,9497016,t[max],"Quetiapine was shown to bind to dopamine D2 receptors in striatum and 2 h (t[max]) after the last dose, 44% receptor occupancy was calculated.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),%,44,114314,DB00988,Dopamine
,9497016,terminal plasma half-life,The terminal plasma half-life of quetiapine was 5.3 h.,Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,5.3,114315,DB00988,Dopamine
,9497016,occupancy half-life,"Our data shows that quetiapine has a relatively low affinity for dopamine D2 receptors, with an occupancy half-life (10 h), which was about twice as long as that for plasma.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,10,114316,DB00988,Dopamine
,9497016,receptor occupancy half-life,"A more prolonged blockade of the serotonin 5HT2 receptors was found in the frontal cortex, with receptor occupancy half-life of 27 h.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,27,114317,DB00988,Dopamine
,20462211,IC(50),One representative compound S-17b (WYE-103231) had low nanomolar hNET potency (IC(50) = 1.2 nM) and excellent selectivity for hNET over hSERT (>1600-fold) and hDAT (>600-fold).,"Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462211/),nM,1.2,115266,DB00988,Dopamine
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,47,116256,DB00988,Dopamine
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,42,116257,DB00988,Dopamine
,22154896,occupancies,"Dopamine transporter occupancies in the right caudate were 47% at 8 hours with 20 mg, 42% at hour 10 with 30 mg, and 46% (extrapolated) at hour 12 with 40 mg.",Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154896/),%,46,116258,DB00988,Dopamine
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,4.1,117581,DB00988,Dopamine
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,2.9,117582,DB00988,Dopamine
,10424323,AUC,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[micog] / [h·ml],68.6,117799,DB00988,Dopamine
,10424323,AUC,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[μg] / [h·ml],70.0,117800,DB00988,Dopamine
,10424323,Cmax,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[μg] / [ml],11.07,117801,DB00988,Dopamine
,10424323,Cmax,"Co-administration of ropinirole did not significantly change the pharmacokinetics of i.v. theophylline (mean AUC with and without ropinirole: 68.6 micog x h(-1) x ml(-1) and 70.0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11.07 microg x ml(-1) and 11.83 microg x ml(-1), respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[μg] / [ml],11.83,117802,DB00988,Dopamine
,10424323,AUC,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [h·ml],21.91,117803,DB00988,Dopamine
,10424323,AUC,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [h·ml],22.09,117804,DB00988,Dopamine
,10424323,Cmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [ml],5.65,117805,DB00988,Dopamine
,10424323,Cmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),[ng] / [ml],5.54,117806,DB00988,Dopamine
,10424323,tmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),h,2.0,117807,DB00988,Dopamine
,10424323,tmax,"Similarly, there were no significant changes in ropinirole pharmacokinetics when the drug was co-administered with oral theophylline (mean AUC for ropinirole with and without theophylline: 21.91 ng x h(-1) x ml(-1) and 22.09 ng x h(-1) x ml(-1), respectively; mean Cmax for ropinirole with and without theophylline: 5.65 ng x ml(-1) and 5.54 ng x ml(-1), respectively; median tmax for ropinirole with and without theophylline: 2.0 h and 1.5 h, respectively).",Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424323/),h,1.5,117808,DB00988,Dopamine
,27658484,Tmax,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,15-45,119370,DB00988,Dopamine
,27658484,t1/2,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,60-90,119371,DB00988,Dopamine
,27658484,Tmax,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,60-120,119372,DB00988,Dopamine
,27658484,t1/2,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,120-180,119373,DB00988,Dopamine
,22615620,maximum cumulative percentage of drug release,"The optimized formulation F6 showed maximum cumulative percentage of drug release (90.7%), permeation (6806.64 µg) in 24 hrs, flux (86.02 µg /hr/cm(2)) and permeation coefficient of 0.86x10(-2) cm/hr.","Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615620/),%,90.7,121506,DB00988,Dopamine
,22615620,permeation,"The optimized formulation F6 showed maximum cumulative percentage of drug release (90.7%), permeation (6806.64 µg) in 24 hrs, flux (86.02 µg /hr/cm(2)) and permeation coefficient of 0.86x10(-2) cm/hr.","Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615620/),μg,6806.64,121507,DB00988,Dopamine
,22615620,flux,"The optimized formulation F6 showed maximum cumulative percentage of drug release (90.7%), permeation (6806.64 µg) in 24 hrs, flux (86.02 µg /hr/cm(2)) and permeation coefficient of 0.86x10(-2) cm/hr.","Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615620/),[h·μg] / [cm(2],86.02,121508,DB00988,Dopamine
,22615620,permeation coefficient,"The optimized formulation F6 showed maximum cumulative percentage of drug release (90.7%), permeation (6806.64 µg) in 24 hrs, flux (86.02 µg /hr/cm(2)) and permeation coefficient of 0.86x10(-2) cm/hr.","Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615620/),[cm] / [h],0.86x10(-2),121509,DB00988,Dopamine
,22615620,tensile strength,Values of tensile strength (4.34 kg/mm(2)) and elastic modulus (5.89 kg/cm(2)) revealed that formulation F6 was strong but not brittle.,"Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615620/),[kg] / [mm(2],4.34,121510,DB00988,Dopamine
,22615620,elastic modulus,Values of tensile strength (4.34 kg/mm(2)) and elastic modulus (5.89 kg/cm(2)) revealed that formulation F6 was strong but not brittle.,"Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615620/),[kg] / [cm(2],5.89,121511,DB00988,Dopamine
,22615620,shelf life,A shelf life of 2 years is predicted for the TDDS.,"Development of domperidone bilayered matrix type transdermal patches: physicochemical, in vitro and ex vivo characterization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615620/),years,2,121512,DB00988,Dopamine
,9450511,ED50s,"The ED50s (50% occupancy of DAT by cocaine) were 0.27 and 0.17 mg/kg for [11C]d-threo-methylphenidate and [11C]cocaine, respectively.",Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],0.27,121660,DB00988,Dopamine
,9450511,ED50s,"The ED50s (50% occupancy of DAT by cocaine) were 0.27 and 0.17 mg/kg for [11C]d-threo-methylphenidate and [11C]cocaine, respectively.",Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],0.17,121661,DB00988,Dopamine
,9450511,ED50s,This is significantly lower than values obtained with labeled beta-CIT and other similar radiotracers with a slow uptake and clearance (ED50s: 3-7 mg/kg).,Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450511/),[mg] / [kg],3-7,121662,DB00988,Dopamine
,9488509,half-life,"Therefore, due to the relatively long half-life of 18F (109.8 min), PET scans with [18F]CFT could easily be conducted during the binding equilibrium, allowing estimation of Bmax/Kd values (i.e., binding potential).","[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488509/),min,109.8,122234,DB00988,Dopamine
,9488509,Binding potentials,"Binding potentials for putamen and caudate measured at equilibrium were 4.79+/-0.11 and 4.50+/-0.23, respectively.","[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488509/),,4.79,122235,DB00988,Dopamine
,9488509,Binding potentials,"Binding potentials for putamen and caudate measured at equilibrium were 4.79+/-0.11 and 4.50+/-0.23, respectively.","[18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488509/),,4.50,122236,DB00988,Dopamine
,7479562,AUC0-->3,"The AUC0-->3 values for the non-protein bound L-DOPA did not differ significantly between the dialysis (141.3 +/- 16.0 nmol.h/ml) and traditional whole blood sampling (145.3 +/- 18.7 nmol.h/ml), confirming that microdialysis combined with accurate calibration is a reliable technique for studying the kinetics of drugs in vivo in different tissues.",Quantitative microdialysis for studying the in vivo L-DOPA kinetics in blood and skeletal muscle of the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479562/),[h·nM] / [ml],141.3,123322,DB00988,Dopamine
,7479562,AUC0-->3,"The AUC0-->3 values for the non-protein bound L-DOPA did not differ significantly between the dialysis (141.3 +/- 16.0 nmol.h/ml) and traditional whole blood sampling (145.3 +/- 18.7 nmol.h/ml), confirming that microdialysis combined with accurate calibration is a reliable technique for studying the kinetics of drugs in vivo in different tissues.",Quantitative microdialysis for studying the in vivo L-DOPA kinetics in blood and skeletal muscle of the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479562/),[h·nM] / [ml],145.3,123323,DB00988,Dopamine
,30713247,milk/plasma concentration ratio,"5) In breastfeeding women, the median milk/plasma concentration ratio of amlodipine was 0.85.",Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713247/),,0.85,123684,DB00988,Dopamine
,7701044,elimination rate constant,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),[l] / [h],0.42,123689,DB00988,Dopamine
,7701044,elimination rate constant,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),[l] / [h],0.67,123690,DB00988,Dopamine
,7701044,elimination half-life,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),h,1.68,123691,DB00988,Dopamine
,7701044,elimination half-life,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),h,1.07,123692,DB00988,Dopamine
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,35.3,123919,DB00988,Dopamine
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,225,123920,DB00988,Dopamine
,27207183,absolute bioavailability,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),%,60.5,123921,DB00988,Dopamine
,27207183,LD50,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),[mg] / [kg],346,123922,DB00988,Dopamine
,16789796,peak plasma concentrations,"In children with ADHD, MTS patches releasing MPH doses of 10-30 mg over a 9-hour period (12.5-37.5 cm2 patch size) is steadily absorbed, with mean peak plasma concentrations of d-MPH (20-46.5 ng/mL) reached in approximately 8 hours.",Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16789796/),[ng] / [ml],20-46.5,123979,DB00988,Dopamine
,11996211,absolute bioavailability,The absolute bioavailability of the sustained release formulation (fasting state) was 58% and thus about 17% lower than the bioavailability of the immediate release formulation.,Analysis of formulation and food effect on the absorption of metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996211/),%,58,124700,DB00988,Dopamine
,11996211,absolute bioavailability,The absolute bioavailability of the sustained release formulation (fasting state) was 58% and thus about 17% lower than the bioavailability of the immediate release formulation.,Analysis of formulation and food effect on the absorption of metoclopramide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996211/),%,17,124701,DB00988,Dopamine
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,300.1,125545,DB00988,Dopamine
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,226.9,125546,DB00988,Dopamine
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,342.0,125547,DB00988,Dopamine
,23149484,m/z,"MCP and levosulpiride (internal standard) were analyzed in the precursor/product ion pair of m/z 300.1/226.9 and 342.0/112.0, respectively.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),,112.0,125548,DB00988,Dopamine
,23149484,recoveries,"Mean recoveries were 96-103%, and the coefficient of variation was less than 6.5%.",Simple and sensitive method for measurement of metoclopramide in cattle plasma by LC-MS/MS using a multimode chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23149484/),%,96-103,125549,DB00988,Dopamine
,8095299,elimination half-life,"Pharmacokinetic analysis based on a two-compartment model with elimination from the central compartment yielded the following parameters for male rats (mean +/- standard deviation, n = 3): elimination half-life was 108 +/- 7 min, apparent volume of distribution of the central compartment was 397 +/- 44 mL.kg-1, the plasma clearance was 32 +/- 4 mL.min-1.kg-1, and the apparent volume of distribution at steady state was 2.29 +/- 0.25 L.kg-1.",Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095299/),min,108,126716,DB00988,Dopamine
,8095299,apparent volume of distribution of the central compartment,"Pharmacokinetic analysis based on a two-compartment model with elimination from the central compartment yielded the following parameters for male rats (mean +/- standard deviation, n = 3): elimination half-life was 108 +/- 7 min, apparent volume of distribution of the central compartment was 397 +/- 44 mL.kg-1, the plasma clearance was 32 +/- 4 mL.min-1.kg-1, and the apparent volume of distribution at steady state was 2.29 +/- 0.25 L.kg-1.",Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095299/),[ml] / [kg],397,126717,DB00988,Dopamine
,8095299,plasma clearance,"Pharmacokinetic analysis based on a two-compartment model with elimination from the central compartment yielded the following parameters for male rats (mean +/- standard deviation, n = 3): elimination half-life was 108 +/- 7 min, apparent volume of distribution of the central compartment was 397 +/- 44 mL.kg-1, the plasma clearance was 32 +/- 4 mL.min-1.kg-1, and the apparent volume of distribution at steady state was 2.29 +/- 0.25 L.kg-1.",Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095299/),[ml] / [kg·min],32,126718,DB00988,Dopamine
,8095299,apparent volume of distribution at steady state,"Pharmacokinetic analysis based on a two-compartment model with elimination from the central compartment yielded the following parameters for male rats (mean +/- standard deviation, n = 3): elimination half-life was 108 +/- 7 min, apparent volume of distribution of the central compartment was 397 +/- 44 mL.kg-1, the plasma clearance was 32 +/- 4 mL.min-1.kg-1, and the apparent volume of distribution at steady state was 2.29 +/- 0.25 L.kg-1.",Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095299/),[l] / [kg],2.29,126719,DB00988,Dopamine
,8095299,bioavailability,"The bioavailability (mean +/- standard deviation, n = 3) was 7.9 +/- 2.7% for male rats and 6.5 +/- 2.1% for female rats.",Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095299/),%,7.9,126720,DB00988,Dopamine
,8095299,bioavailability,"The bioavailability (mean +/- standard deviation, n = 3) was 7.9 +/- 2.7% for male rats and 6.5 +/- 2.1% for female rats.",Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095299/),%,6.5,126721,DB00988,Dopamine
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1599,127166,DB00988,Dopamine
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1821,127167,DB00988,Dopamine
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1094,127168,DB00988,Dopamine
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1129,127169,DB00988,Dopamine
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],430,127170,DB00988,Dopamine
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),1/[ng+ml],315,127171,DB00988,Dopamine
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,1.9,127172,DB00988,Dopamine
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,3.0,127173,DB00988,Dopamine
,1572185,half-life,The half-life for the alpha phase was 2.2 mins and was 38.7 mins for the beta phase.,Plasma catecholamine concentrations after successful resuscitation in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),min,2.2,127274,DB00988,Dopamine
,1572185,half-life,The half-life for the alpha phase was 2.2 mins and was 38.7 mins for the beta phase.,Plasma catecholamine concentrations after successful resuscitation in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),min,38.7,127275,DB00988,Dopamine
,1572185,plasma glucose concentrations,Median plasma glucose concentrations were between 8.2 mmol/L (147.7 mg/dL; range 5.8 to 11.2 mmol/L [104.5 to 201.8 mg/dL]) at 1 min and 13.9 mmol/L (250.4 mg/dL; range 9.7 to 16.6 mmol/L [174.8 to 299.1 mg/dL]) at 30 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],8.2,127276,DB00988,Dopamine
,1572185,plasma glucose concentrations,Median plasma glucose concentrations were between 8.2 mmol/L (147.7 mg/dL; range 5.8 to 11.2 mmol/L [104.5 to 201.8 mg/dL]) at 1 min and 13.9 mmol/L (250.4 mg/dL; range 9.7 to 16.6 mmol/L [174.8 to 299.1 mg/dL]) at 30 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],13.9,127277,DB00988,Dopamine
,1572185,Lactate,Lactate values were between 11.4 mmol/L (range 4.7 to 16.5) at 1 min and 5.2 mmol/L (range 2.7 to 12.5) at 60 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],11.4,127278,DB00988,Dopamine
,1572185,Lactate,Lactate values were between 11.4 mmol/L (range 4.7 to 16.5) at 1 min and 5.2 mmol/L (range 2.7 to 12.5) at 60 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],5.2,127279,DB00988,Dopamine
,32935460,tmax,Solriamfetol median tmax was 2-3 hours; exposure was dose-proportional.,"A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935460/),h,2-3,128175,DB00988,Dopamine
,8830979,Cmax,"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),[pg] / [ml],44,129359,DB00988,Dopamine
,8830979,Cmax,"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),[pg] / [ml],54,129360,DB00988,Dopamine
,8830979,AUC(0-336 h),"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),[h·pg] / [ml],6392,129361,DB00988,Dopamine
,8830979,AUC(0-336 h),"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),[h·pg] / [ml],5331,129362,DB00988,Dopamine
,8830979,Ae(0-168 h),"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),μg,12.7,129363,DB00988,Dopamine
,8830979,Ae(0-168 h),"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),μg,11.9,129364,DB00988,Dopamine
,8830979,t1/2,"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),h,109.7,129365,DB00988,Dopamine
,8830979,t1/2,"In subjects receiving cabergoline under fed or fasting conditions, Cmax values averaged 44 and 54 pg mL(-1), AUC(0-336 h) averaged 6392 and 5331 pg h mL(-1), Ae(0-168 h) averaged 12.7 and 11.9 micrograms, and t1/2 averaged 109.7 and 101.3 h, respectively.",The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),h,101.3,129366,DB00988,Dopamine
,8830979,tmax,Median tmax values in subjects treated under fasting or fed conditions were identical (2.5 h).,The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830979/),h,2.5,129367,DB00988,Dopamine
,15366325,AUC(0-infinity),"The mean (SD) AUC(0-infinity) of deramciclane was 1,251 (385) ng x h/ml after the first dose.",Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366325/),[h·ng] / [ml],"1,251",130172,DB00988,Dopamine
,15366325,accumulation indices,"The mean accumulation indices at weeks 1, 2, 3 and 4 varied between 2.3 and 2.7 with no tendency to increase over time.",Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366325/),,2.3 and 2.7,130173,DB00988,Dopamine
,15366325,apparent elimination half-life,The mean apparent elimination half-life of deramciclane was 24.9 (3.5) hours after the first dose and 29.3 (9.3) hours after 4-week repeated dosing; this difference was not statistically significant.,Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366325/),h,24.9,130174,DB00988,Dopamine
,15366325,apparent elimination half-life,The mean apparent elimination half-life of deramciclane was 24.9 (3.5) hours after the first dose and 29.3 (9.3) hours after 4-week repeated dosing; this difference was not statistically significant.,Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366325/),h,29.3,130175,DB00988,Dopamine
,28796889,half-life,"The dopamine displayed first-order kinetics in piglets and had a half-life of 2.5 minutes, while the median plasma clearance was 627.9 mL/kg/minute (interquartile range 452.6-1914.4).",Dopamine plasma clearance is increased in piglets compared to neonates during continuous dopamine infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28796889/),min,2.5,130659,DB00988,Dopamine
,28796889,plasma clearance,"The dopamine displayed first-order kinetics in piglets and had a half-life of 2.5 minutes, while the median plasma clearance was 627.9 mL/kg/minute (interquartile range 452.6-1914.4).",Dopamine plasma clearance is increased in piglets compared to neonates during continuous dopamine infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28796889/),[ml] / [kg·min],627.9,130660,DB00988,Dopamine
,28796889,plasma clearance,"Both piglets and neonates showed large interindividual variations in plasma clearance, but the median tended to be lower in neonates (384.9, interquartile range 114.2-480.2 mL/kg/minute).",Dopamine plasma clearance is increased in piglets compared to neonates during continuous dopamine infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28796889/),[ml] / [kg·min],384.9,130661,DB00988,Dopamine
,2089102,Ki,Ro 40-7592 was found to inhibit COMT in a competitive fashion both in the CNS and in the periphery (Ki for the liver enzyme = 30 nM).,Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089102/),nM,30,131877,DB00988,Dopamine
,27363313,AUC0→∞,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[h·ng] / [ml],211.5,132038,DB00988,Dopamine
,27363313,AUC0→∞,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[h·ng] / [ml],261.4,132039,DB00988,Dopamine
,27363313,Cmax,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[ng] / [ml],83.3,132040,DB00988,Dopamine
,27363313,Cmax,"The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively.","Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27363313/),[ng] / [ml],104.5,132041,DB00988,Dopamine
,23585286,k,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.079,132331,DB00988,Dopamine
,23585286,t1/2,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),h,9.0,132332,DB00988,Dopamine
,23585286,Vd /F,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),l,330.5,132333,DB00988,Dopamine
,23585286,Cl/F,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),[l] / [h],38.2,132334,DB00988,Dopamine
,23585286,AUC0→∞,"The non-compartmental parameters determined were k (0.079±0.008 h(-1)), t1/2 (9.0±2.9 h), Vd /F (330.5±87.3 L), Cl/F (38.2±9.8 L/h) and AUC0→∞ (1402.5±404.7 ng.h/mL).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),[h·ng] / [ml],1402.5,132335,DB00988,Dopamine
,23585286,k21,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.68,132336,DB00988,Dopamine
,23585286,ka1,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.7,132337,DB00988,Dopamine
,23585286,ka2,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],2.7,132338,DB00988,Dopamine
,23585286,Vc/F,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),l,45.1,132339,DB00988,Dopamine
,23585286,α,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],33.3,132340,DB00988,Dopamine
,23585286,β,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),1/[h],0.11,132341,DB00988,Dopamine
,23585286,time for the beginning of,"The parameters determined were k21 (0.68±0.2 h(-1)), ka1 (0.7±0.27 h(-1)), ka2 (2.7±1.8 h(-1)) Vc/F (45.1±15.7 L), α (33.3±1.5 h(-1)), β (0.11±0.03 h(-1)) and time for the beginning of the absorption from the second site (4.4±2.1 h).",Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585286/),h,4.4,132342,DB00988,Dopamine
,2055074,Infusion rates,Infusion rates for dobutamine ranged from 2 to 15 micrograms/kg.min.,Nonlinear dobutamine pharmacokinetics in a pediatric population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055074/),[μg] / [kg·min],2 to 15,132428,DB00988,Dopamine
,2055074,Serum concentrations,Serum concentrations varied from 6.4 to 347 ng/mL (21 to 1151 nmol/L).,Nonlinear dobutamine pharmacokinetics in a pediatric population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055074/),[ng] / [ml],6.4 to 347,132429,DB00988,Dopamine
,2055074,Serum concentrations,Serum concentrations varied from 6.4 to 347 ng/mL (21 to 1151 nmol/L).,Nonlinear dobutamine pharmacokinetics in a pediatric population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055074/),[nM] / [l],21 to 1151,132430,DB00988,Dopamine
,2055074,clearance,Values for clearance varied from 32 to 625 mL/kg.min.,Nonlinear dobutamine pharmacokinetics in a pediatric population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055074/),[ml] / [kg·min],32 to 625,132431,DB00988,Dopamine
,23846146,AUC0-24,"The AUC0-24 and cmax values were 3.38 ± 0.81 μg h mL-1 and 0.44 ± 0.03 μg mL-1 for SMEDDS-B formulation in comparison with 1.74 ± 0.18 μg h mL-1 and 0.24 ± 0.02 μg mL-1 for domperidone suspension, suggesting a significant increase (p < 0.05) in oral bioavailability of domperidone from SMEDDSS.",Development of a self-microemulsifying drug delivery system of domperidone: In vitro and in vivo characterization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23846146/),[h·μg] / [ml],3.38,133228,DB00988,Dopamine
,23846146,AUC0-24,"The AUC0-24 and cmax values were 3.38 ± 0.81 μg h mL-1 and 0.44 ± 0.03 μg mL-1 for SMEDDS-B formulation in comparison with 1.74 ± 0.18 μg h mL-1 and 0.24 ± 0.02 μg mL-1 for domperidone suspension, suggesting a significant increase (p < 0.05) in oral bioavailability of domperidone from SMEDDSS.",Development of a self-microemulsifying drug delivery system of domperidone: In vitro and in vivo characterization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23846146/),[h·μg] / [ml],1.74,133229,DB00988,Dopamine
,23846146,cmax,"The AUC0-24 and cmax values were 3.38 ± 0.81 μg h mL-1 and 0.44 ± 0.03 μg mL-1 for SMEDDS-B formulation in comparison with 1.74 ± 0.18 μg h mL-1 and 0.24 ± 0.02 μg mL-1 for domperidone suspension, suggesting a significant increase (p < 0.05) in oral bioavailability of domperidone from SMEDDSS.",Development of a self-microemulsifying drug delivery system of domperidone: In vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23846146/),[μg] / [ml],0.44,133230,DB00988,Dopamine
,23846146,cmax,"The AUC0-24 and cmax values were 3.38 ± 0.81 μg h mL-1 and 0.44 ± 0.03 μg mL-1 for SMEDDS-B formulation in comparison with 1.74 ± 0.18 μg h mL-1 and 0.24 ± 0.02 μg mL-1 for domperidone suspension, suggesting a significant increase (p < 0.05) in oral bioavailability of domperidone from SMEDDSS.",Development of a self-microemulsifying drug delivery system of domperidone: In vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23846146/),[μg] / [ml],0.24,133231,DB00988,Dopamine
,20959524,time to maximum plasma concentration,"Dexpramipexole was rapidly absorbed, with time to maximum plasma concentration ranging from 1.8 to 2.6 hours and half-life ranging from 6.4 to 8.1 hours under fasted conditions, and was mostly eliminated in urine as unchanged parent drug (84%-90% of dose).","Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959524/),h,1.8 to 2.6,133307,DB00988,Dopamine
,20959524,half-life,"Dexpramipexole was rapidly absorbed, with time to maximum plasma concentration ranging from 1.8 to 2.6 hours and half-life ranging from 6.4 to 8.1 hours under fasted conditions, and was mostly eliminated in urine as unchanged parent drug (84%-90% of dose).","Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959524/),h,6.4 to 8.1,133308,DB00988,Dopamine
,19488984,retention times,The retention times of levosulpiride (0.63 min) and IS (0.66 min) presented a significant time saving benefit of the proposed method.,Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488984/),min,0.63,134113,DB00988,Dopamine
,19488984,retention times,The retention times of levosulpiride (0.63 min) and IS (0.66 min) presented a significant time saving benefit of the proposed method.,Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488984/),min,0.66,134114,DB00988,Dopamine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.96,134211,DB00988,Dopamine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.73,134212,DB00988,Dopamine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.25,134213,DB00988,Dopamine
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,7.7-11.9,134439,DB00988,Dopamine
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,1.2-1.3,134440,DB00988,Dopamine
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,26.4-31.4,134441,DB00988,Dopamine
,14764214,half-life,Mean half-life of dopamine D2 receptor occupancy of risperidone was 80.2 h while that of the plasma concentration was 17.8 h.,Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,80.2,134555,DB00988,Dopamine
,14764214,half-life,Mean half-life of dopamine D2 receptor occupancy of risperidone was 80.2 h while that of the plasma concentration was 17.8 h.,Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,17.8,134556,DB00988,Dopamine
,14764214,half-life of receptor occupancy,"When the ED50 value was changed to one-tenth and 10-fold, the simulated half-life of receptor occupancy changed to 117.6 h and 27.3 h respectively.",Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,117.6,134557,DB00988,Dopamine
,14764214,half-life of receptor occupancy,"When the ED50 value was changed to one-tenth and 10-fold, the simulated half-life of receptor occupancy changed to 117.6 h and 27.3 h respectively.",Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764214/),h,27.3,134558,DB00988,Dopamine
,10570026,brain half-lives,"The brain half-lives of nicotine, cotinine, and nornicotine were 52, 333, and 166 min, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),min,52,134597,DB00988,Dopamine
,10570026,brain half-lives,"The brain half-lives of nicotine, cotinine, and nornicotine were 52, 333, and 166 min, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),min,333,134598,DB00988,Dopamine
,10570026,brain half-lives,"The brain half-lives of nicotine, cotinine, and nornicotine were 52, 333, and 166 min, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),min,166,134599,DB00988,Dopamine
,10570026,Peak brain concentrations,"Peak brain concentrations of nicotine metabolites were 300, 70, and 7 nM for cotinine, nornicotine, and norcotinine, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),nM,300,134600,DB00988,Dopamine
,10570026,Peak brain concentrations,"Peak brain concentrations of nicotine metabolites were 300, 70, and 7 nM for cotinine, nornicotine, and norcotinine, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),nM,70,134601,DB00988,Dopamine
,10570026,Peak brain concentrations,"Peak brain concentrations of nicotine metabolites were 300, 70, and 7 nM for cotinine, nornicotine, and norcotinine, respectively.",Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2'-(14)C]nicotine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10570026/),nM,7,134602,DB00988,Dopamine
,10484011,maximum plasma concentration (Cmax),"In healthy subjects, maximum plasma concentration (Cmax), time taken to reach Cmax (Tmax), elimination half-life (T(1/2)), and area under the plasma concentration-time curve (AUC) of plasma free dopamine were 76.8 +/- 24.1 ng/ml, 1.3 +/- 0.2 h, 0.8 +/- 0.1 h, and 97.5 +/- 21.1 ng x h/ml, respectively.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),[ng] / [ml],76.8,134825,DB00988,Dopamine
,10484011,time taken to reach Cmax (Tmax),"In healthy subjects, maximum plasma concentration (Cmax), time taken to reach Cmax (Tmax), elimination half-life (T(1/2)), and area under the plasma concentration-time curve (AUC) of plasma free dopamine were 76.8 +/- 24.1 ng/ml, 1.3 +/- 0.2 h, 0.8 +/- 0.1 h, and 97.5 +/- 21.1 ng x h/ml, respectively.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),h,1.3,134826,DB00988,Dopamine
,10484011,elimination half-life (T(1/2)),"In healthy subjects, maximum plasma concentration (Cmax), time taken to reach Cmax (Tmax), elimination half-life (T(1/2)), and area under the plasma concentration-time curve (AUC) of plasma free dopamine were 76.8 +/- 24.1 ng/ml, 1.3 +/- 0.2 h, 0.8 +/- 0.1 h, and 97.5 +/- 21.1 ng x h/ml, respectively.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),h,1.3,134827,DB00988,Dopamine
,10484011,elimination half-life (T(1/2)),"In healthy subjects, maximum plasma concentration (Cmax), time taken to reach Cmax (Tmax), elimination half-life (T(1/2)), and area under the plasma concentration-time curve (AUC) of plasma free dopamine were 76.8 +/- 24.1 ng/ml, 1.3 +/- 0.2 h, 0.8 +/- 0.1 h, and 97.5 +/- 21.1 ng x h/ml, respectively.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),h,0.8,134828,DB00988,Dopamine
,10484011,area under the plasma concentration-time curve (AUC),"In healthy subjects, maximum plasma concentration (Cmax), time taken to reach Cmax (Tmax), elimination half-life (T(1/2)), and area under the plasma concentration-time curve (AUC) of plasma free dopamine were 76.8 +/- 24.1 ng/ml, 1.3 +/- 0.2 h, 0.8 +/- 0.1 h, and 97.5 +/- 21.1 ng x h/ml, respectively.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),[h·ng] / [ml],97.5,134829,DB00988,Dopamine
,10484011,Cmax,"In patients with cirrhosis, Cmax (53.1 +/- 24.9 ng/ml), T(1/2) (0.8 +/- 0.1 h), and AUC (100.6 +/- 45.6 ng x h/ml) were no different from healthy subjects when comparing each parameter, whereas Tmax (2.7 +/- 0.2) was significantly longer than that of healthy subjects.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),[ng] / [ml],53.1,134830,DB00988,Dopamine
,10484011,T(1/2),"In patients with cirrhosis, Cmax (53.1 +/- 24.9 ng/ml), T(1/2) (0.8 +/- 0.1 h), and AUC (100.6 +/- 45.6 ng x h/ml) were no different from healthy subjects when comparing each parameter, whereas Tmax (2.7 +/- 0.2) was significantly longer than that of healthy subjects.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),h,0.8,134831,DB00988,Dopamine
,10484011,AUC,"In patients with cirrhosis, Cmax (53.1 +/- 24.9 ng/ml), T(1/2) (0.8 +/- 0.1 h), and AUC (100.6 +/- 45.6 ng x h/ml) were no different from healthy subjects when comparing each parameter, whereas Tmax (2.7 +/- 0.2) was significantly longer than that of healthy subjects.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),[h·ng] / [ml],100.6,134832,DB00988,Dopamine
,10484011,Tmax,"In patients with cirrhosis, Cmax (53.1 +/- 24.9 ng/ml), T(1/2) (0.8 +/- 0.1 h), and AUC (100.6 +/- 45.6 ng x h/ml) were no different from healthy subjects when comparing each parameter, whereas Tmax (2.7 +/- 0.2) was significantly longer than that of healthy subjects.","Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10484011/),,2.7,134833,DB00988,Dopamine
,8786247,CL app,"Mean (+/- SD) CL app of bupropion was 1.6 +/- 0.4 L/hr/kg, approximately 80% of the corresponding value reported for younger patients.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),[l] / [h·kg],1.6,136560,DB00988,Dopamine
,8786247,t1/2,"Mean bupropion t1/2 was 34.2 +/- 8.7 hours, and average apparent Vd (Vd app) was 79.3 +/- 29.4 L/kg.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,34.2,136561,DB00988,Dopamine
,8786247,apparent Vd (Vd app),"Mean bupropion t1/2 was 34.2 +/- 8.7 hours, and average apparent Vd (Vd app) was 79.3 +/- 29.4 L/kg.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),[l] / [kg],79.3,136562,DB00988,Dopamine
,8786247,Apparent half-lives (t1/2 app),"Apparent half-lives (t1/2 app) of the metabolites hydroxybupropion, erythrobupropion, and threohydrobupropion were 34.2 +/- 4.6 hours, 61.4 +/- 21.6 hours, and 38.8 +/- 7.6 hours, respectively.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,34.2,136563,DB00988,Dopamine
,8786247,Apparent half-lives (t1/2 app),"Apparent half-lives (t1/2 app) of the metabolites hydroxybupropion, erythrobupropion, and threohydrobupropion were 34.2 +/- 4.6 hours, 61.4 +/- 21.6 hours, and 38.8 +/- 7.6 hours, respectively.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,61.4,136564,DB00988,Dopamine
,8786247,Apparent half-lives (t1/2 app),"Apparent half-lives (t1/2 app) of the metabolites hydroxybupropion, erythrobupropion, and threohydrobupropion were 34.2 +/- 4.6 hours, 61.4 +/- 21.6 hours, and 38.8 +/- 7.6 hours, respectively.",Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786247/),h,38.8,136565,DB00988,Dopamine
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"2,169",136647,DB00988,Dopamine
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"1,200",136648,DB00988,Dopamine
,12865145,steady-state concentration,"The final infusion protocol, with a target steady-state concentration of 600 ng/ml, was well-tolerated (mild nausea in 11% of subjects was the only side effect occurring significantly more than in single-blind saline infusions), produced the desired plasma levodopa concentration (612+/-187 ng/ml, mean+/-S.D.), and produced statistically significant antiparkinsonian benefit (16% mean reduction in a standard rating of parkinsonian motor signs, P<0.0005).",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],600,136649,DB00988,Dopamine
,9260033,peak plasma concentration (Cmax),The mean peak plasma concentration (Cmax) is approximately 2 micrograms/L and the time to reach the peak is under an hour.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[μg] / [l],2,136781,DB00988,Dopamine
under,9260033,time to reach the peak,The mean peak plasma concentration (Cmax) is approximately 2 micrograms/L and the time to reach the peak is under an hour.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),h,an,136782,DB00988,Dopamine
,9260033,absolute bioavailability,The absolute bioavailability of selegiline is approximately 10%.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),%,10,136783,DB00988,Dopamine
,9260033,apparent volume of distribution,It has an apparent volume of distribution of 1854 L.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),l,1854,136784,DB00988,Dopamine
,9260033,oral clearance,"The oral clearance of selegiline (59 L/min) is many fold higher than the liver blood flow (1.5 L/min), indicating that extrahepatic processes are involved in the elimination of selegiline.",Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[l] / [min],59,136785,DB00988,Dopamine
,9260033,oral clearance,"The oral clearance of selegiline (59 L/min) is many fold higher than the liver blood flow (1.5 L/min), indicating that extrahepatic processes are involved in the elimination of selegiline.",Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),[l] / [min],1.5,136786,DB00988,Dopamine
,9260033,elimination half-life,The elimination half-life of selegiline is about 1.5 hours.,Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260033/),h,1.5,136787,DB00988,Dopamine
,8062493,Clearance (CL),"Two-compartment final regression equations were as follows: Clearance (CL) = 0.0590 L/kg/hr (multiplied by 0.460 if exposed to dopamine and 0.643 if gestational age was < or = 32 weeks), central volume (VC) = 0.440 L/kg, intercompartmental clearance (Q) = 0.0313 L/hr/kg, and steady-state volume of distribution (Vss) = 0.764 L/kg.",Population pharmacokinetics of vancomycin in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),[l] / [h·kg],0.0590,136997,DB00988,Dopamine
,8062493,central volume (VC),"Two-compartment final regression equations were as follows: Clearance (CL) = 0.0590 L/kg/hr (multiplied by 0.460 if exposed to dopamine and 0.643 if gestational age was < or = 32 weeks), central volume (VC) = 0.440 L/kg, intercompartmental clearance (Q) = 0.0313 L/hr/kg, and steady-state volume of distribution (Vss) = 0.764 L/kg.",Population pharmacokinetics of vancomycin in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),[l] / [kg],0.440,136998,DB00988,Dopamine
,8062493,intercompartmental clearance (Q),"Two-compartment final regression equations were as follows: Clearance (CL) = 0.0590 L/kg/hr (multiplied by 0.460 if exposed to dopamine and 0.643 if gestational age was < or = 32 weeks), central volume (VC) = 0.440 L/kg, intercompartmental clearance (Q) = 0.0313 L/hr/kg, and steady-state volume of distribution (Vss) = 0.764 L/kg.",Population pharmacokinetics of vancomycin in neonates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),[l] / [h·kg],0.0313,136999,DB00988,Dopamine
,8062493,steady-state volume of distribution (Vss),"Two-compartment final regression equations were as follows: Clearance (CL) = 0.0590 L/kg/hr (multiplied by 0.460 if exposed to dopamine and 0.643 if gestational age was < or = 32 weeks), central volume (VC) = 0.440 L/kg, intercompartmental clearance (Q) = 0.0313 L/hr/kg, and steady-state volume of distribution (Vss) = 0.764 L/kg.",Population pharmacokinetics of vancomycin in neonates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),[l] / [kg],0.764,137000,DB00988,Dopamine
,8062493,Residual variability,Residual variability was 3.3 micrograms/ml.,Population pharmacokinetics of vancomycin in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),[μg] / [ml],3.3,137001,DB00988,Dopamine
,8062493,CL,"One-compartment final regression equations were: CL = 0.0626 L/kg/hr (multiplied by 0.455 if exposed to dopamine and 0.656 if gestational age was < or = 32 weeks), and Vd = 0.496 L/kg.",Population pharmacokinetics of vancomycin in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),[l] / [h·kg],0.0626,137002,DB00988,Dopamine
,8062493,Vd,"One-compartment final regression equations were: CL = 0.0626 L/kg/hr (multiplied by 0.455 if exposed to dopamine and 0.656 if gestational age was < or = 32 weeks), and Vd = 0.496 L/kg.",Population pharmacokinetics of vancomycin in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),[l] / [kg],0.496,137003,DB00988,Dopamine
,8062493,alpha Half-lives,alpha Half-lives of 2.8 to 3.7 hours and beta half-lives of 13.4 to 33.7 hours suggest that some individuals in this neonatal population have considerably longer half-lives than those previously reported.,Population pharmacokinetics of vancomycin in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),h,2.8 to 3.7,137004,DB00988,Dopamine
,8062493,beta half-lives,alpha Half-lives of 2.8 to 3.7 hours and beta half-lives of 13.4 to 33.7 hours suggest that some individuals in this neonatal population have considerably longer half-lives than those previously reported.,Population pharmacokinetics of vancomycin in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8062493/),h,13.4 to 33.7,137005,DB00988,Dopamine
,8268437,clearance,"Pharmacokinetic analysis in 12 children showed a clearance of 3.4 mL/min/kg, a volume of distribution of 1.65 L/kg, and an elimination half-life of 5.75 hours.",Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268437/),[ml] / [kg·min],3.4,137464,DB00988,Dopamine
,8268437,volume of distribution,"Pharmacokinetic analysis in 12 children showed a clearance of 3.4 mL/min/kg, a volume of distribution of 1.65 L/kg, and an elimination half-life of 5.75 hours.",Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268437/),[l] / [kg],1.65,137465,DB00988,Dopamine
,8268437,elimination half-life,"Pharmacokinetic analysis in 12 children showed a clearance of 3.4 mL/min/kg, a volume of distribution of 1.65 L/kg, and an elimination half-life of 5.75 hours.",Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268437/),h,5.75,137466,DB00988,Dopamine
,32010367,Bioavailability,"Bioavailability of the drug - nasal drops were 244.4% compared with the drug ""Madopar 125"".",Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32010367/),%,244.4,138331,DB00988,Dopamine
,10552081,half-life,The fast component of the decay accounted for 40%-50% of the radioactivity and had a half-life of about 5 min.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),min,5,138434,DB00988,Dopamine
,10552081,half-life,The slow component of the decay had a half-life of about 6 h in the subjects not taking carbidopa and 20 h in the patients taking carbidopa.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),h,6,138435,DB00988,Dopamine
,10552081,half-life,The slow component of the decay had a half-life of about 6 h in the subjects not taking carbidopa and 20 h in the patients taking carbidopa.,The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552081/),h,20,138436,DB00988,Dopamine
,23090059,clearance,"The calculated clearance, volume of distribution (V(d)), and elimination half-life were 378 ml/min, 40.7 l, and 97.1 min, respectively.",Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090059/),[ml] / [min],378,138873,DB00988,Dopamine
,23090059,volume of distribution (V(d)),"The calculated clearance, volume of distribution (V(d)), and elimination half-life were 378 ml/min, 40.7 l, and 97.1 min, respectively.",Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090059/),l,40.7,138874,DB00988,Dopamine
,23090059,elimination half-life,"The calculated clearance, volume of distribution (V(d)), and elimination half-life were 378 ml/min, 40.7 l, and 97.1 min, respectively.",Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090059/),min,97.1,138875,DB00988,Dopamine
,17899046,apparent terminal half-life,Plasma concentrations declined in a bi-phased manner with an apparent terminal half-life of 5.2-8.1 h.,"Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: first-in-man study of BAY 63-9044, a new 5-HT1A-receptor agonist with dopamine agonistic properties. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17899046/),h,5.2-8.1,138959,DB00988,Dopamine
<,21508084,t(1/2),"Profiling of AMN082 in rat liver microsomes revealed rapid metabolism (t(1/2) < 1 min) to a major metabolite, N-benzhydrylethane-1,2-diamine (Met-1).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),min,1,139081,DB00988,Dopamine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,323,139082,DB00988,Dopamine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,3020,139083,DB00988,Dopamine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,3410,139084,DB00988,Dopamine
,21508084,binding affinity,"In vitro selectivity profiling of Met-1 demonstrated physiologically relevant transporter binding affinity at serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) (323, 3020, and 3410 nM, respectively); whereas the parent compound AMN082 had appreciable affinity at NET (1385 nM).",The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508084/),nM,1385,139085,DB00988,Dopamine
,22948856,AUC0-∞,"At Day 1, total exposure in PMs was almost three times higher than those in EMs (AUC0-∞ = 11,192 and 3,782 h·ng/mL, respectively; PM/EM ratio = 2.96; p < 0.001).","Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22948856/),[h·ng] / [ml],"11,192",139870,DB00988,Dopamine
,22948856,AUC0-∞,"At Day 1, total exposure in PMs was almost three times higher than those in EMs (AUC0-∞ = 11,192 and 3,782 h·ng/mL, respectively; PM/EM ratio = 2.96; p < 0.001).","Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22948856/),[h·ng] / [ml],"3,782",139871,DB00988,Dopamine
,22815533,K(i),"ABT-288 is a competitive antagonist with high affinity and selectivity for human and rat H(3)Rs (K(i) = 1.9 and 8.2 nM, respectively) that enhances the release of acetylcholine and dopamine in rat prefrontal cortex.","Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22815533/),nM,1.9,140018,DB00988,Dopamine
,22815533,K(i),"ABT-288 is a competitive antagonist with high affinity and selectivity for human and rat H(3)Rs (K(i) = 1.9 and 8.2 nM, respectively) that enhances the release of acetylcholine and dopamine in rat prefrontal cortex.","Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22815533/),nM,8.2,140019,DB00988,Dopamine
,22815533,oral bioavailability,"ABT-288 demonstrated a number of other favorable attributes, including good pharmacokinetics and oral bioavailability of 37 to 66%, with a wide central nervous system and cardiovascular safety margin.","Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22815533/),%,37 to 66,140020,DB00988,Dopamine
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,71.0,140211,DB00988,Dopamine
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,54.0,140212,DB00988,Dopamine
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,74.4,140213,DB00988,Dopamine
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,65.4,140214,DB00988,Dopamine
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,81.5,140215,DB00988,Dopamine
,16513859,occupancy,"Mean post- and preinjection D(2) occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively.",A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513859/),%,75.0,140216,DB00988,Dopamine
,9181602,bioavailable,The intramuscular administration of metoclopramide was also about 100% bioavailable compared to the intravenous route of administration.,"Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181602/),%,100,140484,DB00988,Dopamine
,7885353,Maximal plasma apomorphine concentration,"Maximal plasma apomorphine concentration (25.04 ng/ml) is found 20 min after subcutaneous injection (50 micrograms/kg), and the mean area under the curve is 1,439.37 ng/ml for 120 min.",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],25.04,142039,DB00988,Dopamine
,7885353,area under the curve,"Maximal plasma apomorphine concentration (25.04 ng/ml) is found 20 min after subcutaneous injection (50 micrograms/kg), and the mean area under the curve is 1,439.37 ng/ml for 120 min.",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],"1,439.37",142040,DB00988,Dopamine
,7885353,maximal ventricular CSF apomorphine concentration,"In contrast to plasma values, the maximal ventricular CSF apomorphine concentration (1.08 ng/ml) is found 30 min after injection and the mean area under that curve is 7% of that of plasma (96.69 ng/ml for 120 min).",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],1.08,142041,DB00988,Dopamine
,7885353,area under that curve,"In contrast to plasma values, the maximal ventricular CSF apomorphine concentration (1.08 ng/ml) is found 30 min after injection and the mean area under that curve is 7% of that of plasma (96.69 ng/ml for 120 min).",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),,7,142042,DB00988,Dopamine
,7885353,area under that curve,"In contrast to plasma values, the maximal ventricular CSF apomorphine concentration (1.08 ng/ml) is found 30 min after injection and the mean area under that curve is 7% of that of plasma (96.69 ng/ml for 120 min).",Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885353/),[ng] / [ml],96.69,142043,DB00988,Dopamine
,12404702,bioavailability,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,48,142126,DB00988,Dopamine
,12404702,protein binding,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,17,142127,DB00988,Dopamine
,12404702,elimination half-life,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),h,12,142128,DB00988,Dopamine
,24267481,plasma dopamine,"The median (range) baseline CSF dopamine level for the combined control and dopamine groups (n = 9) was 0.10(0.03-0.16) ng/mL, and baseline plasma dopamine was 0.30(0.13-0.84) ng/mL.",Preterm lambs given intravenous dopamine show increased dopamine in their cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24267481/),[ng] / [m],0.30,142371,DB00988,Dopamine
,10091630,concentrations,"Plasma piribedil concentrations at the end of treatment were 6.74+/-1.10 and 9.31+/-3.33 ng/mL in the 1 PP and 2 PP groups, respectively.","A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10091630/),[ng] / [ml],6.74,142639,DB00988,Dopamine
,10091630,concentrations,"Plasma piribedil concentrations at the end of treatment were 6.74+/-1.10 and 9.31+/-3.33 ng/mL in the 1 PP and 2 PP groups, respectively.","A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10091630/),[ng] / [ml],9.31,142640,DB00988,Dopamine
,34148244,t1/2z,"All trazpiroben doses were rapidly absorbed and eliminated (t1/2z 4-5 hours), and D2 /D3 receptor target engagement confirmed by increased serum prolactin (peaking at trazpiroben 25 mg).","Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34148244/),h,4-5,143701,DB00988,Dopamine
,34148244,volume,"No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182).","Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34148244/),m,88.5,143702,DB00988,Dopamine
,34148244,volume,"No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182).","Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34148244/),m,26.,143703,DB00988,Dopamine
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],19.9,143867,DB00988,Dopamine
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],6.2,143868,DB00988,Dopamine
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],22.5,143869,DB00988,Dopamine
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],21.0,143870,DB00988,Dopamine
,16227334,CL,"CL and T(1/2) varied from 3 litre min(-1) and 2 min, respectively, when SAPS II=20 to 0.9 litre min(-1) and 6.8 min when SAPS II=60.",Norepinephrine kinetics and dynamics in septic shock and trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227334/),[l] / [min],3,144950,DB00988,Dopamine
,16227334,T(1/2),"CL and T(1/2) varied from 3 litre min(-1) and 2 min, respectively, when SAPS II=20 to 0.9 litre min(-1) and 6.8 min when SAPS II=60.",Norepinephrine kinetics and dynamics in septic shock and trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227334/),min,2,144951,DB00988,Dopamine
,16227334,T(1/2),"CL and T(1/2) varied from 3 litre min(-1) and 2 min, respectively, when SAPS II=20 to 0.9 litre min(-1) and 6.8 min when SAPS II=60.",Norepinephrine kinetics and dynamics in septic shock and trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16227334/),min,6.8,144952,DB00988,Dopamine
,2682731,halflife time,Acute pharmacokinetic data showed a wide interindividual range with a mean halflife time of 6.0 h.,Clozapine--pharmacokinetic investigations and biochemical effects in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2682731/),h,6.0,145385,DB00988,Dopamine
,12444812,peak D(2) occupancy,"Quetiapine administration led to a mean peak D(2) occupancy of 62% +/- 10% 2 hours postdose, which declined to 14% +/- 8% approximately 20 hours postdose.",Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12444812/),%,62,146182,DB00988,Dopamine
,12444812,peak D(2) occupancy,"Quetiapine administration led to a mean peak D(2) occupancy of 62% +/- 10% 2 hours postdose, which declined to 14% +/- 8% approximately 20 hours postdose.",Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12444812/),%,14,146183,DB00988,Dopamine
,9453072,maximum concentrations,The maximum concentrations that were attained were related to the applied current density: 1.3 +/- 0.6 ng.,Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9453072/),ng,1.3,146499,DB00988,Dopamine
,15039292,clearance,"Using an alternative method, based on normalization of in vitro human data with the ratio of in vivo to in vitro animal data, the in vivo clearance in humans was predicted to be 0.39 l/h/kg.","Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039292/),[l] / [h·kg],0.39,147080,DB00988,Dopamine
,29478239,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7.,"A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),h,3.35,149136,DB00988,Dopamine
,29478239,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7.,"A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),h,3.19,149137,DB00988,Dopamine
,29478239,Cmax,"Geometric mean Cmax and area under the plasma concentration-time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively.","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),[ng] / [ml],92.51,149138,DB00988,Dopamine
,29478239,area under the plasma concentration-time profile from time 0 to 24 h,"Geometric mean Cmax and area under the plasma concentration-time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively.","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),[h·ng] / [ml],1626,149139,DB00988,Dopamine
,1349751,elimination half-life,"SCH 23390 (0.25 mg/kg, SC) had a very short elimination half-life of about 30 min in plasma, and disappeared in a slightly slower manner from striatum and cortex.","Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1349751/),min,30,149592,DB00988,Dopamine
,1349751,elimination half-life,"SCH 39166 (0.25 and 2.5 mg/kg, SC), however, had a longer elimination half-life of about 1.5-2.5 h in plasma and brain.","Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1349751/),h,1.5-2.5,149593,DB00988,Dopamine
,2354553,steady state concentrations,2. In patients and volunteers steady state concentrations of free DA showing fairly large inter-individual variations (12.4-73.4 micrograms/L) were reached within 10 min of the beginning of the infusion.,Dopamine infusion in healthy subjects and critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[μg] / [l],12.4-73.4,150239,DB00988,Dopamine
,2354553,steady state concentrations,In patients steady state concentrations of conjugated DA (63-80 micrograms/L) were reached within 5-10 h of DA infusion.,Dopamine infusion in healthy subjects and critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[μg] / [l],63-80,150240,DB00988,Dopamine
,2354553,distribution volumes,The large distribution volumes of 19.8-75 L/kg indicate that DA has been taken up by peripheral tissues.,Dopamine infusion in healthy subjects and critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[l] / [kg],19.8-75,150241,DB00988,Dopamine
,2354553,clearance,5. Substantial inter-individual variations in the patients' clearance of free DA (3.9-16.5 L/kg per h) may partly explain the variability in haemodynamic responses to DA infusion reported in clinical studies.,Dopamine infusion in healthy subjects and critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[l] / [h·kg],3.9-16.5,150242,DB00988,Dopamine
,1974290,t 1/2 alpha,"By the i.v. route, elimination followed apparent first order kinetics and was biphasic with a t 1/2 alpha of 7 min and terminal half-life of 67 min.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,7,150493,DB00988,Dopamine
,1974290,terminal half-life,"By the i.v. route, elimination followed apparent first order kinetics and was biphasic with a t 1/2 alpha of 7 min and terminal half-life of 67 min.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,67,150494,DB00988,Dopamine
,1974290,t 1/2 ab,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,6,150495,DB00988,Dopamine
,1974290,terminal half-life,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,65,150496,DB00988,Dopamine
,1974290,bioavailability,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),%,40,150497,DB00988,Dopamine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],82,150674,DB00988,Dopamine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],85,150675,DB00988,Dopamine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],128,150676,DB00988,Dopamine
,16413248,steady-state maximum concentration,"Simulations predicted steady-state maximum concentration values of 82 ng/mL (95% CI, 70-95 ng/mL), 85 ng/mL (95% CI, 70-101 ng/mL), and 128 ng/mL (95% CI, 109-147 ng/mL) in healthy subjects, those with mild renal impairment, and those with moderate renal impairment, respectively, for the recommended dosing regimen of 10 mg twice daily; for subjects with severe renal impairment, a steady-state maximum concentration value of 84 ng/mL (95% CI, 68-101 ng/mL) was predicted for a dosing regimen of 5 mg twice daily.",Pharmacokinetic study of memantine in healthy and renally impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413248/),[ng] / [ml],84,150677,DB00988,Dopamine
<,12393160,peak,"The first-order rate constant for DA clearance, which reflects the V(max)/K(m) ratio or clearance efficiency, did not vary significantly when small volumes of DA were ejected resulting in peak DA signal amplitudes (A(max)) of <5 microM.",Kinetic analysis of striatal clearance of exogenous dopamine recorded by chronoamperometry in freely-moving rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393160/),μM,5,150777,DB00988,Dopamine
,3411618,peak plasma rH-TNF levels,Pharmacokinetic studies using an enzyme-linked immunosorbent assay demonstrated peak plasma rH-TNF levels of 90-900 pg/mL.,Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411618/),[pg] / [ml],90-900,150826,DB00988,Dopamine
,1355542,systemic extraction ratio,"When L-dopa was administered into the vascular perfusate, a systemic extraction ratio of 0.38 was found, the major part being decarboxylated to dopamine.",Decarboxylation of L-dopa in the rat isolated vascularly perfused small intestine: contribution to systemic elimination and dose-dependent first pass effect. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355542/),,0.38,150936,DB00988,Dopamine
,1355542,clearance,The intestinal L-dopa clearance was estimated to be 17.1 mL min-1 kg-1.,Decarboxylation of L-dopa in the rat isolated vascularly perfused small intestine: contribution to systemic elimination and dose-dependent first pass effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355542/),[ml] / [kg·min],17.1,150937,DB00988,Dopamine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0.50,151070,DB00988,Dopamine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0.75,151071,DB00988,Dopamine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0.28,151072,DB00988,Dopamine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0. 67,151073,DB00988,Dopamine
<,20740670,oral bioavailability,"Apomorphine, a dopamine receptor agonist for treating Parkinson's disease, has very poor oral bioavailability (<2%) due to the first-pass effect.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),%,2,151760,DB00988,Dopamine
,20740670,diameters,"Mean diameters of the GMS and PMS systems were 155 and 63 nm, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),nm,155,151761,DB00988,Dopamine
,20740670,diameters,"Mean diameters of the GMS and PMS systems were 155 and 63 nm, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),nm,63,151762,DB00988,Dopamine
,20740670,total number of rotations,"The total number of rotations increased from 20 to 94 and from 20 to 115 when the drug was administered from SLNs containing GMS and PMS, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),,20 to 94,151763,DB00988,Dopamine
,20740670,total number of rotations,"The total number of rotations increased from 20 to 94 and from 20 to 115 when the drug was administered from SLNs containing GMS and PMS, respectively.",Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740670/),,20 to 115,151764,DB00988,Dopamine
,2906602,maximum concentrations,The maximum concentrations of free DA in plasma after oral administration of TA-870 were 150 ng/ml in the rat (30 mg/kg) and 234 ng/ml in the dog (33.5 mg/kg).,"Comparative study on the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine hydrochloride in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906602/),[ng] / [ml],150,152015,DB00988,Dopamine
,2906602,maximum concentrations,The maximum concentrations of free DA in plasma after oral administration of TA-870 were 150 ng/ml in the rat (30 mg/kg) and 234 ng/ml in the dog (33.5 mg/kg).,"Comparative study on the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine hydrochloride in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906602/),[ng] / [ml],234,152016,DB00988,Dopamine
,2906602,maximum plasma concentrations,"On the contrary, the maximum plasma concentrations after oral administration of DA at an equimolar dose to TA-870 were 12 ng/ml in the rat (12 mg/kg) and 36 ng/ml in the dog (13.5 mg/kg).","Comparative study on the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine hydrochloride in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906602/),[ng] / [ml],12,152017,DB00988,Dopamine
,2906602,maximum plasma concentrations,"On the contrary, the maximum plasma concentrations after oral administration of DA at an equimolar dose to TA-870 were 12 ng/ml in the rat (12 mg/kg) and 36 ng/ml in the dog (13.5 mg/kg).","Comparative study on the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine hydrochloride in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906602/),[ng] / [ml],36,152018,DB00988,Dopamine
,2906602,total recoveries,The total recoveries of radioactivity in the urine and feces were 91-96% of the dose within 24 hr for both compounds.,"Comparative study on the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine hydrochloride in rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906602/),%,91-96,152019,DB00988,Dopamine
,25747988,maximum concentrations,The maximum concentrations of THP and THB in brain following multiple oral DA-9701 for 7 d (150 mg/kg/d) was observed at 30 min after the last oral DA-9701 treatment: 131±67.7 ng/g for THP and 6.97±4.03 ng/g for THB.,"Pharmacokinetics and brain distribution of tetrahydropalmatine and tetrahydroberberine after oral administration of DA-9701, a new botanical gastroprokinetic agent, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25747988/),[ng] / [g],131,152515,DB00988,Dopamine
,25747988,maximum concentrations,The maximum concentrations of THP and THB in brain following multiple oral DA-9701 for 7 d (150 mg/kg/d) was observed at 30 min after the last oral DA-9701 treatment: 131±67.7 ng/g for THP and 6.97±4.03 ng/g for THB.,"Pharmacokinetics and brain distribution of tetrahydropalmatine and tetrahydroberberine after oral administration of DA-9701, a new botanical gastroprokinetic agent, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25747988/),[ng] / [g],6.97,152516,DB00988,Dopamine
greater,25747988,brain-to-plasma concentration ratios,"Although both THP and THB pass through the blood-brain barrier, as indicated by brain-to-plasma concentration ratios greater than unity (approximately 2-4), oral administration of DA-9701 at the effective dose in humans is not expected to lead to sufficient brain concentrations to exert central dopamine D2 receptor antagonism.","Pharmacokinetics and brain distribution of tetrahydropalmatine and tetrahydroberberine after oral administration of DA-9701, a new botanical gastroprokinetic agent, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25747988/),,2-4,152517,DB00988,Dopamine
,15918525,AUC0-60h,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[h·ng] / [ml],17.21,154001,DB00988,Dopamine
,15918525,AUC0-60h,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[h·ng] / [ml],17.31,154002,DB00988,Dopamine
,15918525,Cmax,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[ng] / [ml],0.87,154003,DB00988,Dopamine
,15918525,Cmax,"The geometric means of AUC0-60h and Cmax between test and reference formulations were 17.21 +/- 8.26 ng x h/mL vs 17.31 +/- 13.24 ng x h/mL and 0.87 +/- 0.74 ng/mL vs 0.85 +/- 0.62 ng/mL, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[ng] / [ml],0.85,154004,DB00988,Dopamine
,15918525,AUCinf,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[h·ng] / [ml],21.75,154005,DB00988,Dopamine
,15918525,t1/2,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),l,12.90,154006,DB00988,Dopamine
,15918525,Vd/F,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),l,12.90,154007,DB00988,Dopamine
,15918525,CL/F,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[l] / [h],0.26,154008,DB00988,Dopamine
,15918525,CL/F,"The geometric means of other pharmacokinetic parameters (AUCinf, t1/2, Vd/F, and CL/F) between test drug and reference drug were 21.75 +/- 8.50 ng x h/mL vs 21.77 +/- 15.63 ng x h/mL, 29.87 +/- 8.25 h vs 29.60 +/- 7.56 h, 11.51 +/- 5.45 L vs 12.90 +/- 6.12 L and 0.26 +/- 0.09 L/h vs 0.31 +/- 0.17 L/h, respectively.",Pharmacokinetics and bioequivalence of haloperidol tablet by liquid chromatographic mass spectrometry with electrospray ionization. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918525/),[l] / [h],0.31,154009,DB00988,Dopamine
,3701908,total dose,An estimated total dose of 1.2 gm.,Intravenous lidocaine overdosage in a child. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701908/),gm,1.2,154160,DB00988,Dopamine
,10508450,area under the curve (AUC,The serum samples gave a significantly higher mean area under the curve (AUC; 491 +/- 139 micromol.,"Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508450/),μM,491,154333,DB00988,Dopamine
,10508450,protein binding,"min/L), suggesting a protein binding of 50%.","Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508450/),%,50,154334,DB00988,Dopamine
<,9844789,plasma half-life,Pharmacokinetic studies yielded a plasma half-life < 5 minutes.,Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9844789/),min,5,154559,DB00988,Dopamine
,21839863,entrapment efficiency,The NP were 91.2±5.2 nm in diameter and had entrapment efficiency 68.91±2.31%.,Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21839863/),%,68.91,154959,DB00988,Dopamine
,8527292,tmax,"In the evaluated dose range of MK-0476 (20 to 800 mg) the median value of tmax ranged from 2 to 4 h, while the apparent t1/2 value averaged 4 to 5 h.","Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527292/),h,2 to 4,155477,DB00988,Dopamine
,8527292,apparent t1/2,"In the evaluated dose range of MK-0476 (20 to 800 mg) the median value of tmax ranged from 2 to 4 h, while the apparent t1/2 value averaged 4 to 5 h.","Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527292/),h,4 to 5,155478,DB00988,Dopamine
,21548660,C(max),"Etamicastat C(max), AUC(last), and AUC(∞) were 229 ng/mL, 1856 ng · h/mL, and 2238 ng · h/mL, respectively, following etamicastat in the fasting, and 166 ng/mL, 1737 ng · h/mL, and 2119 ng · h/mL, respectively, following etamicastat in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[ng] / [ml],229,155732,DB00988,Dopamine
,21548660,AUC(last),"Etamicastat C(max), AUC(last), and AUC(∞) were 229 ng/mL, 1856 ng · h/mL, and 2238 ng · h/mL, respectively, following etamicastat in the fasting, and 166 ng/mL, 1737 ng · h/mL, and 2119 ng · h/mL, respectively, following etamicastat in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],1856,155733,DB00988,Dopamine
,21548660,AUC(last),"Etamicastat C(max), AUC(last), and AUC(∞) were 229 ng/mL, 1856 ng · h/mL, and 2238 ng · h/mL, respectively, following etamicastat in the fasting, and 166 ng/mL, 1737 ng · h/mL, and 2119 ng · h/mL, respectively, following etamicastat in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[ng] / [ml],166,155734,DB00988,Dopamine
,21548660,AUC(last),"Etamicastat C(max), AUC(last), and AUC(∞) were 229 ng/mL, 1856 ng · h/mL, and 2238 ng · h/mL, respectively, following etamicastat in the fasting, and 166 ng/mL, 1737 ng · h/mL, and 2119 ng · h/mL, respectively, following etamicastat in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],1737,155735,DB00988,Dopamine
,21548660,AUC(∞),"Etamicastat C(max), AUC(last), and AUC(∞) were 229 ng/mL, 1856 ng · h/mL, and 2238 ng · h/mL, respectively, following etamicastat in the fasting, and 166 ng/mL, 1737 ng · h/mL, and 2119 ng · h/mL, respectively, following etamicastat in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],2238,155736,DB00988,Dopamine
,21548660,AUC(∞),"Etamicastat C(max), AUC(last), and AUC(∞) were 229 ng/mL, 1856 ng · h/mL, and 2238 ng · h/mL, respectively, following etamicastat in the fasting, and 166 ng/mL, 1737 ng · h/mL, and 2119 ng · h/mL, respectively, following etamicastat in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],2119,155737,DB00988,Dopamine
,21548660,C(max),"The C(max), AUC(last), and AUC(∞) values of the inactive metabolite BIA 5-961 were 275 ng/mL, 1827 ng · h/mL, and 2009 ng · h/mL, respectively, in the fasting, and 172 ng/mL, 1450 ng · h/mL, and 1677 ng · h/mL, respectively, in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[ng] / [ml],275,155738,DB00988,Dopamine
,21548660,AUC(last),"The C(max), AUC(last), and AUC(∞) values of the inactive metabolite BIA 5-961 were 275 ng/mL, 1827 ng · h/mL, and 2009 ng · h/mL, respectively, in the fasting, and 172 ng/mL, 1450 ng · h/mL, and 1677 ng · h/mL, respectively, in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],1827,155739,DB00988,Dopamine
,21548660,AUC(last),"The C(max), AUC(last), and AUC(∞) values of the inactive metabolite BIA 5-961 were 275 ng/mL, 1827 ng · h/mL, and 2009 ng · h/mL, respectively, in the fasting, and 172 ng/mL, 1450 ng · h/mL, and 1677 ng · h/mL, respectively, in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[ng] / [ml],172,155740,DB00988,Dopamine
,21548660,AUC(last),"The C(max), AUC(last), and AUC(∞) values of the inactive metabolite BIA 5-961 were 275 ng/mL, 1827 ng · h/mL, and 2009 ng · h/mL, respectively, in the fasting, and 172 ng/mL, 1450 ng · h/mL, and 1677 ng · h/mL, respectively, in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],1450,155741,DB00988,Dopamine
,21548660,AUC(∞),"The C(max), AUC(last), and AUC(∞) values of the inactive metabolite BIA 5-961 were 275 ng/mL, 1827 ng · h/mL, and 2009 ng · h/mL, respectively, in the fasting, and 172 ng/mL, 1450 ng · h/mL, and 1677 ng · h/mL, respectively, in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],2009,155742,DB00988,Dopamine
,21548660,AUC(∞),"The C(max), AUC(last), and AUC(∞) values of the inactive metabolite BIA 5-961 were 275 ng/mL, 1827 ng · h/mL, and 2009 ng · h/mL, respectively, in the fasting, and 172 ng/mL, 1450 ng · h/mL, and 1677 ng · h/mL, respectively, in the fed condition.",Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21548660/),[h·ng] / [ml],1677,155743,DB00988,Dopamine
,19339028,Cp,PropCp reached 7.65+/-2.1 microg ml(-1) at the end of the study.,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),[μg] / [ml],7.65,156197,DB00988,Dopamine
,19339028,CSI,CSI values at T0 were 89.2+/-3.8.,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),,89.2,156198,DB00988,Dopamine
,19339028,HR,MAP decreased significantly from T0 until loss of corneal reflex (from 98+/-14 mm Hg to 82+/-12 mm Hg); HR did not change significantly (from 101+/-30 bpm to 113+/-16 bpm).,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),bpm,101,156199,DB00988,Dopamine
,19339028,HR,MAP decreased significantly from T0 until loss of corneal reflex (from 98+/-14 mm Hg to 82+/-12 mm Hg); HR did not change significantly (from 101+/-30 bpm to 113+/-16 bpm).,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),bpm,113,156200,DB00988,Dopamine
,21507153,K(i-High),"In vitro receptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors with K(i-High) (0.68 × 10(-4) nM) and K(i-Low) (2.11 nM), and displays > 150-fold selectivity for D3 over D2 receptors and > 1000-fold selectivity for D3 over other DA receptors.","YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21507153/),nM,0.68 × 10(-4),157373,DB00988,Dopamine
,21507153,K(i-Low),"In vitro receptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors with K(i-High) (0.68 × 10(-4) nM) and K(i-Low) (2.11 nM), and displays > 150-fold selectivity for D3 over D2 receptors and > 1000-fold selectivity for D3 over other DA receptors.","YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21507153/),nM,2.11,157374,DB00988,Dopamine
,17410120,maximum increases,"Mean maximum increases in the QTc interval following thioridazine (37.3+/-4.1 ms, P=0.023) and mesoridazine (46.6+/-7.4 ms, P=0.021) were similar and significantly greater than following placebo (12.9+/-8.1 ms).",Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410120/),ms,37.3,157564,DB00988,Dopamine
,17410120,maximum increases,"Mean maximum increases in the QTc interval following thioridazine (37.3+/-4.1 ms, P=0.023) and mesoridazine (46.6+/-7.4 ms, P=0.021) were similar and significantly greater than following placebo (12.9+/-8.1 ms).",Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410120/),ms,46.6,157565,DB00988,Dopamine
,17410120,maximum increases,"Mean maximum increases in the QTc interval following thioridazine (37.3+/-4.1 ms, P=0.023) and mesoridazine (46.6+/-7.4 ms, P=0.021) were similar and significantly greater than following placebo (12.9+/-8.1 ms).",Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410120/),ms,12.9,157566,DB00988,Dopamine
,17410120,area under the effect-time curve over 8 h,The area under the effect-time curve over 8 h following drug administration was similar between the two drugs (129.3+/-22.1 vs 148.3+/-43.0 ms h).,Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410120/),h·ms,129.3,157567,DB00988,Dopamine
,17410120,area under the effect-time curve over 8 h,The area under the effect-time curve over 8 h following drug administration was similar between the two drugs (129.3+/-22.1 vs 148.3+/-43.0 ms h).,Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410120/),h·ms,148.3,157568,DB00988,Dopamine
,29959802,Cmax,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,88.4,157833,DB00988,Dopamine
,29959802,AUC0-t,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.5,157834,DB00988,Dopamine
,29959802,AUC0-inf,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.6,157835,DB00988,Dopamine
,33296447,zeta potential,The mean (SD) size of levodopa microparticles was 0.5 (0.05) µm with polydispersity index of 0.41 and a zeta potential of 10.8 mV.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),mv,10.8,158058,DB00988,Dopamine
,33296447,drug loading capacity,"Of the expected 20% drug loading, the actual drug loading capacity of levodopa microparticles was found to be 19.1%, giving an encapsulation efficiency of 95.7%.",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),%,19.1,158059,DB00988,Dopamine
,33296447,AUC,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[h·ng] / [ml],612.7,158060,DB00988,Dopamine
,33296447,Cmax,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[ng] / [ml],262.4,158061,DB00988,Dopamine
,33296447,AUC,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[h·ng] / [ml],354.7,158062,DB00988,Dopamine
,33296447,Cmax,In vivo pharmacokinetic studies showed that rats administered levodopa/carbidopa microparticles had greater AUC (612.7 [17.42] ng.h/mL) and higher Cmax (262.4 [38.86] ng/mL) compared with Sinemet CR: AUC 354.7 (98.09) ng.h/mL and Cmax 95.5 (20.87) ng/mL.,Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),[ng] / [ml],95.5,158063,DB00988,Dopamine
,33296447,half-life,"However, Sinemet CR had a much longer half-life (6.1 [2.58] hours) compared with levodopa/carbidopa microparticles (2.0 [0.31] hours).",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),h,6.1,158064,DB00988,Dopamine
,33296447,half-life,"However, Sinemet CR had a much longer half-life (6.1 [2.58] hours) compared with levodopa/carbidopa microparticles (2.0 [0.31] hours).",Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33296447/),h,2.0,158065,DB00988,Dopamine
,2391608,Plasma dopamine concentration,Plasma dopamine concentration ranged from 0.5 ng/ml before infusion to almost 70 ng/ml at an infusion rate of 4 to 8 micrograms/kg/min.,Pharmacokinetics of dopamine in critically ill newborn infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391608/),[ng] / [ml],0.5,158163,DB00988,Dopamine
,2391608,Plasma dopamine concentration,Plasma dopamine concentration ranged from 0.5 ng/ml before infusion to almost 70 ng/ml at an infusion rate of 4 to 8 micrograms/kg/min.,Pharmacokinetics of dopamine in critically ill newborn infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391608/),[ng] / [ml],70,158164,DB00988,Dopamine
,30446407,plasma concentration-to-daily dose ratio (C/D),"Median PRA plasma concentration-to-daily dose ratio (C/D) [(ng/mL)/(mg/kg/d)] was 68% higher in patients >65 years than ≤65 years (158 vs 94, p < 0.001), while was not affected by age in ROP and ROT subgroups.","Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30446407/),[ml·ng] / [d·kg·mg],158,159554,DB00988,Dopamine
,30446407,plasma concentration-to-daily dose ratio (C/D),"Median PRA plasma concentration-to-daily dose ratio (C/D) [(ng/mL)/(mg/kg/d)] was 68% higher in patients >65 years than ≤65 years (158 vs 94, p < 0.001), while was not affected by age in ROP and ROT subgroups.","Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30446407/),[ml·ng] / [d·kg·mg],94,159555,DB00988,Dopamine
,19805643,excretion,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[nM] / [24·h],52,160613,DB00988,Dopamine
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.25,160614,DB00988,Dopamine
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.22,160615,DB00988,Dopamine
,10213983,striatum-to-frontal cortex count ratio (-1) (St/Fc-1),"The striatum-to-frontal cortex count ratio (-1) (St/Fc-1), which is a semi-quantitative index of the binding potential of 123I-IBF reached 1.81 +/- 0.19 and 2.21 +/- 0.39 at 90-120 min and 180-210 min after intravenous injection of 123I-IBF.","[Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating Dopamine D2 receptor with SPECT (II); pharmacokinetics study and quantification in the brain]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213983/),,1.81,161435,DB00988,Dopamine
,10213983,striatum-to-frontal cortex count ratio (-1) (St/Fc-1),"The striatum-to-frontal cortex count ratio (-1) (St/Fc-1), which is a semi-quantitative index of the binding potential of 123I-IBF reached 1.81 +/- 0.19 and 2.21 +/- 0.39 at 90-120 min and 180-210 min after intravenous injection of 123I-IBF.","[Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating Dopamine D2 receptor with SPECT (II); pharmacokinetics study and quantification in the brain]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213983/),,2.21,161436,DB00988,Dopamine
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,7,161535,DB00988,Dopamine
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,14,161536,DB00988,Dopamine
,18719048,C(max),"Compared with 5-HTP/CBD/placebo, granisetron addition decreased C(max) of 5-HTP statistically significantly different (from 1483 to 1272 ng/ml) without influencing AUC(0- infinity).",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),[ng] / [ml],1483,161537,DB00988,Dopamine
,32399634,overall elimination half-life,Naphyrone pharmacokinetics followed a two-compartment model with an overall elimination half-life of 0.3 h.,The neurobehavioral effects of the designer drug naphyrone - an experimental investigation with pharmacokinetics and concentration/effect relationship in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399634/),h,0.3,161634,DB00988,Dopamine
,32399634,EC50,The naphyrone concentration/locomotor effect relationship was described by an additive Emax model with an EC50 of 672 μg/L.,The neurobehavioral effects of the designer drug naphyrone - an experimental investigation with pharmacokinetics and concentration/effect relationship in mice. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32399634/),[μg] / [l],672,161635,DB00988,Dopamine
,6865894,MCR,The DBH MCR computed by stochastic analysis of the disappearance curve of injected DBH activity was about 1.0 ml/hr/100 g body weight; the mean transit time of DBH was about 8 hr.,Metabolic clearance rate of dopamine beta-hydroxylase in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6865894/),[ml] / [100·h],1.0,161817,DB00988,Dopamine
,6865894,mean transit time,The DBH MCR computed by stochastic analysis of the disappearance curve of injected DBH activity was about 1.0 ml/hr/100 g body weight; the mean transit time of DBH was about 8 hr.,Metabolic clearance rate of dopamine beta-hydroxylase in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6865894/),h,8,161818,DB00988,Dopamine
,6865894,MCR,"The disappearance curve of heterologous enzyme (bovine DBH) was more rapid than that of the rat, yielding an MCR of about 8 ml/hr/100 g body weight.",Metabolic clearance rate of dopamine beta-hydroxylase in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6865894/),[ml] / [100·g·h],8,161819,DB00988,Dopamine
,28547577,concentration,"The initial plasma pramipexole concentration was 34.2 ng/mL (therapeutic range 0.2 to 7 ng/mL), 9 h post-overdose.","Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),[ng] / [ml],34.2,162674,DB00988,Dopamine
,28547577,elimination half-life,Concentration time data fitted a one-compartment model with an estimated elimination half-life of 18 h.,"Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),h,18,162675,DB00988,Dopamine
,19237512,ratio of renal clearance to plasma clearance,"Overall the present study showed that 1) absorption of PNU96391 from the gastrointestinal tract was near complete (>90% of the dose), 2) PNU96391 was predominantly metabolized to M1 (approximately 70% of the dose), and 3) M1 was exclusively eliminated into urine with negligible biotransformation (ratio of renal clearance to plasma clearance approximately 0.9).","Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19237512/),,0,164247,DB00988,Dopamine
,10219970,Terminal phase elimination half-lives,"Terminal phase elimination half-lives for the compound were relatively short (0.5 and 1.3 h in rat and monkey respectively), although there was evidence of a second elimination phase in the monkey with an elimination half-life of approximately 5-11 h.",Disposition of ropinirole in animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219970/),h,0.5,164410,DB00988,Dopamine
,10219970,Terminal phase elimination half-lives,"Terminal phase elimination half-lives for the compound were relatively short (0.5 and 1.3 h in rat and monkey respectively), although there was evidence of a second elimination phase in the monkey with an elimination half-life of approximately 5-11 h.",Disposition of ropinirole in animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219970/),h,1.3,164411,DB00988,Dopamine
,10219970,elimination half-life,"Terminal phase elimination half-lives for the compound were relatively short (0.5 and 1.3 h in rat and monkey respectively), although there was evidence of a second elimination phase in the monkey with an elimination half-life of approximately 5-11 h.",Disposition of ropinirole in animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219970/),h,5-11,164412,DB00988,Dopamine
,10691218,Plasma concentrations,"Plasma concentrations of dopamine varied from 12,300 to 201,500 ng/l after 10 min of dopamine infusion at 10 microg x kg(-1) x min(-1).",Pharmacokinetics of dopamine in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691218/),[ng] / [l],"12,300 to 201,500",164700,DB00988,Dopamine
,10691218,steady-state dopamine concentrations,"Similarly, steady-state dopamine concentrations varied from 1,880 to 18,300 ng/l in these same subjects receiving 3-microg x kg(-1) x min(-1) infusions for 90 min.",Pharmacokinetics of dopamine in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691218/),[ng] / [l],"1,880 to 18,300",164701,DB00988,Dopamine
,20349050,receptor,Dopamine D(2) receptor occupancy in the temporal cortex of patients ranged from 39.6% to 83.8%.,Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,39.6,164711,DB00988,Dopamine
,20349050,receptor,Dopamine D(2) receptor occupancy in the temporal cortex of patients ranged from 39.6% to 83.8%.,Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,83.8,164712,DB00988,Dopamine
,20349050,occupancy,Dopamine D(2) receptor occupancy in the temporal cortex of patients ranged from 39.6% to 83.8%.,Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,39.6,164713,DB00988,Dopamine
,20349050,occupancy,Dopamine D(2) receptor occupancy in the temporal cortex of patients ranged from 39.6% to 83.8%.,Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,83.8,164714,DB00988,Dopamine
over,20349050,occupancy,"Especially, occupancy in two patients who took 16 mg of perospirone 2.5 h before PET was over 70%.",Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,70,164715,DB00988,Dopamine
,20349050,occupancy,"Mean occupancy in the striatum of healthy subjects was 74.8% at 1.5 h, 60.1% at 8 h, and 31.9% at 25.5 h after administration.",Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,74.8,164716,DB00988,Dopamine
,20349050,occupancy,"Mean occupancy in the striatum of healthy subjects was 74.8% at 1.5 h, 60.1% at 8 h, and 31.9% at 25.5 h after administration.",Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,60.1,164717,DB00988,Dopamine
,20349050,occupancy,"Mean occupancy in the striatum of healthy subjects was 74.8% at 1.5 h, 60.1% at 8 h, and 31.9% at 25.5 h after administration.",Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20349050/),%,31.9,164718,DB00988,Dopamine
,20648686,recovery,The recovery of pramipexole from plasma ranged from 82.4 ± 7.1 to 87.8 ± 5.7%.,Development and validation of GC/MS method for determination of pramipexole in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20648686/),%,82.4,165263,DB00988,Dopamine
,20648686,recovery,The recovery of pramipexole from plasma ranged from 82.4 ± 7.1 to 87.8 ± 5.7%.,Development and validation of GC/MS method for determination of pramipexole in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20648686/),%,87.8,165264,DB00988,Dopamine
,28442937,bioavailability,It was found that the coadministration resulted in a significant increase in the bioavailability of STT in the plasma (41.8%) and brain (68.7%) compared to administration of STT alone (p<0.05).,"Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28442937/),%,41.8,166072,DB00988,Dopamine
,28442937,bioavailability,It was found that the coadministration resulted in a significant increase in the bioavailability of STT in the plasma (41.8%) and brain (68.7%) compared to administration of STT alone (p<0.05).,"Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28442937/),%,68.7,166073,DB00988,Dopamine
,10663455,steady-state levels,The steady-state levels averaged 151.3 +/- 8.2 nmol/l.,"Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 h after infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663455/),[nM] / [l],151.3,167521,DB00988,Dopamine
,10663455,initial half-life of elimination,Plasma DA concentrations after cessation of the infusion decreased rapidly with an initial half-life of elimination of 4.8 min.,"Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 h after infusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663455/),min,4.8,167522,DB00988,Dopamine
,10663455,half-life,Concentrations of plasma DA-S declined with a half-life of 4.5 h.,"Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 h after infusion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663455/),h,4.5,167523,DB00988,Dopamine
,7735207,peak concentration,"The dopamine concentration in the striatum increased immediately after L-dopa injection, with the peak concentration (15.9 +/- 0.5 micrograms/g) occurring at 3 min; then it returned to the pre-medication level until 2 h at 100 mg/kg dosing.",Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat striatum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735207/),[μg] / [g],15.9,167895,DB00988,Dopamine
,11599591,recovery,Cocaine recovery was 94.4% and benzoylecgonine was 80.3% at 2.5 ng/mL.,A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599591/),%,94.4,168316,DB00988,Dopamine
,11599591,recovery,Cocaine recovery was 94.4% and benzoylecgonine was 80.3% at 2.5 ng/mL.,A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599591/),%,80.3,168317,DB00988,Dopamine
,2129121,oral bioavailability,4. The oral bioavailability of gludopa is only 1 to 2% and this rules out the dipeptide as an effective dopaminergic prodrug.,Five years' experience with gamma-L-glutamyl-L-dopa: a relatively renally specific dopaminergic prodrug in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129121/),%,1 to 2,168601,DB00988,Dopamine
,4014357,half-life,"With the use of acute 3H-dopamine injection studies into the amniotic sac of pregnant rhesus monkeys, the dopamine half-life was observed to be 29 minutes, the amniotic fluid volume was 113 ml, the metabolic clearance rate was 164 ml/hr, and the calculated production rate was 436 ng/hr.",Clearance of 3H-dopamine from the amniotic fluid in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014357/),min,29,170157,DB00988,Dopamine
,4014357,metabolic clearance rate,"With the use of acute 3H-dopamine injection studies into the amniotic sac of pregnant rhesus monkeys, the dopamine half-life was observed to be 29 minutes, the amniotic fluid volume was 113 ml, the metabolic clearance rate was 164 ml/hr, and the calculated production rate was 436 ng/hr.",Clearance of 3H-dopamine from the amniotic fluid in the rhesus monkey. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014357/),[ml] / [h],164,170158,DB00988,Dopamine
,4014357,production rate,"With the use of acute 3H-dopamine injection studies into the amniotic sac of pregnant rhesus monkeys, the dopamine half-life was observed to be 29 minutes, the amniotic fluid volume was 113 ml, the metabolic clearance rate was 164 ml/hr, and the calculated production rate was 436 ng/hr.",Clearance of 3H-dopamine from the amniotic fluid in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014357/),[ng] / [h],436,170159,DB00988,Dopamine
,7205625,peak blood ethanol concentration,The mean peak blood ethanol concentration was 3.36 +/- 0.14 mg/ml.,Ethanol and functional tolerance: interactions with pimozide and clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205625/),[mg] / [ml],3.36,170430,DB00988,Dopamine
,7205625,rate of clearance,The rate of clearance of ethanol from blood was found to be 0.34 +/- 0.01 mg/ml/hr in ethanol vapor-treated and control animals when ethanol was administered acutely 48 hr after the inhalation period.,Ethanol and functional tolerance: interactions with pimozide and clonidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205625/),[mg] / [h·ml],0.34,170431,DB00988,Dopamine
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,6,170488,DB00988,Dopamine
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,18,170489,DB00988,Dopamine
,16778727,flow rate,"The elution was achieved isocratically with a mobile phase of 2 mM NH4COOH buffer pH 3.8/acetonitrile (50/50, vol/vol) at a flow rate of 200 microL per minute.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),[μl] / [min],200,170729,DB00988,Dopamine
,16778727,Retention times,"Retention times were 2.03 and 2.11 minutes for boldine and apomorphine, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),min,2.03,170730,DB00988,Dopamine
,16778727,Retention times,"Retention times were 2.03 and 2.11 minutes for boldine and apomorphine, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),min,2.11,170731,DB00988,Dopamine
,16778727,limits of detection,"The limits of detection and quantification were 0.010 ng/mL and 0.025 ng/mL, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),[ng] / [ml],0.010,170732,DB00988,Dopamine
,16778727,limits of detection,"The limits of detection and quantification were 0.010 ng/mL and 0.025 ng/mL, respectively.",Sensitive quantification of apomorphine in human plasma using a LC-ESI-MS-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778727/),[ng] / [ml],0.025,170733,DB00988,Dopamine
,31773210,EC50,The best estimate of the EC50 was 19 ng ml-1 (~ 40 nM).,Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31773210/),[ng] / [ml],19,170947,DB00988,Dopamine
,29036640,serum elimination half-life,"Although serum concentrations at early time points were lacking, the obtained curve was consistent with a two-compartment model and indicated a serum elimination half-life of 37 h.",Toxicokinetics of the Synthetic Cathinone α-Pyrrolidinohexanophenone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29036640/),h,37,171416,DB00988,Dopamine
,10702552,D(a),"D(a) values were similar to D(M) in 10 patients (D(a) approximately D(M) group) (20.52 +/- 8.40 mg/kg/day versus 18.81 +/- 7.24 mg/kg; P = 0.15), whereas much higher dosages were required in the other eight patients (D(a) >>",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [d·kg],20.52,172327,DB00988,Dopamine
,10702552,D(a),"D(a) values were similar to D(M) in 10 patients (D(a) approximately D(M) group) (20.52 +/- 8.40 mg/kg/day versus 18.81 +/- 7.24 mg/kg; P = 0.15), whereas much higher dosages were required in the other eight patients (D(a) >>",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [kg],18.81,172328,DB00988,Dopamine
,10702552,steady-state trough concentration (C(min ss)),D(M) group) (26.78 +/- 3.01 mg/kg/day versus 18.95 +/- 3.41 mg/kg/day; P < 0.0001) despite no major difference in attained vancomycin steady-state trough concentration (C(min ss)) (9.22 +/- 1. 33 mg/L versus 8.99 +/- 1.26 mg/L; = 0.75) or estimated creatinine clearance (1.23 +/- 0.49 mL/min/kg versus 1.21 +/- 0.24 mL/min/kg; P = 0.95) being found between the two groups.,High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],9.22,172329,DB00988,Dopamine
,10702552,steady-state trough concentration (C(min ss)),D(M) group) (26.78 +/- 3.01 mg/kg/day versus 18.95 +/- 3.41 mg/kg/day; P < 0.0001) despite no major difference in attained vancomycin steady-state trough concentration (C(min ss)) (9.22 +/- 1. 33 mg/L versus 8.99 +/- 1.26 mg/L; = 0.75) or estimated creatinine clearance (1.23 +/- 0.49 mL/min/kg versus 1.21 +/- 0.24 mL/min/kg; P = 0.95) being found between the two groups.,High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],8.99,172330,DB00988,Dopamine
,10702552,C(min ss),"D(M) patients the withdrawal of cotreatment with haemodynamically active drugs was followed by a sudden substantial increase in the vancomycin C(min ss) (13.30 +/- 1. 13 mg/L versus 8.79 +/- 0.87 mg/L; P < 0.01), despite no major change in bodyweight or estimated creatinine clearance being observed.",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],13.30,172331,DB00988,Dopamine
,10702552,C(min ss),"D(M) patients the withdrawal of cotreatment with haemodynamically active drugs was followed by a sudden substantial increase in the vancomycin C(min ss) (13.30 +/- 1. 13 mg/L versus 8.79 +/- 0.87 mg/L; P < 0.01), despite no major change in bodyweight or estimated creatinine clearance being observed.",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],8.79,172332,DB00988,Dopamine
,29332198,time lag,"After single-dose administration of rotigotine patches (using 2, 4 or 8 mg/day) in healthy subjects, a constant in vivo absorption was present after a minor time lag (2-3 h).",Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332198/),h,2-3,172550,DB00988,Dopamine
,11303043,bioavailability,The bioavailability of the orally administered cocaine was calculated as 25%.,Pharmacokinetics of cocaine in maternal and fetal rhesus monkeys at mid-gestation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11303043/),%,25,172815,DB00988,Dopamine
,7813574,time to reach this maximum (tmax),"The maximal concentrations (Cmax) differed dose dependently, whereas the time to reach this maximum (tmax) was almost identical (68.5 +/- 3.4 min).",Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813574/),min,68.5,172840,DB00988,Dopamine
,7813574,half-life,From the flat elimination profile a half-life of 2.8 +/- 0.5 h (range 2-3.4 h) was calculated.,Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813574/),h,2.8,172841,DB00988,Dopamine
,1572184,plasma clearance rates,Dobutamine plasma clearance rates ranged from 40 to 130 mL/kg/min.,Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572184/),[ml] / [kg·min],40 to 130,173638,DB00988,Dopamine
,15545306,plasma t(max),"DOV 216,303 was rapidly absorbed (plasma t(max) of 0.7-1.2 hours and t(1/2) of 3.3-4.4 hours), with dose-proportional C(max) and AUC values.","DOV 216,303, a ""triple"" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545306/),h,0.7-1.2,174558,DB00988,Dopamine
,15545306,t(1/2),"DOV 216,303 was rapidly absorbed (plasma t(max) of 0.7-1.2 hours and t(1/2) of 3.3-4.4 hours), with dose-proportional C(max) and AUC values.","DOV 216,303, a ""triple"" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545306/),h,3.3-4.4,174559,DB00988,Dopamine
,1359583,Maximal plasma levels,Maximal plasma levels of 30 pmol.,Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359583/),pM,30,174650,DB00988,Dopamine
,8222680,clearances,"The clearances were independent of the infusion rate at 1, 3, and 6 micrograms/kg/min, and ranged between 0.050 and 0.056 L/min/kg.",Steady-state pharmacokinetics of dopamine in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222680/),[l] / [kg·min],0.050 and 0.056,175386,DB00988,Dopamine
,19475539,potency,"PK/PD modelling after administration of dehydrosertindole resulted in potency estimates of 165 and 424 ng/ml for D(2)-occupancy (Kd) and CAR measurements (EC(50)), respectively.",Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],165,175482,DB00988,Dopamine
,19475539,potency,"PK/PD modelling after administration of dehydrosertindole resulted in potency estimates of 165 and 424 ng/ml for D(2)-occupancy (Kd) and CAR measurements (EC(50)), respectively.",Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],424,175483,DB00988,Dopamine
,19475539,D,"PK/PD modelling after administration of dehydrosertindole resulted in potency estimates of 165 and 424 ng/ml for D(2)-occupancy (Kd) and CAR measurements (EC(50)), respectively.",Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],165,175484,DB00988,Dopamine
,19475539,D,"PK/PD modelling after administration of dehydrosertindole resulted in potency estimates of 165 and 424 ng/ml for D(2)-occupancy (Kd) and CAR measurements (EC(50)), respectively.",Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],424,175485,DB00988,Dopamine
,19475539,half-maximal effect,"Based on this approach, effect compartment concentrations of sertindole needed to attain 50% occupancy and half-maximal effect in the CAR paradigm were 133 and 338 ng/ml, respectively.",Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],133,175486,DB00988,Dopamine
,19475539,half-maximal effect,"Based on this approach, effect compartment concentrations of sertindole needed to attain 50% occupancy and half-maximal effect in the CAR paradigm were 133 and 338 ng/ml, respectively.",Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],338,175487,DB00988,Dopamine
,19475539,potency,The corresponding potency-estimates obtained after conventional modelling of the sertindole data without accounting for the metabolite amounted to 102 and 345 ng/ml.,Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],102,175488,DB00988,Dopamine
,19475539,potency,The corresponding potency-estimates obtained after conventional modelling of the sertindole data without accounting for the metabolite amounted to 102 and 345 ng/ml.,Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19475539/),[ng] / [ml],345,175489,DB00988,Dopamine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,12.0,176883,DB00988,Dopamine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,10.7,176884,DB00988,Dopamine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,11.4,176885,DB00988,Dopamine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,16.2,176886,DB00988,Dopamine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,16,176887,DB00988,Dopamine
,7791104,elimination half-life,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,2.66,177336,DB00988,Dopamine
,7791104,volume of distribution by area,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177337,DB00988,Dopamine
,7791104,AUC,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177338,DB00988,Dopamine
,7791104,t1/2,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177339,DB00988,Dopamine
,24178238,apparent dose,The mean apparent dose of rotigotine was 2.0±0.5 mg for Japanese subjects and 2.08±0.58 mg for Caucasians.,"Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),mg,2.0,177396,DB00988,Dopamine
,24178238,apparent dose,The mean apparent dose of rotigotine was 2.0±0.5 mg for Japanese subjects and 2.08±0.58 mg for Caucasians.,"Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),mg,2.08,177397,DB00988,Dopamine
,24178238,terminal half-life,The terminal half-life for unconjugated rotigotine was 5.3 h in Japanese subjects and 5.7 h in Caucasians; corresponding values for total rotigotine were 8.6 h and 9.6 h.,"Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),h,5.3,177398,DB00988,Dopamine
,24178238,terminal half-life,The terminal half-life for unconjugated rotigotine was 5.3 h in Japanese subjects and 5.7 h in Caucasians; corresponding values for total rotigotine were 8.6 h and 9.6 h.,"Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),h,5.7,177399,DB00988,Dopamine
,24178238,terminal half-life,The terminal half-life for unconjugated rotigotine was 5.3 h in Japanese subjects and 5.7 h in Caucasians; corresponding values for total rotigotine were 8.6 h and 9.6 h.,"Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),h,8.6,177400,DB00988,Dopamine
,24178238,terminal half-life,The terminal half-life for unconjugated rotigotine was 5.3 h in Japanese subjects and 5.7 h in Caucasians; corresponding values for total rotigotine were 8.6 h and 9.6 h.,"Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),h,9.6,177401,DB00988,Dopamine
,24178238,renal elimination,"Renal elimination of total rotigotine covers 11.7% of absorbed dose in Japanese subjects and 10.8% of the absorbed dose in Caucasians, whereas the renal elimination via total despropyl rotigotine was 8.2 and 7.1%, respectively.","Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),%,8.2,177402,DB00988,Dopamine
,24178238,renal elimination,"Renal elimination of total rotigotine covers 11.7% of absorbed dose in Japanese subjects and 10.8% of the absorbed dose in Caucasians, whereas the renal elimination via total despropyl rotigotine was 8.2 and 7.1%, respectively.","Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24178238/),%,7.1,177403,DB00988,Dopamine
,16123749,half-life,"We developed a computer-controlled intravenous methamphetamine (METH) administration procedure (dynamic infusion), which enables us to compensate for an important pharmacokinetic difference between rats and humans by imposing a 12-h half-life for the drug in rats.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h,12,177784,DB00988,Dopamine
,16123749,apparent half-life,"Dynamic infusion of 0.5 mg/kg METH produced a pharmacokinetic profile that closely simulates the METH exposure pattern in humans, including an apparent half-life of 11.6+/-1.3 h, and an area under the concentration vs time curve of 9.4 microM h, about 20-fold larger than results obtained with typical rat pharmacokinetics.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h,11.6,177785,DB00988,Dopamine
,16123749,area under the concentration vs time curve,"Dynamic infusion of 0.5 mg/kg METH produced a pharmacokinetic profile that closely simulates the METH exposure pattern in humans, including an apparent half-life of 11.6+/-1.3 h, and an area under the concentration vs time curve of 9.4 microM h, about 20-fold larger than results obtained with typical rat pharmacokinetics.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h·μM,9.4,177786,DB00988,Dopamine
,22751085,maximum plasma concentration (Cmax),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],14.1,177975,DB00988,Dopamine
,22751085,maximum plasma concentration (Cmax),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],9.7,177976,DB00988,Dopamine
,22751085,plasma concentration at 30 min (C30 min),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],13.7,177977,DB00988,Dopamine
,22751085,plasma concentration at 30 min (C30 min),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],8.1,177978,DB00988,Dopamine
,22751085,area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [h·l],15.9,177979,DB00988,Dopamine
,22751085,area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [h·l],12.1,177980,DB00988,Dopamine
,1672458,AUC,"The mean ""dose corrected"" AUC values for the total concentrations were 96.8 at day 1 (4 X 24.2, 50 mg single oral dose) and 92.2 mumol.h/l at day 15 (200 mg).",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),[h·μM] / [l],96.8,179025,DB00988,Dopamine
,1672458,AUC,"The mean ""dose corrected"" AUC values for the total concentrations were 96.8 at day 1 (4 X 24.2, 50 mg single oral dose) and 92.2 mumol.h/l at day 15 (200 mg).",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),[h·μM] / [l],92.2,179026,DB00988,Dopamine
,1672458,unbound fraction,"The unbound fraction of remoxipride calculated on AUC was slightly higher on day 15 (20%) than on day 1 (15%) (P less than 0.05), indicating slightly concentration-dependent protein binding of the drug.",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),%,20,179027,DB00988,Dopamine
,1672458,unbound fraction,"The unbound fraction of remoxipride calculated on AUC was slightly higher on day 15 (20%) than on day 1 (15%) (P less than 0.05), indicating slightly concentration-dependent protein binding of the drug.",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),%,15,179028,DB00988,Dopamine
,1672458,elimination half-life,"The mean elimination half-life of total remoxipride was slightly longer on day 15 than day 1 (7.5 versus 5.3 h, P less than 0.01) The corresponding half-lives for the unbound concentrations were 6.4 and 3.9 h, respectively (P less than 0.01).",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),h,7.5,179029,DB00988,Dopamine
,1672458,elimination half-life,"The mean elimination half-life of total remoxipride was slightly longer on day 15 than day 1 (7.5 versus 5.3 h, P less than 0.01) The corresponding half-lives for the unbound concentrations were 6.4 and 3.9 h, respectively (P less than 0.01).",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),h,5.3,179030,DB00988,Dopamine
,1672458,half-lives,"The mean elimination half-life of total remoxipride was slightly longer on day 15 than day 1 (7.5 versus 5.3 h, P less than 0.01) The corresponding half-lives for the unbound concentrations were 6.4 and 3.9 h, respectively (P less than 0.01).",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),h,6.4,179031,DB00988,Dopamine
,1672458,half-lives,"The mean elimination half-life of total remoxipride was slightly longer on day 15 than day 1 (7.5 versus 5.3 h, P less than 0.01) The corresponding half-lives for the unbound concentrations were 6.4 and 3.9 h, respectively (P less than 0.01).",Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672458/),h,3.9,179032,DB00988,Dopamine
,29721078,t1/2,"The liposomal nanohybrid cerasome exhibited superior stability towards PS 80 surfactant solubilization and longer circulation lifetime (t1/2 = 6.22 h), much longer than free curcumin (t1/2 = 0.76 h).",Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721078/),h,6.22,179978,DB00988,Dopamine
,29721078,t1/2,"The liposomal nanohybrid cerasome exhibited superior stability towards PS 80 surfactant solubilization and longer circulation lifetime (t1/2 = 6.22 h), much longer than free curcumin (t1/2 = 0.76 h).",Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29721078/),h,0.76,179979,DB00988,Dopamine
,24549007,Cmax,"In the treated horse, Cmax was 0.40ng/mL and the assay easily allowed determination of plasma levels in the elimination phase to 48h.",Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549007/),[ng] / [ml],0.40,183648,DB00988,Dopamine
,19482449,half-life,The median half-life of cocaine in hair was 1.5 months (95% CI 1.2-1.8) in females and 1.5 months (95% CI 1.1-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183710,DB00988,Dopamine
,19482449,half-life,The median half-life of cocaine in hair was 1.5 months (95% CI 1.2-1.8) in females and 1.5 months (95% CI 1.1-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183711,DB00988,Dopamine
,19482449,half-life,The median half-life of BE was 1.5 months (95% CI 1.1-2) in females and 1.5 months (95% CI 0.8-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183712,DB00988,Dopamine
,19482449,half-life,The median half-life of BE was 1.5 months (95% CI 1.1-2) in females and 1.5 months (95% CI 0.8-1.8) in males.,Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1.5,183713,DB00988,Dopamine
over,19482449,half-life,"The calculated half-life of over 1 month for cocaine implies that, assuming first order elimination, approximately 3-4 months have to pass for hair testing to become negative in the segment proximal to the scalp.",Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19482449/),month,1,183714,DB00988,Dopamine
,8331202,biologic half-life,"As the serum creatinine concentration returned slowly to baseline with good diuresis, the concentration of atenolol decreased (biologic half-life = 2.95 days) and the blood pressure gradually recovered.",Impaired elimination of atenolol in a nephropathic patient with self-medication overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8331202/),d,2.95,184252,DB00988,Dopamine
,21503604,EC(50),The EC(50) was 7.6 ng/ml (95% confidence interval (CI) 6.2-9.0) in healthy volunteers and 8.6 (95% CI 7.4-9.9) in patients.,The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21503604/),[ng] / [ml],7.6,186977,DB00988,Dopamine
,21503604,EC(50),The EC(50) was 7.6 ng/ml (95% confidence interval (CI) 6.2-9.0) in healthy volunteers and 8.6 (95% CI 7.4-9.9) in patients.,The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21503604/),[ng] / [ml],8.6,186978,DB00988,Dopamine
,16586462,V(dss),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [kg],18.7,187473,DB00988,Dopamine
,16586462,Cl,"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [h·kg],1.8,187474,DB00988,Dopamine
,16586462,t(1/2),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,7.69,187475,DB00988,Dopamine
,16586462,V(dss),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [kg],17.4,187476,DB00988,Dopamine
,16586462,Cl,"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),[l] / [h·kg],1.9,187477,DB00988,Dopamine
,16586462,t(1/2),"No significant (p< 0.05) differences were found in the PK parameters of AHN 1-055 alone (V(dss) = 18.7 l/kg, Cl = 1.8 l/h/kg and t(1/2) = 7.69 h) or AHN 1-055 with cocaine (V(dss)=17.4 l/kg, Cl = 1.9 l/h/kg and t(1/2) = 6.82 h).","Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,6.82,187478,DB00988,Dopamine
,16586462,B/P,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),,4.8,187479,DB00988,Dopamine
,16586462,B/P,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),,4.4,187480,DB00988,Dopamine
,16586462,half-lives (t(1/2,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,6.2,187481,DB00988,Dopamine
,16586462,t(1/2,The brain-to-plasma (B/P) ratios (B/P(AHN 1-055) = 4.8 vs B/P(with cocaine) = 4.4) and half-lives (t(1/2(AHN 1-055)) = 6.2 h vs t(1/2(cocaine) = )5.6 h for AHN 1-055 alone and with cocaine were comparable.,"Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586462/),h,5.6,187482,DB00988,Dopamine
,20228156,elimination half-lives,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),h,1.49 to 3.27,187646,DB00988,Dopamine
,20228156,volumes of distribution,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),[l] / [kg],5.95-14.19,187647,DB00988,Dopamine
,20228156,brain-to-plasma ratios,The brain-to-plasma ratios ranged from 2.93 to 11.81 and were higher than those previously reported for cocaine.,"Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),,2.93 to 11.81,187648,DB00988,Dopamine
,24076172,K(i),"Previous studies have shown that compound 1 displayed high affinity towards histamine H3 receptor (H3R), (human (h-H3R), K(i)=8.6 nM, rhesus monkey (rh-H3R), K(i)=1.2 nM, and rat (r-H3R), K(i)=16.5 nM), but exhibited high affinity for hERG channel.","Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076172/),nM,8.6,188739,DB00988,Dopamine
,24076172,K(i),"Previous studies have shown that compound 1 displayed high affinity towards histamine H3 receptor (H3R), (human (h-H3R), K(i)=8.6 nM, rhesus monkey (rh-H3R), K(i)=1.2 nM, and rat (r-H3R), K(i)=16.5 nM), but exhibited high affinity for hERG channel.","Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076172/),nM,1.2,188740,DB00988,Dopamine
,24076172,K(i),"Previous studies have shown that compound 1 displayed high affinity towards histamine H3 receptor (H3R), (human (h-H3R), K(i)=8.6 nM, rhesus monkey (rh-H3R), K(i)=1.2 nM, and rat (r-H3R), K(i)=16.5 nM), but exhibited high affinity for hERG channel.","Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24076172/),nM,16.5,188741,DB00988,Dopamine
,14686220,oral availability,The oral availability is 87%.,Aripiprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),%,87,189040,DB00988,Dopamine
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,75,189041,DB00988,Dopamine
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,94,189042,DB00988,Dopamine
exceeded,33514803,steady state trough concentrations,"Then, the individual dosing regimens of the 92 patients hospitalized in the ICU whose steady state trough concentrations exceeded the target range (10-20 μg/ml) were adjusted by the Bayes feedback method.",Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33514803/),[μg] / [ml],10-20,189614,DB00988,Dopamine
,33514803,CL,"The population pharmacokinetic parameters (CL and V) according to the final model were 3.16 (95%CI 2.83, 3.40) L/h and 60.71 (95%CI 53.15, 67.46).",Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33514803/),[l] / [h],3.16,189615,DB00988,Dopamine
,33514803,V,"The population pharmacokinetic parameters (CL and V) according to the final model were 3.16 (95%CI 2.83, 3.40) L/h and 60.71 (95%CI 53.15, 67.46).",Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33514803/),,60.71,189616,DB00988,Dopamine
,33514803,trough concentrations,"Finally, the prediction accuracy of 90.21% of the patients' detected trough concentrations that were distributed in the target range of 10-20 μg/ml after dosing adjustment was found to be adequate.",Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33514803/),[μg] / [ml],10-20,189617,DB00988,Dopamine
,21704242,plasma C(max),"After a single dose of etamicastat 100 mg, mean (SD) plasma C(max) and plasma AUC(0-∞) were, respectively, 1.3 (0.5) ng/mL/kg and 12.4 (7.8) ng × h/mL/kg in elderly subjects, and 1.3 (0.4) ng/mL/kg and 10.0 (6.6) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],1.3,190171,DB00988,Dopamine
,21704242,plasma C(max),"After a single dose of etamicastat 100 mg, mean (SD) plasma C(max) and plasma AUC(0-∞) were, respectively, 1.3 (0.5) ng/mL/kg and 12.4 (7.8) ng × h/mL/kg in elderly subjects, and 1.3 (0.4) ng/mL/kg and 10.0 (6.6) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],1.3,190172,DB00988,Dopamine
,21704242,plasma AUC(0-∞),"After a single dose of etamicastat 100 mg, mean (SD) plasma C(max) and plasma AUC(0-∞) were, respectively, 1.3 (0.5) ng/mL/kg and 12.4 (7.8) ng × h/mL/kg in elderly subjects, and 1.3 (0.4) ng/mL/kg and 10.0 (6.6) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[h·ng] / [kg·ml],12.4,190173,DB00988,Dopamine
,21704242,plasma AUC(0-∞),"After a single dose of etamicastat 100 mg, mean (SD) plasma C(max) and plasma AUC(0-∞) were, respectively, 1.3 (0.5) ng/mL/kg and 12.4 (7.8) ng × h/mL/kg in elderly subjects, and 1.3 (0.4) ng/mL/kg and 10.0 (6.6) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[h·ng] / [kg·ml],10.0,190174,DB00988,Dopamine
,21704242,At steady-state,"At steady-state, C(max) and AUC(0-24) were 1.8 (0.5) ng/mL/kg and 15.0 (6.4) ng × h/mL/kg in elderly subjects, and 1.5 (0.7) ng/mL/kg and 12.5 (6.5) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],1.8,190175,DB00988,Dopamine
,21704242,At steady-state,"At steady-state, C(max) and AUC(0-24) were 1.8 (0.5) ng/mL/kg and 15.0 (6.4) ng × h/mL/kg in elderly subjects, and 1.5 (0.7) ng/mL/kg and 12.5 (6.5) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],1.5,190176,DB00988,Dopamine
,21704242,C(max),"At steady-state, C(max) and AUC(0-24) were 1.8 (0.5) ng/mL/kg and 15.0 (6.4) ng × h/mL/kg in elderly subjects, and 1.5 (0.7) ng/mL/kg and 12.5 (6.5) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],1.5,190177,DB00988,Dopamine
,21704242,AUC(0-24),"At steady-state, C(max) and AUC(0-24) were 1.8 (0.5) ng/mL/kg and 15.0 (6.4) ng × h/mL/kg in elderly subjects, and 1.5 (0.7) ng/mL/kg and 12.5 (6.5) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[h·ng] / [kg·ml],15.0,190178,DB00988,Dopamine
,21704242,AUC(0-24),"At steady-state, C(max) and AUC(0-24) were 1.8 (0.5) ng/mL/kg and 15.0 (6.4) ng × h/mL/kg in elderly subjects, and 1.5 (0.7) ng/mL/kg and 12.5 (6.5) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[h·ng] / [kg·ml],12.5,190179,DB00988,Dopamine
,21704242,accumulation ratio,The mean etamicastat accumulation ratio was 1.7 in both age groups.,"Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),,1.7,190180,DB00988,Dopamine
,21704242,C(max),"Following etamicastat single dose, mean (SD) BIA 5-961 C(max) and AUC(0-∞) were, respectively, 3.5 (2.1) ng/mL/kg and 28.4 (14.7) ng × h/mL/kg in elderly subjects, and 2.5 (1.5) ng/mL/kg and 16.5 (9.7) in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],3.5,190181,DB00988,Dopamine
,21704242,C(max),"Following etamicastat single dose, mean (SD) BIA 5-961 C(max) and AUC(0-∞) were, respectively, 3.5 (2.1) ng/mL/kg and 28.4 (14.7) ng × h/mL/kg in elderly subjects, and 2.5 (1.5) ng/mL/kg and 16.5 (9.7) in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],2.5,190182,DB00988,Dopamine
,21704242,AUC(0-∞),"Following etamicastat single dose, mean (SD) BIA 5-961 C(max) and AUC(0-∞) were, respectively, 3.5 (2.1) ng/mL/kg and 28.4 (14.7) ng × h/mL/kg in elderly subjects, and 2.5 (1.5) ng/mL/kg and 16.5 (9.7) in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[h·ng] / [kg·ml],28.4,190183,DB00988,Dopamine
,21704242,AUC(0-∞),"Following etamicastat single dose, mean (SD) BIA 5-961 C(max) and AUC(0-∞) were, respectively, 3.5 (2.1) ng/mL/kg and 28.4 (14.7) ng × h/mL/kg in elderly subjects, and 2.5 (1.5) ng/mL/kg and 16.5 (9.7) in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),,16.5,190184,DB00988,Dopamine
,21704242,BIA 5-961,"At steady state, BIA 5-961, C(max), and AUC(0-24) were 4.3 (2.6) ng/mL/kg and 34.6 (17.6) ng × h/mL/kg in elderly subjects, and 3.1 (2.0) ng/mL/kg and 22.2 (11.8) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],4.3,190185,DB00988,Dopamine
,21704242,BIA 5-961,"At steady state, BIA 5-961, C(max), and AUC(0-24) were 4.3 (2.6) ng/mL/kg and 34.6 (17.6) ng × h/mL/kg in elderly subjects, and 3.1 (2.0) ng/mL/kg and 22.2 (11.8) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],3.1,190186,DB00988,Dopamine
,21704242,C(max),"At steady state, BIA 5-961, C(max), and AUC(0-24) were 4.3 (2.6) ng/mL/kg and 34.6 (17.6) ng × h/mL/kg in elderly subjects, and 3.1 (2.0) ng/mL/kg and 22.2 (11.8) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[ng] / [kg·ml],3.1,190187,DB00988,Dopamine
,21704242,AUC(0-24),"At steady state, BIA 5-961, C(max), and AUC(0-24) were 4.3 (2.6) ng/mL/kg and 34.6 (17.6) ng × h/mL/kg in elderly subjects, and 3.1 (2.0) ng/mL/kg and 22.2 (11.8) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[h·ng] / [kg·ml],34.6,190188,DB00988,Dopamine
,21704242,AUC(0-24),"At steady state, BIA 5-961, C(max), and AUC(0-24) were 4.3 (2.6) ng/mL/kg and 34.6 (17.6) ng × h/mL/kg in elderly subjects, and 3.1 (2.0) ng/mL/kg and 22.2 (11.8) ng × h/mL/kg in young subjects.","Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704242/),[h·ng] / [kg·ml],22.2,190189,DB00988,Dopamine
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,8.8,190327,DB00988,Dopamine
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,24.0,190328,DB00988,Dopamine
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,63,190329,DB00988,Dopamine
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,75,190330,DB00988,Dopamine
,2591992,half-life,"As much as half the dose was vomited back, but nonetheless the plasma diltiazem concentration reached 6090 micrograms/l before falling mono-exponentially with a half-life of 8.6 h.",Pharmacokinetics and toxic effects of diltiazem in massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591992/),h,8.6,191620,DB00988,Dopamine
,1473613,sodium clearance,"Low- and high-dose insulin infusions were followed by a fall in sodium clearance from 1.6 +/- 0.1 ml/min to 1.2 +/- 0.1 and 1.0 +/- 0.1 ml/min, respectively.",Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473613/),[ml] / [min],1.6,191657,DB00988,Dopamine
,1473613,sodium clearance,"Low- and high-dose insulin infusions were followed by a fall in sodium clearance from 1.6 +/- 0.1 ml/min to 1.2 +/- 0.1 and 1.0 +/- 0.1 ml/min, respectively.",Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473613/),[ml] / [min],1.2,191658,DB00988,Dopamine
,1473613,sodium clearance,"Low- and high-dose insulin infusions were followed by a fall in sodium clearance from 1.6 +/- 0.1 ml/min to 1.2 +/- 0.1 and 1.0 +/- 0.1 ml/min, respectively.",Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473613/),[ml] / [min],1.0,191659,DB00988,Dopamine
,9450505,clearance,Cocaine clearance was dose-dependent with clearance decreasing from 1.53 +/- 0.31 to 1.09 +/- 0.11 l/min as the dose was increased from 1 to 5 mg/kg (p<0.05).,Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [min],1.53,192600,DB00988,Dopamine
,9450505,clearance,Cocaine clearance was dose-dependent with clearance decreasing from 1.53 +/- 0.31 to 1.09 +/- 0.11 l/min as the dose was increased from 1 to 5 mg/kg (p<0.05).,Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [min],1.09,192601,DB00988,Dopamine
,9450505,Vmax x Vss,"Vmax x Vss and Km for cocaine were 0.95 +/- 0.40 l/min/kg and 11.2 +/- 6.2 mg/kg, respectively.",Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [kg·min],0.95,192602,DB00988,Dopamine
,9450505,Km,"Vmax x Vss and Km for cocaine were 0.95 +/- 0.40 l/min/kg and 11.2 +/- 6.2 mg/kg, respectively.",Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[mg] / [kg],11.2,192603,DB00988,Dopamine
,7839313,t1/2,"dl-threo-Methylphenidate (Ritalin) was labeled with carbon-11 (t1/2:20.4 minutes) in order to measure its pharmacokinetics, to evaluate it as a radiotracer for the presynaptic dopaminergic neuron, and to examine its sensitivity to the loss of dopaminergic neurons.",Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),min,20.4,192690,DB00988,Dopamine
,7839313,Peak uptake,Peak uptake (0.04%/cc) occurred at 5-15 minutes post-injection.,Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),[%] / [cc],0.04,192691,DB00988,Dopamine
,7839313,half-time for clearance from peak uptake,The half-time for clearance from peak uptake for [11C]MP was 60 minutes and the ratio between the radioactivity in the striatum and that in the cerebellum (ST/CB) ranged from 2.2 to 2.6 at 40 minutes.,Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),min,60,192692,DB00988,Dopamine
,10985584,absolute extraction recovery,The absolute extraction recovery from plasma samples was 83%.,High-performance liquid chromatographic analysis for the determination of domperidone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985584/),%,83,193049,DB00988,Dopamine
,7892416,relative systemic bioavailability,Comparison of dose corrected areas under the curve of the two routes of administration for each drug indicated that relative systemic bioavailability of cocaethylene following intraperitoneal administration is only 58% that of cocaine.,Differences in bioavailability between cocaine and cocaethylene and their implications for drug-reward studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7892416/),%,58,193589,DB00988,Dopamine
,8681493,elimination half-life,The elimination half-life was about 5 to 10 hours.,Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681493/),h,5 to 10,193667,DB00988,Dopamine
,26356245,intestinal availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.45,194246,DB00988,Dopamine
,26356245,hepatic availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.31,194247,DB00988,Dopamine
,26356245,fraction absorbed,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.89,194248,DB00988,Dopamine
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],246,194495,DB00988,Dopamine
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],180,194496,DB00988,Dopamine
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],205,194497,DB00988,Dopamine
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],0.98,194498,DB00988,Dopamine
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],1.70,194499,DB00988,Dopamine
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],3.67,194500,DB00988,Dopamine
,3171942,absolute bioavailability,The absolute bioavailability of DA after oral administration was calculated to be approximately 3%.,Bioavailability and pharmacokinetics of oral dopamine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171942/),%,3,194518,DB00988,Dopamine
,21171669,Elimination half-lives,Elimination half-lives ranged from 18.1 to 25.7 hours for etamicastat and 6.7 to 22.5 hours for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),h,18.1 to 25.7,195575,DB00988,Dopamine
,21171669,Elimination half-lives,Elimination half-lives ranged from 18.1 to 25.7 hours for etamicastat and 6.7 to 22.5 hours for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),h,6.7 to 22.5,195576,DB00988,Dopamine
,21171669,observed accumulation ratio,The mean observed accumulation ratio was 1.3-1.9 for etamicastat and 1.3-1.6 for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),,1.3-1.9,195577,DB00988,Dopamine
,21171669,observed accumulation ratio,The mean observed accumulation ratio was 1.3-1.9 for etamicastat and 1.3-1.6 for BIA 5-961.,"Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171669/),,1.3-1.6,195578,DB00988,Dopamine
,8289134,elimination half-lives,"The mean elimination half-lives were 53.5 and 66.0 h at 75 and 125 mg/day, respectively, in accordance with the observed time to reach near steady-state conditions.",Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8289134/),h,53.5,195858,DB00988,Dopamine
,8289134,elimination half-lives,"The mean elimination half-lives were 53.5 and 66.0 h at 75 and 125 mg/day, respectively, in accordance with the observed time to reach near steady-state conditions.",Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8289134/),h,66.0,195859,DB00988,Dopamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],348.0,195990,DB00988,Dopamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],68,195991,DB00988,Dopamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,29.,195992,DB00988,Dopamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243,195993,DB00988,Dopamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],401.8,195994,DB00988,Dopamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],671.1,195995,DB00988,Dopamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,159.9,195996,DB00988,Dopamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243.4,195997,DB00988,Dopamine
,26916207,steady-state brain extracellular fluid/plasma unbound concentration ratio,"The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steady-state brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry.","Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26916207/),,1.9,196043,DB00988,Dopamine
,26916207,steady-state brain extracellular fluid/plasma unbound concentration ratio,"The population model revealed rapid equilibration of both entities across the blood-brain barrier, with resultant steady-state brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry.","Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26916207/),,1.7,196044,DB00988,Dopamine
,9234352,terminal half-life,"Arterial input curves for IBF and epidepride fit three-exponential models with terminal half-life of 54-76 and 50-59 min, respectively.","Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234352/),min,54-76,196067,DB00988,Dopamine
,9234352,terminal half-life,"Arterial input curves for IBF and epidepride fit three-exponential models with terminal half-life of 54-76 and 50-59 min, respectively.","Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234352/),min,50-59,196068,DB00988,Dopamine
,9234352,Peak whole brain uptake,"Peak whole brain uptake, observed within 20 min for all three tracers, was estimated as 7% injected dose for [123I]IBF, 8% for [123I]epidepride and 5% for [123I]2'-ISP.","Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234352/),%,7,196069,DB00988,Dopamine
,9234352,Peak whole brain uptake,"Peak whole brain uptake, observed within 20 min for all three tracers, was estimated as 7% injected dose for [123I]IBF, 8% for [123I]epidepride and 5% for [123I]2'-ISP.","Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234352/),%,8,196070,DB00988,Dopamine
,9234352,Peak whole brain uptake,"Peak whole brain uptake, observed within 20 min for all three tracers, was estimated as 7% injected dose for [123I]IBF, 8% for [123I]epidepride and 5% for [123I]2'-ISP.","Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234352/),%,5,196071,DB00988,Dopamine
,17938734,apparent half-life,"Paraquat (10 mg/kg, ip) was found to be persistent in mouse ventral midbrain (VM) with an apparent half-life of approximately 28 days and was cumulative with a linear pattern between one and five doses.",Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17938734/),d,28,196132,DB00988,Dopamine
more,11918857,recovery,The recovery of domperidone from human plasma was more than 75 %.,Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918857/),%,75,197651,DB00988,Dopamine
,11918857,Tmax,"Its main pharmacokinetic parameters were: Tmax = (0.8 +/- 0.7) h, Cmax = (50 +/- 32) microg/L, T1/2 = (7.8 +/- 1.6) h.",Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918857/),h,0.8,197652,DB00988,Dopamine
,11918857,Cmax,"Its main pharmacokinetic parameters were: Tmax = (0.8 +/- 0.7) h, Cmax = (50 +/- 32) microg/L, T1/2 = (7.8 +/- 1.6) h.",Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918857/),[μg] / [l],50,197653,DB00988,Dopamine
,11918857,T1/2,"Its main pharmacokinetic parameters were: Tmax = (0.8 +/- 0.7) h, Cmax = (50 +/- 32) microg/L, T1/2 = (7.8 +/- 1.6) h.",Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918857/),h,7.8,197654,DB00988,Dopamine
,21925241,K(i),"Competitive radioligand binding assays were performed using cells expressing the human dopamine (DA) transporter (hDAT), the human serotonin (5-HT) transporter (hSERT), and the human norepinephrine (NE) transporter (hNET) with K(i) values for TP1 of 190 nM, 2076 nM, and 1023 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,190,197720,DB00988,Dopamine
,21925241,K(i),"Competitive radioligand binding assays were performed using cells expressing the human dopamine (DA) transporter (hDAT), the human serotonin (5-HT) transporter (hSERT), and the human norepinephrine (NE) transporter (hNET) with K(i) values for TP1 of 190 nM, 2076 nM, and 1023 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,2076,197721,DB00988,Dopamine
,21925241,K(i),"Competitive radioligand binding assays were performed using cells expressing the human dopamine (DA) transporter (hDAT), the human serotonin (5-HT) transporter (hSERT), and the human norepinephrine (NE) transporter (hNET) with K(i) values for TP1 of 190 nM, 2076 nM, and 1023 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,1023,197722,DB00988,Dopamine
,21925241,IC(50),"Uptake assays were performed with IC(50) values for TP1 of 712 nM, 521 nM, and 628 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,712,197723,DB00988,Dopamine
,21925241,IC(50),"Uptake assays were performed with IC(50) values for TP1 of 712 nM, 521 nM, and 628 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,521,197724,DB00988,Dopamine
,21925241,IC(50),"Uptake assays were performed with IC(50) values for TP1 of 712 nM, 521 nM, and 628 nM, respectively.","Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21925241/),nM,628,197725,DB00988,Dopamine
,21903866,Brain ECF/plasma area under the curve ratios,"Brain ECF/plasma area under the curve ratios were 0.28 and 0.19 after IN and IV administration, respectively.",Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903866/),,0.28,198700,DB00988,Dopamine
,21903866,Brain ECF/plasma area under the curve ratios,"Brain ECF/plasma area under the curve ratios were 0.28 and 0.19 after IN and IV administration, respectively.",Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903866/),,0.19,198701,DB00988,Dopamine
,21903866,Total bioavailability,"Total bioavailability after IN administration was 89%, of which 75% was attributed to direct nose-to brain transport.",Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903866/),%,89,198702,DB00988,Dopamine
,21903866,Total bioavailability,"Total bioavailability after IN administration was 89%, of which 75% was attributed to direct nose-to brain transport.",Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903866/),%,75,198703,DB00988,Dopamine
,23897037,f 2,"The formulations F8A and F9A having similar dissolution profiles among themselves and with Requip® XL™ (f 2 value 72, 77, 71 respectively) were evaluated.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),,72,198829,DB00988,Dopamine
,23897037,f 2,"The formulations F8A and F9A having similar dissolution profiles among themselves and with Requip® XL™ (f 2 value 72, 77, 71 respectively) were evaluated.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),,77,198830,DB00988,Dopamine
,23897037,f 2,"The formulations F8A and F9A having similar dissolution profiles among themselves and with Requip® XL™ (f 2 value 72, 77, 71 respectively) were evaluated.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),,71,198831,DB00988,Dopamine
,23897037,C max,"The C max of formulation F8A comprising hypromellose 100,000 cP was 1005.16 pg/ml as compared to 973.70 pg/ml of formulation F9A comprising hypromellose 4000 cP irrespective of T max of 5 and 5.75 h, respectively.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),[pg] / [ml],1005.16,198832,DB00988,Dopamine
,23897037,C max,"The C max of formulation F8A comprising hypromellose 100,000 cP was 1005.16 pg/ml as compared to 973.70 pg/ml of formulation F9A comprising hypromellose 4000 cP irrespective of T max of 5 and 5.75 h, respectively.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),[pg] / [ml],973.70,198833,DB00988,Dopamine
,23897037,T max,"The C max of formulation F8A comprising hypromellose 100,000 cP was 1005.16 pg/ml as compared to 973.70 pg/ml of formulation F9A comprising hypromellose 4000 cP irrespective of T max of 5 and 5.75 h, respectively.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),h,5,198834,DB00988,Dopamine
,23897037,T max,"The C max of formulation F8A comprising hypromellose 100,000 cP was 1005.16 pg/ml as compared to 973.70 pg/ml of formulation F9A comprising hypromellose 4000 cP irrespective of T max of 5 and 5.75 h, respectively.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),h,5.75,198835,DB00988,Dopamine
≥,23897037,f 2,"Thus, in vivo studies are required for proving the therapeutic equivalency of different formulation technologies even though f 2 ≥ 50.",Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23897037/),,50,198836,DB00988,Dopamine
,20079628,t(max),"Pharmacokinetics after a single dose were median t(max)=8.0-24.2h, median t(1/2)=81.0-115.9h and mean(geo) CL/f=0.28-0.43mL/min/kg.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),h,8.0-24.2,198963,DB00988,Dopamine
,20079628,t(1/2),"Pharmacokinetics after a single dose were median t(max)=8.0-24.2h, median t(1/2)=81.0-115.9h and mean(geo) CL/f=0.28-0.43mL/min/kg.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),h,81.0-115.9,198964,DB00988,Dopamine
,20079628,CL/f,"Pharmacokinetics after a single dose were median t(max)=8.0-24.2h, median t(1/2)=81.0-115.9h and mean(geo) CL/f=0.28-0.43mL/min/kg.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),[ml] / [kg·min],0.28-0.43,198965,DB00988,Dopamine
below,20079628,Urinary excretion,Urinary excretion was below 1%.,First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),%,1,198966,DB00988,Dopamine
,20079628,half-life,"Based on its half-life of about 4days, a weekly regimen may be appropriate.",First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079628/),d,4,198967,DB00988,Dopamine
,12966155,Transport,Transport of both AHN 1-055 (2.15 x 10-4 cm/s) and JHW 007 (2.83 x 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 x 10-4 cm/s).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[cm] / [s],2.15 x 10-4,200743,DB00988,Dopamine
,12966155,Transport,Transport of both AHN 1-055 (2.15 x 10-4 cm/s) and JHW 007 (2.83 x 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 x 10-4 cm/s).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[cm] / [s],2.83 x 10-4,200744,DB00988,Dopamine
,12966155,Transport,Transport of both AHN 1-055 (2.15 x 10-4 cm/s) and JHW 007 (2.83 x 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 x 10-4 cm/s).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[cm] / [s],1.63 x 10-4,200745,DB00988,Dopamine
,12966155,volume of distribution,The volume of distribution (12.3-30.5 l/kg) of the analogs was significantly higher than cocaine (0.9 l/kg).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[l] / [kg],12.3-30.5,200746,DB00988,Dopamine
,12966155,volume of distribution,The volume of distribution (12.3-30.5 l/kg) of the analogs was significantly higher than cocaine (0.9 l/kg).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),[l] / [kg],0.9,200747,DB00988,Dopamine
,12966155,elimination half-life,The BZT analogs displayed a > or =8-fold higher elimination half-life (4.12-16.49 h) compared with cocaine (0.49 h).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),h,4.12-16.49,200748,DB00988,Dopamine
,12966155,elimination half-life,The BZT analogs displayed a > or =8-fold higher elimination half-life (4.12-16.49 h) compared with cocaine (0.49 h).,"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966155/),h,0.49,200749,DB00988,Dopamine
,11313155,receptor,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,41,201024,DB00988,Dopamine
,11313155,receptor,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,30,201025,DB00988,Dopamine
,11313155,occupancies,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,41,201026,DB00988,Dopamine
,11313155,occupancies,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,30,201027,DB00988,Dopamine
,11313155,occupancies,"Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively.",D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,74,201028,DB00988,Dopamine
,11313155,occupancies,"Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively.",D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,57,201029,DB00988,Dopamine
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB00988,Dopamine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB00988,Dopamine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB00988,Dopamine
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB00988,Dopamine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB00988,Dopamine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB00988,Dopamine
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB00988,Dopamine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB00988,Dopamine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB00988,Dopamine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB00988,Dopamine
,8094094,specific activity,"Radiochemical yields of 15% at the end of bombardment (EOB) for the racemic mixture, and 5% for each enantiomer with a specific activity of 2-5 Ci/mumol at EOB were obtained.",Synthesis and PET studies of fluorine-18-BMY 14802: a potential antipsychotic drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094094/),c,2-5,202286,DB00988,Dopamine
,18308793,D,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202598,DB00988,Dopamine
,18308793,RO,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202599,DB00988,Dopamine
,18308793,C(P),"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),[ng] / [ml],9.4-60.5,202600,DB00988,Dopamine
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,0.2,202649,DB00988,Dopamine
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,2.2,202650,DB00988,Dopamine
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.2 × 10(-5),203539,DB00988,Dopamine
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.1 × 10(-6 ),203540,DB00988,Dopamine
greater,25915108,efflux ratio,"The secretory efflux ratio in MDCK-II cells overexpressing human P-gp showed an efflux ratio greater than 2, for both compounds, which was significantly decreased by elacridar.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),,2,203541,DB00988,Dopamine
,25915108,plasma free fraction,"Despite its lower bioavailability and higher clearance, as compared to nepicastat, etamicastat showed preferential distribution to peripheral tissues and high plasma free fraction (15.5%), which may explain its effects upon peripheral DBH and catecholamine levels.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),%,15.5,203542,DB00988,Dopamine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],389,203783,DB00988,Dopamine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],346,203784,DB00988,Dopamine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],543,203785,DB00988,Dopamine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],711,203786,DB00988,Dopamine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,10,203787,DB00988,Dopamine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,12,203788,DB00988,Dopamine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,24,203789,DB00988,Dopamine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,18,203790,DB00988,Dopamine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],36.5,204004,DB00988,Dopamine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],73.8,204005,DB00988,Dopamine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],207,204006,DB00988,Dopamine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],5.81,204007,DB00988,Dopamine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],5.51,204008,DB00988,Dopamine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],3.91,204009,DB00988,Dopamine
,28643852,occupancy,"In three participants, imaged during optimal treatment (50 mg/day; 41-70 ng/ml), caudate occupancy was 44-59% (58-74% in AD across a comparable Caverage).",Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28643852/),%,44-59,204098,DB00988,Dopamine
,28643852,occupancy,"In three participants, imaged during optimal treatment (50 mg/day; 41-70 ng/ml), caudate occupancy was 44-59% (58-74% in AD across a comparable Caverage).",Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28643852/),%,58-74,204099,DB00988,Dopamine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],3.8,205627,DB00988,Dopamine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],2.5,205628,DB00988,Dopamine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,3.3,205629,DB00988,Dopamine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,5.9,205630,DB00988,Dopamine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],1.5,205631,DB00988,Dopamine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],2.1,205632,DB00988,Dopamine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,26.3,205633,DB00988,Dopamine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,25.0,205634,DB00988,Dopamine
,10454044,systemic clearances,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[ml] / [kg·min],146,205635,DB00988,Dopamine
,1768559,Plasma clearance,Plasma clearance was high (0.98 1 kg-1 h) and the volume of distribution was large (12.9 1 kg-1) after i.v. dosing.,Clinical pharmacology of prochlorperazine in healthy young males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768559/),[1·h] / [kg],0.98,206099,DB00988,Dopamine
,1768559,volume of distribution,Plasma clearance was high (0.98 1 kg-1 h) and the volume of distribution was large (12.9 1 kg-1) after i.v. dosing.,Clinical pharmacology of prochlorperazine in healthy young males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768559/),[1] / [kg],12.9,206100,DB00988,Dopamine
,1768559,terminal elimination half-life,"3. The terminal elimination half-life of PCZ was 9 +/- 1 h and 8 +/- 2 h after i.v. and single oral dosing, respectively.",Clinical pharmacology of prochlorperazine in healthy young males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768559/),h,9,206101,DB00988,Dopamine
,1768559,terminal elimination half-life,"3. The terminal elimination half-life of PCZ was 9 +/- 1 h and 8 +/- 2 h after i.v. and single oral dosing, respectively.",Clinical pharmacology of prochlorperazine in healthy young males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768559/),h,8,206102,DB00988,Dopamine
,1768559,half-life,The half-life at the end of 14 days therapy was 18 +/- 4 h.,Clinical pharmacology of prochlorperazine in healthy young males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768559/),h,18,206103,DB00988,Dopamine
,29619682,oral clearance (Cl/F),"The pharmacokinetic analysis identified a one-compartment model incorporating body mass index influence on volume as the optimum construct, with fixed-effect parameters: (1) oral clearance (Cl/F), 5.11 ± 0.11 L/h; (2) volume of distribution (Vc/F), 328.00 ± 31.40 L; (3) absorption constant (ka) 0.42 ± 0.17 h-1; (4) lag time (t lag) of 0.41 ± 0.02 h; and (5) a calculated half-life of 44.5 h.",A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),[l] / [h],5.11,207420,DB00988,Dopamine
,29619682,volume of distribution (Vc/F),"The pharmacokinetic analysis identified a one-compartment model incorporating body mass index influence on volume as the optimum construct, with fixed-effect parameters: (1) oral clearance (Cl/F), 5.11 ± 0.11 L/h; (2) volume of distribution (Vc/F), 328.00 ± 31.40 L; (3) absorption constant (ka) 0.42 ± 0.17 h-1; (4) lag time (t lag) of 0.41 ± 0.02 h; and (5) a calculated half-life of 44.5 h.",A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),l,328.00,207421,DB00988,Dopamine
,29619682,absorption constant (ka),"The pharmacokinetic analysis identified a one-compartment model incorporating body mass index influence on volume as the optimum construct, with fixed-effect parameters: (1) oral clearance (Cl/F), 5.11 ± 0.11 L/h; (2) volume of distribution (Vc/F), 328.00 ± 31.40 L; (3) absorption constant (ka) 0.42 ± 0.17 h-1; (4) lag time (t lag) of 0.41 ± 0.02 h; and (5) a calculated half-life of 44.5 h.",A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),1/[h],0.42,207422,DB00988,Dopamine
,29619682,lag time (t lag),"The pharmacokinetic analysis identified a one-compartment model incorporating body mass index influence on volume as the optimum construct, with fixed-effect parameters: (1) oral clearance (Cl/F), 5.11 ± 0.11 L/h; (2) volume of distribution (Vc/F), 328.00 ± 31.40 L; (3) absorption constant (ka) 0.42 ± 0.17 h-1; (4) lag time (t lag) of 0.41 ± 0.02 h; and (5) a calculated half-life of 44.5 h.",A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),h,0.41,207423,DB00988,Dopamine
,29619682,half-life,"The pharmacokinetic analysis identified a one-compartment model incorporating body mass index influence on volume as the optimum construct, with fixed-effect parameters: (1) oral clearance (Cl/F), 5.11 ± 0.11 L/h; (2) volume of distribution (Vc/F), 328.00 ± 31.40 L; (3) absorption constant (ka) 0.42 ± 0.17 h-1; (4) lag time (t lag) of 0.41 ± 0.02 h; and (5) a calculated half-life of 44.5 h.",A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),h,44.5,207424,DB00988,Dopamine
,29619682,Eo,An Emax model for total Positive and Negative Syndrome Scale (PANSS) scores as the response factor against cumulative area under the curve (AUC) provided fixed-effect estimates: (1) Eo = 87.3 ± 0.71 (PANSS Units; pu); (2) Emax = - 31.60 ± 4.05 (pu); and (3) AUC50 = 89.60 ± 30.10 (µg·h/mL).,A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),,87.3,207425,DB00988,Dopamine
,29619682,Emax,An Emax model for total Positive and Negative Syndrome Scale (PANSS) scores as the response factor against cumulative area under the curve (AUC) provided fixed-effect estimates: (1) Eo = 87.3 ± 0.71 (PANSS Units; pu); (2) Emax = - 31.60 ± 4.05 (pu); and (3) AUC50 = 89.60 ± 30.10 (µg·h/mL).,A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),,31.60,207426,DB00988,Dopamine
,29619682,AUC50,An Emax model for total Positive and Negative Syndrome Scale (PANSS) scores as the response factor against cumulative area under the curve (AUC) provided fixed-effect estimates: (1) Eo = 87.3 ± 0.71 (PANSS Units; pu); (2) Emax = - 31.60 ± 4.05 (pu); and (3) AUC50 = 89.60 ± 30.10 (µg·h/mL).,A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29619682/),[h·μg] / [ml],89.60,207427,DB00988,Dopamine
,1604422,total brain uptake,Medicated schizophrenics showed a total brain uptake of 4.0% and had a significant clearance of [18F]haloperidol from brain and a higher concentration of [18F]haloperidol in plasma.,Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F]haloperidol. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1604422/),%,4.0,207486,DB00988,Dopamine
,33227193,t1/2,The average t1/2 was 54 ± 19 min.,Application of Magnetic Core-Shell Imprinted Nanoconjugates for the Analysis of Hordenine in Human Plasma-Preliminary Data on Pharmacokinetic Study after Oral Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33227193/),min,54,207809,DB00988,Dopamine
,33227193,apparent volume of distribution,The apparent volume of distribution was 6000 ± 2600 L (66 ± 24 L/kg when adjusted for weight).,Application of Magnetic Core-Shell Imprinted Nanoconjugates for the Analysis of Hordenine in Human Plasma-Preliminary Data on Pharmacokinetic Study after Oral Administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33227193/),l,6000,207810,DB00988,Dopamine
,33227193,apparent volume of distribution,The apparent volume of distribution was 6000 ± 2600 L (66 ± 24 L/kg when adjusted for weight).,Application of Magnetic Core-Shell Imprinted Nanoconjugates for the Analysis of Hordenine in Human Plasma-Preliminary Data on Pharmacokinetic Study after Oral Administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33227193/),[l] / [kg],66,207811,DB00988,Dopamine
less,2116808,oral bioavailability,In a second study the oral bioavailability of gludopa was estimated in normal subjects and found to be low (less than 2%).,Effect of prolonged intravenous infusion of gludopa in humans and a preliminary study of its oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116808/),%,2,208091,DB00988,Dopamine
,2484082,peak free-DA concentration,"At an equimolar dose of 71 mumols/kg, p.o., the effect of TA-870 continued for greater than 4 h, while that of DA-HCl lasted for only 2 h: the peak free-DA concentration and maximum increase in RBF were 155 +/- 57 ng/ml and 56 +/- 15%, respectively, for TA-870, and those for DA-HCl were 32 +/- 13 ng/ml and 36 +/- 10%.",A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484082/),[ng] / [ml],155,209051,DB00988,Dopamine
,2484082,maximum increase,"At an equimolar dose of 71 mumols/kg, p.o., the effect of TA-870 continued for greater than 4 h, while that of DA-HCl lasted for only 2 h: the peak free-DA concentration and maximum increase in RBF were 155 +/- 57 ng/ml and 56 +/- 15%, respectively, for TA-870, and those for DA-HCl were 32 +/- 13 ng/ml and 36 +/- 10%.",A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484082/),%,56,209052,DB00988,Dopamine
,2484082,maximum increase,"At an equimolar dose of 71 mumols/kg, p.o., the effect of TA-870 continued for greater than 4 h, while that of DA-HCl lasted for only 2 h: the peak free-DA concentration and maximum increase in RBF were 155 +/- 57 ng/ml and 56 +/- 15%, respectively, for TA-870, and those for DA-HCl were 32 +/- 13 ng/ml and 36 +/- 10%.",A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484082/),[ng] / [ml],32,209053,DB00988,Dopamine
,2484082,maximum increase,"At an equimolar dose of 71 mumols/kg, p.o., the effect of TA-870 continued for greater than 4 h, while that of DA-HCl lasted for only 2 h: the peak free-DA concentration and maximum increase in RBF were 155 +/- 57 ng/ml and 56 +/- 15%, respectively, for TA-870, and those for DA-HCl were 32 +/- 13 ng/ml and 36 +/- 10%.",A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484082/),%,36,209054,DB00988,Dopamine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,75.6,210192,DB00988,Dopamine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,66.8,210193,DB00988,Dopamine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,72.3,210194,DB00988,Dopamine
,25099201,occupancy,Estimated dopamine D₂ occupancy (mean ± SD) decreased following dose reduction from 75.6% ± 4.9% to 66.8% ± 6.4% at peak and 72.3% ± 5.7% to 62.0% ± 6.8% at trough.,"Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25099201/),%,62.0,210195,DB00988,Dopamine
,3795020,free fractions,"In dogs, the free fractions in plasma of unchanged 1, 2, and 3, determined by in vitro studies, were 74, 86, and 63%, respectively, and the protein binding was constant with increasing concentration.",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),%,74,210392,DB00988,Dopamine
,3795020,free fractions,"In dogs, the free fractions in plasma of unchanged 1, 2, and 3, determined by in vitro studies, were 74, 86, and 63%, respectively, and the protein binding was constant with increasing concentration.",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),%,86,210393,DB00988,Dopamine
,3795020,free fractions,"In dogs, the free fractions in plasma of unchanged 1, 2, and 3, determined by in vitro studies, were 74, 86, and 63%, respectively, and the protein binding was constant with increasing concentration.",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),%,63,210394,DB00988,Dopamine
,3795020,blood-to-plasma partition ratios,"The blood-to-plasma partition ratios of the respective compounds were 1.22, 1.14, and 1.16 in dogs, and the ratios were constant with increasing concentration.",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),,1.22,210395,DB00988,Dopamine
,3795020,blood-to-plasma partition ratios,"The blood-to-plasma partition ratios of the respective compounds were 1.22, 1.14, and 1.16 in dogs, and the ratios were constant with increasing concentration.",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),,1.14,210396,DB00988,Dopamine
,3795020,blood-to-plasma partition ratios,"The blood-to-plasma partition ratios of the respective compounds were 1.22, 1.14, and 1.16 in dogs, and the ratios were constant with increasing concentration.",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),,1.16,210397,DB00988,Dopamine
,3795020,mean residence time,"Importantly, the mean residence time of 3 (147 min) in dogs was significantly longer than those of 1 (90 min) and 2 (96 min).",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),min,147,210398,DB00988,Dopamine
,3795020,mean residence time,"Importantly, the mean residence time of 3 (147 min) in dogs was significantly longer than those of 1 (90 min) and 2 (96 min).",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),min,90,210399,DB00988,Dopamine
,3795020,mean residence time,"Importantly, the mean residence time of 3 (147 min) in dogs was significantly longer than those of 1 (90 min) and 2 (96 min).",Pharmacokinetics of dopamine-2 agonists in rats and dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795020/),min,96,210400,DB00988,Dopamine
,12844325,elimination half-life,The elimination half-life of cabergoline estimated from urinary data of healthy subjects ranges between 63 and 109 hours.,Clinical pharmacokinetics of cabergoline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844325/),h,63 and 109,210629,DB00988,Dopamine
,2891530,mean residence time,The mean residence time of the unchanged drug was 2.75 h after intravenous administration.,"Disposition of [3H]cloflumide, a new neuroleptic drug, in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891530/),h,2.75,211025,DB00988,Dopamine
,18655221,run time,A run time of 2.0 min for each sample made it possible to analyze more than 275 human plasma samples per day.,Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with LLOQ of 100 pg/mL using 100 microL of plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655221/),min,2.0,211122,DB00988,Dopamine
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,3.25,211606,DB00988,Dopamine
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,6.05,211607,DB00988,Dopamine
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,12.6,211608,DB00988,Dopamine
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,18.5,211609,DB00988,Dopamine
,17192503,"first Cmax peak, Cmax0-4","Geometric means (%gCV) for the first Cmax peak, Cmax0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),[ng] / [ml],25.2,211610,DB00988,Dopamine
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,3.18,211611,DB00988,Dopamine
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,5.84,211612,DB00988,Dopamine
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),%,12.5,211613,DB00988,Dopamine
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,17.7,211614,DB00988,Dopamine
,17192503,Cmax4-10,"Geometric means (%gCV) for Cmax4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),[ng] / [ml],23.6,211615,DB00988,Dopamine
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,24.3,211616,DB00988,Dopamine
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,45.9,211617,DB00988,Dopamine
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,96.4,211618,DB00988,Dopamine
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),,144,211619,DB00988,Dopamine
,17192503,AUC(0-infinity),"Geometric means for AUC(0-infinity) were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng x h/mL (30.9%), respectively.",Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192503/),[h·ng] / [ml],195,211620,DB00988,Dopamine
,3795021,apparent conversion,"On the basis of plasma concentrations of 1 in dogs, the apparent conversion of 3 to 1 was 9%.",Functional group metabolism of dopamine-2 agonists: conversion of 4-(2-di-n-propylaminoethyl)-2-(3H)-indolone to 4-(2-di-n-propylaminoethyl)-7-hydroxy-2-(3H)-indolone. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795021/),%,9,211750,DB00988,Dopamine
,16555163,plasma levels,"However, dose-corrected steady-state amisulpride plasma levels (men 0.41 +/- 0.31 ng/mL/mg; women 0.60 +/- 0.39 ng/mL/mg; P = 0.007) were significantly higher in female patients even after age adjustment.",Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16555163/),[ng] / [mg·ml],0.41,212065,DB00988,Dopamine
,16555163,plasma levels,"However, dose-corrected steady-state amisulpride plasma levels (men 0.41 +/- 0.31 ng/mL/mg; women 0.60 +/- 0.39 ng/mL/mg; P = 0.007) were significantly higher in female patients even after age adjustment.",Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16555163/),[ng] / [mg·ml],0.60,212066,DB00988,Dopamine
,3795018,flow rate,"The peaks from the drug, its metabolite, and at least three other substances were best resolved at 60 degrees C using a mobile phase of water:acetonitrile:acetic acid:triethylamine (65:33:2:0.15) at a flow rate of 0.6 mL/min; the 4.6 mm X 10 cm column contained 5 micron of octadecylsilane packing.",Direct injection high-performance liquid chromatography of tetrabenazine and its metabolite in plasma of humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795018/),[ml] / [min],0.6,213094,DB00988,Dopamine
,3795018,Minimum quantifiable concentrations,"Minimum quantifiable concentrations of the drug and its metabolite were 0.5 and 2.0 ng/mL, respectively.",Direct injection high-performance liquid chromatography of tetrabenazine and its metabolite in plasma of humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795018/),[ng] / [ml],0.5,213095,DB00988,Dopamine
,3795018,Minimum quantifiable concentrations,"Minimum quantifiable concentrations of the drug and its metabolite were 0.5 and 2.0 ng/mL, respectively.",Direct injection high-performance liquid chromatography of tetrabenazine and its metabolite in plasma of humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795018/),[ng] / [ml],2.0,213096,DB00988,Dopamine
,26794682,tmax,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,10-12,213346,DB00988,Dopamine
,26794682,elimination (t1/2,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,47-77,213347,DB00988,Dopamine
,17443131,occupancy,"Mean striatal D(2) receptor occupancy, as measured by [(11)C]-raclopride PET, was 69% on oral olanzapine (5-20 mg/day) and 50% (trough) on OP depot at steady state.",D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443131/),%,69,214022,DB00988,Dopamine
,17443131,occupancy,"Mean striatal D(2) receptor occupancy, as measured by [(11)C]-raclopride PET, was 69% on oral olanzapine (5-20 mg/day) and 50% (trough) on OP depot at steady state.",D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443131/),%,50,214023,DB00988,Dopamine
,17443131,occupancy,"OP depot resulted in mean D(2) receptor occupancy of approximately 60% or higher at the end of the 6-month study period, a level consistent with antipsychotic efficacy and found during treatment with oral olanzapine.",D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443131/),%,60,214024,DB00988,Dopamine
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,2.207,214678,DB00988,Dopamine
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,0.093,214679,DB00988,Dopamine
,16715499,binding potential (BP),"The binding potential (BP) calculated by the simplified reference tissue model was 3-fold higher than that measured with [11C]-(-)-NPA (2.14 +/- 0.50 vs. 0.66 +/- 0.01, respectively).",In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715499/),,2.14,215143,DB00988,Dopamine
,16715499,binding potential (BP),"The binding potential (BP) calculated by the simplified reference tissue model was 3-fold higher than that measured with [11C]-(-)-NPA (2.14 +/- 0.50 vs. 0.66 +/- 0.01, respectively).",In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715499/),,0.66,215144,DB00988,Dopamine
,15180132,half-life,"Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia.",The pharmacokinetics of pergolide in Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15180132/),h,21,215281,DB00988,Dopamine
,9140760,flow-rate,"The chromatographic conditions used for the analysis were a Keystone Scientific C18 BDS 150 x 4.6 mm, 5 microns column with a mobile phase consisting of a 40:60 (v/v) mixture of acetonitrile and water containing 10 mM ammonium acetate and 0.1% formic acid pumped at a flow-rate of 1.2 ml/min, yielding retention times of 3.4 and 5.0 min for I and II, respectively.",Picogram determination of a novel dopamine D4 receptor antagonist in human plasma and urine by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140760/),[ml] / [min],1.2,215617,DB00988,Dopamine
,9140760,retention times,"The chromatographic conditions used for the analysis were a Keystone Scientific C18 BDS 150 x 4.6 mm, 5 microns column with a mobile phase consisting of a 40:60 (v/v) mixture of acetonitrile and water containing 10 mM ammonium acetate and 0.1% formic acid pumped at a flow-rate of 1.2 ml/min, yielding retention times of 3.4 and 5.0 min for I and II, respectively.",Picogram determination of a novel dopamine D4 receptor antagonist in human plasma and urine by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140760/),min,3.4,215618,DB00988,Dopamine
,9140760,retention times,"The chromatographic conditions used for the analysis were a Keystone Scientific C18 BDS 150 x 4.6 mm, 5 microns column with a mobile phase consisting of a 40:60 (v/v) mixture of acetonitrile and water containing 10 mM ammonium acetate and 0.1% formic acid pumped at a flow-rate of 1.2 ml/min, yielding retention times of 3.4 and 5.0 min for I and II, respectively.",Picogram determination of a novel dopamine D4 receptor antagonist in human plasma and urine by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140760/),min,5.0,215619,DB00988,Dopamine
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,25-48,215766,DB00988,Dopamine
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,59-83,215767,DB00988,Dopamine
,15710053,receptor occupancy,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),%,62-72,215768,DB00988,Dopamine
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),,4.4-8.8,215769,DB00988,Dopamine
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),[ng] / [ml],15.0-31.1,215770,DB00988,Dopamine
,15710053,plasma active-moiety levels,"After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively.",Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15710053/),[ng] / [ml],22.5-26.3,215771,DB00988,Dopamine
,23754735,occupancy,D2-receptor occupancy was predicted to be in the 65-80 % range at 10 mg twice daily and partially or fully reaching the 80 % threshold at doses of 20 and 30 mg twice daily.,"Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23754735/),%,65-80,216796,DB00988,Dopamine
,21343348,elimination phase,"Elimination was biphasic, characterized by a first short early elimination half-life followed by a longer elimination phase of 16 to 20 hours for etamicastat doses of 100 mg and above.","Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21343348/),h,16 to 20,216823,DB00988,Dopamine
,16815319,apparent clearance,"Rifampin treatment increased the apparent clearance of bupropion in Chinese subjects and white subjects combined (n = 16) from 2.6 L x h(-1) x kg(-1) (95% confidence interval [CI], 2.3-3.0 L x h(-1) x kg(-1)) after bupropion alone to 7.9 L x h(-1) x kg(-1) (95% CI, 6.8-10.1 L x h(-1) x kg(-1)) during rifampin treatment.",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[l] / [h·kg],2.6,216852,DB00988,Dopamine
,16815319,apparent clearance,"Rifampin treatment increased the apparent clearance of bupropion in Chinese subjects and white subjects combined (n = 16) from 2.6 L x h(-1) x kg(-1) (95% confidence interval [CI], 2.3-3.0 L x h(-1) x kg(-1)) after bupropion alone to 7.9 L x h(-1) x kg(-1) (95% CI, 6.8-10.1 L x h(-1) x kg(-1)) during rifampin treatment.",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[l] / [h·kg],7.9,216853,DB00988,Dopamine
,16815319,half-life,"Rifampin treatment decreased the half-life of bupropion from 15.9 hours (95% CI, 13.5-20.4 hours) to 8.2 hours (95% CI, 6.7-12.4 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,15.9,216854,DB00988,Dopamine
,16815319,half-life,"Rifampin treatment decreased the half-life of bupropion from 15.9 hours (95% CI, 13.5-20.4 hours) to 8.2 hours (95% CI, 6.7-12.4 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,8.2,216855,DB00988,Dopamine
,16815319,maximum concentration,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[ng] / [ml],395,216856,DB00988,Dopamine
,16815319,maximum concentration,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[ng] / [ml],548,216857,DB00988,Dopamine
,16815319,area under the concentration-time curve,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[h·μg] / [ml],14.7,216858,DB00988,Dopamine
,16815319,area under the concentration-time curve,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[h·μg] / [ml],8.4,216859,DB00988,Dopamine
,16815319,elimination half-life,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,21.9,216860,DB00988,Dopamine
,16815319,elimination half-life,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,10.7,216861,DB00988,Dopamine
,26253621,elimination half-life,The elimination half-life in the striatum (61 min) correlates with the decrease in the psychostimulant effect after 60 min.,Concentrations of MDPV in rat striatum correlate with the psychostimulant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26253621/),min,61,217024,DB00988,Dopamine
,11862380,half-life,Occupancy decreased with a half-life of 7.22 h after 5.0 mg/kg clozapine and 5.25 h after 1.0 and 2.0 mg/kg clozapine.,Clozapine can induce high dopamine D(2) receptor occupancy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862380/),h,7.22,217772,DB00988,Dopamine
,11862380,half-life,Occupancy decreased with a half-life of 7.22 h after 5.0 mg/kg clozapine and 5.25 h after 1.0 and 2.0 mg/kg clozapine.,Clozapine can induce high dopamine D(2) receptor occupancy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862380/),h,5.25,217773,DB00988,Dopamine
,6628501,total-body clearance,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),[ml] / [kg·min],4.68,218037,DB00988,Dopamine
,6628501,total-body clearance,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),[ml] / [kg·min],3.29,218038,DB00988,Dopamine
,6628501,plasma half-life,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),h,33.50,218039,DB00988,Dopamine
,6628501,plasma half-life,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),h,41.31,218040,DB00988,Dopamine
,33196868,maximum obtainable receptor occupancy (Omax),"Estimates of maximum obtainable receptor occupancy (Omax) were 89.2% for the putamen and 95.4% for the caudate nucleus; plasma concentrations predicted to provide 50% of Omax (EC50) were 8.13 ng/mL and 7.75 ng/mL, respectively.","An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196868/),%,89.2,218831,DB00988,Dopamine
,33196868,maximum obtainable receptor occupancy (Omax),"Estimates of maximum obtainable receptor occupancy (Omax) were 89.2% for the putamen and 95.4% for the caudate nucleus; plasma concentrations predicted to provide 50% of Omax (EC50) were 8.13 ng/mL and 7.75 ng/mL, respectively.","An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196868/),%,95.4,218832,DB00988,Dopamine
,33196868,Omax (EC50),"Estimates of maximum obtainable receptor occupancy (Omax) were 89.2% for the putamen and 95.4% for the caudate nucleus; plasma concentrations predicted to provide 50% of Omax (EC50) were 8.13 ng/mL and 7.75 ng/mL, respectively.","An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196868/),[ng] / [ml],8.13,218833,DB00988,Dopamine
,33196868,Omax (EC50),"Estimates of maximum obtainable receptor occupancy (Omax) were 89.2% for the putamen and 95.4% for the caudate nucleus; plasma concentrations predicted to provide 50% of Omax (EC50) were 8.13 ng/mL and 7.75 ng/mL, respectively.","An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196868/),[ng] / [ml],7.75,218834,DB00988,Dopamine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,73,219858,DB00988,Dopamine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,55,219859,DB00988,Dopamine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,32,219860,DB00988,Dopamine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,3,219861,DB00988,Dopamine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,9,219862,DB00988,Dopamine
,9754984,Cmax,"The mean Cmax of the racemate amisulpride in elderly people was 64.1+/-6.7 ng ml(-1), and was not different from the value of 56+/-4.1 ng ml(-1) in young subjects.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),[ng] / [ml],64.1,221765,DB00988,Dopamine
,9754984,Cmax,"The mean Cmax of the racemate amisulpride in elderly people was 64.1+/-6.7 ng ml(-1), and was not different from the value of 56+/-4.1 ng ml(-1) in young subjects.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),[ng] / [ml],56,221766,DB00988,Dopamine
,9754984,t1/2,"As with the Cmax, the mean values of t1/2 and AUC in elderly people (15.6+/-1.3 h and 667+/-51 ng.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),h,15.6,221767,DB00988,Dopamine
,9754984,AUC,"As with the Cmax, the mean values of t1/2 and AUC in elderly people (15.6+/-1.3 h and 667+/-51 ng.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),ng,667,221768,DB00988,Dopamine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,16.4,222423,DB00988,Dopamine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.541,222424,DB00988,Dopamine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,28.0,222425,DB00988,Dopamine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],2.00,222426,DB00988,Dopamine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,24.0,222427,DB00988,Dopamine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.106,222428,DB00988,Dopamine
,1490503,bioavailability,Almost equivalent bioavailability (85-90%) of levodopa was demonstrated for the controlled-release formulations relative to that of conventional Madopar capsules.,Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490503/),%,85-90,222528,DB00988,Dopamine
,16715476,limit of detection (LOD),The limit of detection (LOD) obtained was 0.03 ng/mL.,Development of a sensitive and rapid liquid chromatography/tandem mass spectrometry method for the determination of apomorphine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715476/),[ng] / [ml],0.03,222866,DB00988,Dopamine
,20030503,absolute bioavailabilty,The absolute bioavailabilty of ropinirole from the temperature-mediated in situ gelling nasal formulation was 82%.,Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20030503/),%,82,223334,DB00988,Dopamine
,20030503,AUC (0-480 min),"The AUC (0-480 min) in brain after nasal administration of ropinirole in situ gel was 8.5 times (869 +/- 250% x min/g versus 102 +/- 20% x min/g) that obtained following i.v. administration, this value was also considerably higher (869 +/- 250% x min/g versus 281 +/- 52% x min/g) than that achieved with intranasal ropinirole solution.",Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20030503/),[%·min] / [g],869,223335,DB00988,Dopamine
,20030503,AUC (0-480 min),"The AUC (0-480 min) in brain after nasal administration of ropinirole in situ gel was 8.5 times (869 +/- 250% x min/g versus 102 +/- 20% x min/g) that obtained following i.v. administration, this value was also considerably higher (869 +/- 250% x min/g versus 281 +/- 52% x min/g) than that achieved with intranasal ropinirole solution.",Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20030503/),[%·min] / [g],102,223336,DB00988,Dopamine
,20030503,AUC (0-480 min),"The AUC (0-480 min) in brain after nasal administration of ropinirole in situ gel was 8.5 times (869 +/- 250% x min/g versus 102 +/- 20% x min/g) that obtained following i.v. administration, this value was also considerably higher (869 +/- 250% x min/g versus 281 +/- 52% x min/g) than that achieved with intranasal ropinirole solution.",Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20030503/),[%·min] / [g],281,223337,DB00988,Dopamine
,20030503,brain direct drug transport percentage,High brain direct drug transport percentage (DTP; 90.36%) and drug targeting index (DTI) > 1 confirms direct nose to brain transport of the intranasal in situ gel formulation of ropinirole.,Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20030503/),%,90.36,223338,DB00988,Dopamine
>,20030503,drug targeting index (DTI),High brain direct drug transport percentage (DTP; 90.36%) and drug targeting index (DTI) > 1 confirms direct nose to brain transport of the intranasal in situ gel formulation of ropinirole.,Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20030503/),,1,223339,DB00988,Dopamine
,31982339,volume of distribution,"Estimated typical population value (interindividual variability) for volume of distribution and clearance were 10.3 (232%) L kg-1 and 9.9 (508%) L minute-1 kg-1, respectively.",Plasma dopamine concentrations following dopamine infusion to isoflurane-anesthetized New Zealand White rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31982339/),,10.3,223401,DB00988,Dopamine
,31982339,clearance,"Estimated typical population value (interindividual variability) for volume of distribution and clearance were 10.3 (232%) L kg-1 and 9.9 (508%) L minute-1 kg-1, respectively.",Plasma dopamine concentrations following dopamine infusion to isoflurane-anesthetized New Zealand White rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31982339/),,9.9,223402,DB00988,Dopamine
,8453823,time to reach peak plasma concentrations,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),h,1.1 to 3.6,224037,DB00988,Dopamine
,8453823,elimination half-life,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),h,9.1 to 17.4,224038,DB00988,Dopamine
,8453823,clearance,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[l] / [h],8.7 to 53.3,224039,DB00988,Dopamine
,8453823,volume of distribution,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[l] / [kg],1.6 to 7.3,224040,DB00988,Dopamine
,8453823,minimum concentration,"In the treatment of patients with refractory schizophrenia, a minimum concentration of 350 micrograms/L was suggested as needed.",Pharmacokinetics and pharmacodynamics of clozapine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[μg] / [l],350,224041,DB00988,Dopamine
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],5,224309,DB00988,Dopamine
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],8,224310,DB00988,Dopamine
,10829343,Recovery,"Recovery studies ranged from 93.83 to 89.76%, with a relative standard deviation of less than 7%.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),%,93.83 to 89.76,224311,DB00988,Dopamine
less,10829343,half-lives,"The data also indicated a very low accumulation of both levodopa and carbidopa following repeated administration of the drugs, which was consistent with their relatively short half-lives (less than 2 h).",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,2,224312,DB00988,Dopamine
,10829343,half-life,"In contrast, the half-life for the metabolite 3-orthomethyl dopa (3-OMD) is in the order of 13 h.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,13,224313,DB00988,Dopamine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],4.58,224633,DB00988,Dopamine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],60.95,224634,DB00988,Dopamine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],48.79,224635,DB00988,Dopamine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],3.01,224636,DB00988,Dopamine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],41.68,224637,DB00988,Dopamine
,21034737,ED(50),"In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14 days in a dose of 5 mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28 mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice.","Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034737/),[mg] / [kg],37.28,224638,DB00988,Dopamine
,7927855,Vslope,"We found a median Vslope of 1.7408 +/- 0.8461 (S.D.) 1/kg, and a mean Kel of 1.5341 +/- 0.3748 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),[1] / [kg],1.7408,224826,DB00988,Dopamine
,7927855,Kel,"We found a median Vslope of 1.7408 +/- 0.8461 (S.D.) 1/kg, and a mean Kel of 1.5341 +/- 0.3748 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),1/[h],1.5341,224827,DB00988,Dopamine
,7927855,Ka,"The absorption after intranasal administration was extremely rapid: Ka = 20.5 +/- 1.96 h-1, comparable with that found with subcutaneous absorption: Ka = 23.04 +/- 2.20 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),1/[h],20.5,224828,DB00988,Dopamine
,7927855,Ka,"The absorption after intranasal administration was extremely rapid: Ka = 20.5 +/- 1.96 h-1, comparable with that found with subcutaneous absorption: Ka = 23.04 +/- 2.20 h-1.",Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7927855/),1/[h],23.04,224829,DB00988,Dopamine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,76,224901,DB00988,Dopamine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,56,224902,DB00988,Dopamine
,8358345,specific activity,The labeled product was prepared in 65.2 +/- 2.8% yield (mean +/- SEM; n = 18) by reaction of the tributylstannyl precursor with [123I]NaI in the presence of peracetic acid followed by high pressure liquid chromatography (HPLC) purification to give a product with radiochemical purity of 97.5 +/- 0.5% and specific activity of 500-1200 Ci/mmol.,"Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[ci] / [mM],500-1200,225231,DB00988,Dopamine
,8358345,clearance half-lives,"After intravenous administration, whole brain activity peaked at 6-10% injected dose within 1 h post injection (p.i.) and washed out in a biphasic manner with clearance half-lives of 1-2 and 7-35 h for the rapid and slow components, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),h,1-2,225232,DB00988,Dopamine
,8358345,clearance half-lives,"After intravenous administration, whole brain activity peaked at 6-10% injected dose within 1 h post injection (p.i.) and washed out in a biphasic manner with clearance half-lives of 1-2 and 7-35 h for the rapid and slow components, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),h,7-35,225233,DB00988,Dopamine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.01,225234,DB00988,Dopamine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.1,225235,DB00988,Dopamine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.2,225236,DB00988,Dopamine
,8358345,radiation absorbed dose,"Estimates of radiation absorbed dose gave 0.01, 0.1, 0.2 and 0.03 mGy/MBq to the brain, gall bladder wall, lower large intestine wall and urinary bladder wall, respectively.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),[mgy] / [Mbq],0.03,225237,DB00988,Dopamine
,8358345,plasma protein bound fraction,"The plasma protein bound fraction, determined by ultrafiltration, was 74.8 +/- 1.4% (n = 6).","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),%,74.8,225238,DB00988,Dopamine
,8358345,half-lives,"The arterial input function was characterized by the sum of three exponential terms with half-lives of 0.3-1.7, 9.7-24.9 and 77-166 min, respectively, for the concentration of free parent compound.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),min,0.3-1.7,225239,DB00988,Dopamine
,8358345,half-lives,"The arterial input function was characterized by the sum of three exponential terms with half-lives of 0.3-1.7, 9.7-24.9 and 77-166 min, respectively, for the concentration of free parent compound.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),min,9.7-24.9,225240,DB00988,Dopamine
,8358345,half-lives,"The arterial input function was characterized by the sum of three exponential terms with half-lives of 0.3-1.7, 9.7-24.9 and 77-166 min, respectively, for the concentration of free parent compound.","Evaluation of the monoamine uptake site ligand [123I]methyl 3 beta-(4-iodophenyl)-tropane-2 beta-carboxylate ([123I]beta-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8358345/),min,77-166,225241,DB00988,Dopamine
,703854,ED50,"Further, the ED50 for synthesis inhibition of dopamine (0.057 mmoles/kg) was half of the ED50 for synthesis inhibition of noradrenaline (0.117 mmoles/kg).",Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; time- and dose-response relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/703854/),[mmoles] / [kg],0.057,226624,DB00988,Dopamine
,703854,ED50,"Further, the ED50 for synthesis inhibition of dopamine (0.057 mmoles/kg) was half of the ED50 for synthesis inhibition of noradrenaline (0.117 mmoles/kg).",Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; time- and dose-response relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/703854/),[mmoles] / [kg],0.117,226625,DB00988,Dopamine
,1673422,Tmax,"The Tmax of radiocarbon in the 22 tissues varied between 0.5 and 6 hr, with some tissues showing a plateau of radioactivity between these time-points.","Observations on the absorption, distribution, metabolism, and excretion of the dopamine (D2) agonist, quinelorane, in rats, mice, dogs, and monkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673422/),h,0.5 and 6,226738,DB00988,Dopamine
,1673422,systemic bioavailability,"Following the oral and iv administration of quinelorane to rats, the systemic bioavailability was calculated to be 16% and the volume of distribution was found to approximate that of total extracellular water, i.e. approximately 300 ml/kg.","Observations on the absorption, distribution, metabolism, and excretion of the dopamine (D2) agonist, quinelorane, in rats, mice, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673422/),%,16,226739,DB00988,Dopamine
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,17.7,227456,DB00988,Dopamine
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,45.4,227457,DB00988,Dopamine
less,19804823,half-life,"Although the half-life after nasal administration was relatively short (less than 30 min) in both blood and brain regardless of C-dopa addition, the systemic exposure was promising due to rapid absorption.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),min,30,227458,DB00988,Dopamine
,20231306,peak plasma concentration,These effects were associated with a peak plasma concentration of 20.9 microM and an area under the curve from 0 to 24 h of 136.1 h x microM (36 mg/kg).,"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20231306/),μM,20.9,227585,DB00988,Dopamine
,20231306,area under the curve from 0 to 24 h,These effects were associated with a peak plasma concentration of 20.9 microM and an area under the curve from 0 to 24 h of 136.1 h x microM (36 mg/kg).,"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20231306/),h·μM,136.1,227586,DB00988,Dopamine
,17854234,total radioactivity,"In a phase I trial, six healthy male Caucasian subjects were administered a single 10 cm(2) patch containing 4.485mg of unlabelled and 0.015mg of [(14)C]-labelled rotigotine (total radioactivity 0.09 MBq per patch) with a patch-on period of 24 hours.",Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854234/),Mbq,0.09,227744,DB00988,Dopamine
,17854234,Total radioactivity recovered,"Total radioactivity recovered in urine and faeces was 30.4% and 10.2%, respectively, of the radioactivity applied (corresponding to 65.8% and 21.8% of the dose absorbed, respectively).",Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854234/),%,30.4,227745,DB00988,Dopamine
,17854234,Total radioactivity recovered,"Total radioactivity recovered in urine and faeces was 30.4% and 10.2%, respectively, of the radioactivity applied (corresponding to 65.8% and 21.8% of the dose absorbed, respectively).",Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854234/),%,10.2,227746,DB00988,Dopamine
,17854234,Total radioactivity recovered,"Total radioactivity recovered in urine and faeces was 30.4% and 10.2%, respectively, of the radioactivity applied (corresponding to 65.8% and 21.8% of the dose absorbed, respectively).",Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854234/),%,65.8,227747,DB00988,Dopamine
,17854234,Total radioactivity recovered,"Total radioactivity recovered in urine and faeces was 30.4% and 10.2%, respectively, of the radioactivity applied (corresponding to 65.8% and 21.8% of the dose absorbed, respectively).",Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854234/),%,21.8,227748,DB00988,Dopamine
,17854234,total drug content,The mass balance of rotigotine within 96 hours after transdermal delivery of rotigotine via a 10 cm(2) [(14)C]rotigotine patch with a total drug content of 4.5mg (corresponding to the nominal dose of 2mg/24 hours for the marketed rotigotine transdermal system) has been 95% explained.,Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854234/),mg,4.5,227749,DB00988,Dopamine
,17854234,systemic absorption,"The systemic absorption was 46.1% of the administered dose, the majority of which was cleared from the body via urine and faeces within 96 hours after patch application.",Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854234/),%,46.1,227750,DB00988,Dopamine
,18757185,K(iz),"BL-1020 displayed strong DA and serotonin (5HT) receptor inhibition (D(2L)K(iz)=0.066 nM, D(2S)K(i)=0.062 nM, 5-HT(2A)K(i)=0.21 nM).","BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757185/),nM,0.066,227899,DB00988,Dopamine
,18757185,K(i),"BL-1020 displayed strong DA and serotonin (5HT) receptor inhibition (D(2L)K(iz)=0.066 nM, D(2S)K(i)=0.062 nM, 5-HT(2A)K(i)=0.21 nM).","BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757185/),nM,0.062,227900,DB00988,Dopamine
,18757185,K(i),"BL-1020 displayed strong DA and serotonin (5HT) receptor inhibition (D(2L)K(iz)=0.066 nM, D(2S)K(i)=0.062 nM, 5-HT(2A)K(i)=0.21 nM).","BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757185/),nM,0.21,227901,DB00988,Dopamine
,24296323,Tmax,"Etamicastat Tmax was 1 hour postdose, and mean t½ was 19 to 28 hours following repeated administration.","Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24296323/),h,1,228595,DB00988,Dopamine
,24296323,t½,"Etamicastat Tmax was 1 hour postdose, and mean t½ was 19 to 28 hours following repeated administration.","Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24296323/),h,19 to 28,228596,DB00988,Dopamine
,11270804,Cmax,"In patients with impaired hepatic function, the geometric mean Cmax and AUC(0-infinity) values for unchanged DHEC were 571.3 pg/ml (CV: 0.87) and 4038 pg x h/ml (CV: 1.04) and were approximately 2 times (2.04, 95% CI: 0.93 to 4.46 and 2.11, 95% CI: 0.58 to 7.73 for Cmax and AUC(0-infinity), respectively) larger than those measured in age-matched healthy controls.",Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270804/),[pg] / [ml],571.3,228839,DB00988,Dopamine
,11270804,AUC(0-infinity),"In patients with impaired hepatic function, the geometric mean Cmax and AUC(0-infinity) values for unchanged DHEC were 571.3 pg/ml (CV: 0.87) and 4038 pg x h/ml (CV: 1.04) and were approximately 2 times (2.04, 95% CI: 0.93 to 4.46 and 2.11, 95% CI: 0.58 to 7.73 for Cmax and AUC(0-infinity), respectively) larger than those measured in age-matched healthy controls.",Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270804/),[h·pg] / [ml],4038,228840,DB00988,Dopamine
,32533536,time to maximum concentration,The median time to maximum concentration range was 1.00-2.26 h in the single ascending-dose study in the fasted state and 1.25-3.02 h in the multiple ascending-dose study at steady state.,Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,1.00-2.26,229093,DB00988,Dopamine
,32533536,time to maximum concentration,The median time to maximum concentration range was 1.00-2.26 h in the single ascending-dose study in the fasted state and 1.25-3.02 h in the multiple ascending-dose study at steady state.,Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,1.25-3.02,229094,DB00988,Dopamine
,32533536,terminal elimination half-life,The mean terminal elimination half-life was dose independent and had a range from 9.12 to 14.3 h in the single ascending-dose study and from 11.1 to 26.8 h in the multiple ascending-dose study.,Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,9.12 to 14.3,229095,DB00988,Dopamine
,32533536,terminal elimination half-life,The mean terminal elimination half-life was dose independent and had a range from 9.12 to 14.3 h in the single ascending-dose study and from 11.1 to 26.8 h in the multiple ascending-dose study.,Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,11.1 to 26.8,229096,DB00988,Dopamine
,32533536,time to maximum concentration,"Additionally, in the single ascending-dose study, absorption of 300 mg of ASP4345 was slightly delayed when administered in the fed state compared with the fasted state; median time to maximum concentration was 1.5 h under the fasting state and 4.0 h under fed states.",Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,1.5,229097,DB00988,Dopamine
,32533536,time to maximum concentration,"Additionally, in the single ascending-dose study, absorption of 300 mg of ASP4345 was slightly delayed when administered in the fed state compared with the fasted state; median time to maximum concentration was 1.5 h under the fasting state and 4.0 h under fed states.",Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,4.0,229098,DB00988,Dopamine
,32533536,time to maximum concentration,ASP4345 appeared in the cerebrospinal fluid with some delay; time to maximum concentration range was from 2.48 to 7.98 h in cerebrospinal fluid compared with 0.75 to 1.03 h in plasma (median cerebrospinal fluid/plasma = 0.188).,Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,2.48 to 7.98,229099,DB00988,Dopamine
,32533536,time to maximum concentration,ASP4345 appeared in the cerebrospinal fluid with some delay; time to maximum concentration range was from 2.48 to 7.98 h in cerebrospinal fluid compared with 0.75 to 1.03 h in plasma (median cerebrospinal fluid/plasma = 0.188).,Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),h,0.75 to 1.03,229100,DB00988,Dopamine
,32533536,time to maximum concentration,ASP4345 appeared in the cerebrospinal fluid with some delay; time to maximum concentration range was from 2.48 to 7.98 h in cerebrospinal fluid compared with 0.75 to 1.03 h in plasma (median cerebrospinal fluid/plasma = 0.188).,Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533536/),,0.188,229101,DB00988,Dopamine
,16289706,extraction recoveries,"The extraction recoveries for ropinirole and internal standard were 90.45 and 65.42%, respectively.",Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289706/),%,90.45,229356,DB00988,Dopamine
,16289706,extraction recoveries,"The extraction recoveries for ropinirole and internal standard were 90.45 and 65.42%, respectively.",Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289706/),%,65.42,229357,DB00988,Dopamine
,24269287,Flux,"The Flux of the optimized formulation reached the maximum (199.17 μg/cm(2)), which was 3% rotigotine and 7% ST-Elastomer 10 with optimal composition of HPC: Carbomer 934 (5:1).",Preparation and characterization of sustained-release rotigotine film-forming gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24269287/),[μg] / [cm(2],199.17,229573,DB00988,Dopamine
,24269287,Flux,"The Flux of the optimized formulation reached the maximum (199.17 μg/cm(2)), which was 3% rotigotine and 7% ST-Elastomer 10 with optimal composition of HPC: Carbomer 934 (5:1).",Preparation and characterization of sustained-release rotigotine film-forming gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24269287/),,3,229574,DB00988,Dopamine
,24269287,Flux,"The Flux of the optimized formulation reached the maximum (199.17 μg/cm(2)), which was 3% rotigotine and 7% ST-Elastomer 10 with optimal composition of HPC: Carbomer 934 (5:1).",Preparation and characterization of sustained-release rotigotine film-forming gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24269287/),,7,229575,DB00988,Dopamine
,24269287,bioavailability,The bioavailability of the optimized formulation compared with intravenous administration was approximately 20%.,Preparation and characterization of sustained-release rotigotine film-forming gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24269287/),%,20,229576,DB00988,Dopamine
,8873850,extraction ratio,"Results showed a high dialyser extraction ratio averaging 38.3%, but a low dialysis clearance of 67 ml/min.",Effect of dialysis on exogenous dopamine in haemodialysed critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8873850/),%,38.3,229730,DB00988,Dopamine
,8873850,clearance,"Results showed a high dialyser extraction ratio averaging 38.3%, but a low dialysis clearance of 67 ml/min.",Effect of dialysis on exogenous dopamine in haemodialysed critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8873850/),[ml] / [min],67,229731,DB00988,Dopamine
,8873850,fraction removed by dial,The fraction removed by dialysis is 2.5%.,Effect of dialysis on exogenous dopamine in haemodialysed critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8873850/),%,2.5,229732,DB00988,Dopamine
,26597180,apparent half-life,"In an ADHD population treated with dasotraline 4 or 8 mg/day, dasotraline was characterized by a mean apparent half-life of 47 h and plasma concentrations reached steady-state by 10 days of dosing.",Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597180/),h,47,231149,DB00988,Dopamine
,14973308,half-life,The half-life of the drug was short (2 to 6 h).,"Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973308/),h,2 to 6,231309,DB00988,Dopamine
,14973308,t(max),"The main metabolite, PNU-100014, was rapidly formed, with a t(max) ranging from 1 to 6 hours.","Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973308/),h,1 to 6,231310,DB00988,Dopamine
,14973308,half-life,"Peak levels of the metabolite are approximately half of the parent drug, and the half-life is slightly longer (4 to 10 h).","Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973308/),h,4 to 10,231311,DB00988,Dopamine
,1348452,maximum concentrations,"The maximum concentrations of MK-458 observed in plasma after oral administration were 139, 240 and 344 ng/L for the 6, 12 and 18 mg doses, respectively, and occurred after 8.0, 9.0 and 5.5 h, respectively.",Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),[ng] / [l],139,231368,DB00988,Dopamine
,1348452,maximum concentrations,"The maximum concentrations of MK-458 observed in plasma after oral administration were 139, 240 and 344 ng/L for the 6, 12 and 18 mg doses, respectively, and occurred after 8.0, 9.0 and 5.5 h, respectively.",Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),[ng] / [l],240,231369,DB00988,Dopamine
,1348452,maximum concentrations,"The maximum concentrations of MK-458 observed in plasma after oral administration were 139, 240 and 344 ng/L for the 6, 12 and 18 mg doses, respectively, and occurred after 8.0, 9.0 and 5.5 h, respectively.",Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),[ng] / [l],344,231370,DB00988,Dopamine
,1348452,areas under the plasma concentration-time curves,"Mean areas under the plasma concentration-time curves were 1728, 2849 and 5484 ng/L.h, respectively.",Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),[ng] / [h·l],1728,231371,DB00988,Dopamine
,1348452,areas under the plasma concentration-time curves,"Mean areas under the plasma concentration-time curves were 1728, 2849 and 5484 ng/L.h, respectively.",Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),[ng] / [h·l],2849,231372,DB00988,Dopamine
,1348452,areas under the plasma concentration-time curves,"Mean areas under the plasma concentration-time curves were 1728, 2849 and 5484 ng/L.h, respectively.",Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),[ng] / [h·l],5484,231373,DB00988,Dopamine
,1348452,plasma half-life,The mean plasma half-life was 3.8 h and mean plasma clearance was 3390 ml/min (203.4 L/h).,Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),h,3.8,231374,DB00988,Dopamine
,1348452,plasma clearance,The mean plasma half-life was 3.8 h and mean plasma clearance was 3390 ml/min (203.4 L/h).,Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),[ml] / [min],3390,231375,DB00988,Dopamine
,1348452,bioavailability,The bioavailability (approximately 5%) was very similar for the 3 tablet formulations tested.,Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348452/),%,5,231376,DB00988,Dopamine
,9233755,Fractions,"Fractions of plasma dobutamine and dopamine sulfoconjugated were 0.73 +/- 0.05 and 0.76 +/- 0.05, respectively.",Sulfoconjugation and renal excretion contribute to the interpatient variation of exogenous catecholamine clearance in critically ill children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9233755/),,0.73,231397,DB00988,Dopamine
,9233755,Fractions,"Fractions of plasma dobutamine and dopamine sulfoconjugated were 0.73 +/- 0.05 and 0.76 +/- 0.05, respectively.",Sulfoconjugation and renal excretion contribute to the interpatient variation of exogenous catecholamine clearance in critically ill children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9233755/),,0.76,231398,DB00988,Dopamine
,9233755,clearances,"Free plasma dobutamine and dopamine clearances were 102 +/- 15 mL/kg/min and 250 +/- 38 mL/kg/min, respectively.",Sulfoconjugation and renal excretion contribute to the interpatient variation of exogenous catecholamine clearance in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9233755/),[ml] / [kg·min],250,231399,DB00988,Dopamine
,9233755,clearance rates,"Patients with serum creatinine concentrations >2 mg/dL had lower free plasma dobutamine and dopamine clearance rates than those patients with serum creatinine of <2 mg/dL (6 +/- 1 vs. 107 +/- 15 mL/kg/min for dobutamine and 40 +/- 38 vs. 270 +/- 39 mL/kg/min for dopamine, respectively, p < .05 for both by Mann-Whitney U test).",Sulfoconjugation and renal excretion contribute to the interpatient variation of exogenous catecholamine clearance in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9233755/),[ml] / [kg·min],40,231400,DB00988,Dopamine
,9233755,clearance rates,"Patients with serum creatinine concentrations >2 mg/dL had lower free plasma dobutamine and dopamine clearance rates than those patients with serum creatinine of <2 mg/dL (6 +/- 1 vs. 107 +/- 15 mL/kg/min for dobutamine and 40 +/- 38 vs. 270 +/- 39 mL/kg/min for dopamine, respectively, p < .05 for both by Mann-Whitney U test).",Sulfoconjugation and renal excretion contribute to the interpatient variation of exogenous catecholamine clearance in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9233755/),[ml] / [kg·min],270,231401,DB00988,Dopamine
,16732562,steady-state flux (J(ss)),"Population value of steady-state flux (J(ss)) in vivo (31 nmol/cm(2) . h with 95% confidence interval (CI) = 20-41) is closer to J(ss) in vitro in DRS (61 nmol/cm(2) . h, CI = 54-67) than in vitro J(ss) in RSC (98 nmol/cm(2) . h, CI = 79-117).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),[nM] / [cm(2)·h],31,231526,DB00988,Dopamine
,16732562,J(ss),"Population value of steady-state flux (J(ss)) in vivo (31 nmol/cm(2) . h with 95% confidence interval (CI) = 20-41) is closer to J(ss) in vitro in DRS (61 nmol/cm(2) . h, CI = 54-67) than in vitro J(ss) in RSC (98 nmol/cm(2) . h, CI = 79-117).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),[nM] / [cm(2)·h],61,231527,DB00988,Dopamine
,16732562,J(ss),"Population value of steady-state flux (J(ss)) in vivo (31 nmol/cm(2) . h with 95% confidence interval (CI) = 20-41) is closer to J(ss) in vitro in DRS (61 nmol/cm(2) . h, CI = 54-67) than in vitro J(ss) in RSC (98 nmol/cm(2) . h, CI = 79-117).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),[nM] / [cm(2)·h],98,231528,DB00988,Dopamine
,16732562,skin release rate constant (K(R)),"On the other hand, skin release rate constant (K(R)) in vivo was similar to the K(R) in RSC (4.8/h, CI = 2.4-7.1 vs. 2.6/h, CI = 2.5-2.6).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),1/[h],4.8,231529,DB00988,Dopamine
,16732562,skin release rate constant (K(R)),"On the other hand, skin release rate constant (K(R)) in vivo was similar to the K(R) in RSC (4.8/h, CI = 2.4-7.1 vs. 2.6/h, CI = 2.5-2.6).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),1/[h],2.6,231530,DB00988,Dopamine
,16732562,K(R),"On the other hand, skin release rate constant (K(R)) in vivo was similar to the K(R) in RSC (4.8/h, CI = 2.4-7.1 vs. 2.6/h, CI = 2.5-2.6).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),1/[h],4.8,231531,DB00988,Dopamine
,16732562,K(R),"On the other hand, skin release rate constant (K(R)) in vivo was similar to the K(R) in RSC (4.8/h, CI = 2.4-7.1 vs. 2.6/h, CI = 2.5-2.6).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),1/[h],2.6,231532,DB00988,Dopamine
,16732562,lag time (t(L)),"Kinetic lag time (t(L)) in vivo was negligible, which is close to in vitro t(L) in RSC (0.0 h, CI = 0.0-0.1).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),h,0.0,231533,DB00988,Dopamine
,16732562,t(L),"Kinetic lag time (t(L)) in vivo was negligible, which is close to in vitro t(L) in RSC (0.0 h, CI = 0.0-0.1).",Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16732562/),h,0.0,231534,DB00988,Dopamine
,23618742,flow rate,"The mobile phase was acetonitrile: 5mM ammonium formate containing 0.3% formic acid (pH 4.8) (25:75, v/v), with a flow rate of 0.35mL/min.",Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618742/),[ml] / [min],0.35,231535,DB00988,Dopamine
more,23618742,recoveries,"The mean recoveries were more than 78.88%, and the intra- and inter-day precisions were less than 10.24% and accuracy was -5.78 to 5.40%, which indicated that the quantitative method was reliable and accurate.",Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618742/),%,78.88,231536,DB00988,Dopamine
,17005916,Ki,"On the stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate binding to this receptor, BF2.649 behaved as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50 value of 1.5 nM and an intrinsic activity approximately 50% higher than that of ciproxifan.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),nM,0.16,231886,DB00988,Dopamine
,17005916,EC50,"On the stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate binding to this receptor, BF2.649 behaved as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50 value of 1.5 nM and an intrinsic activity approximately 50% higher than that of ciproxifan.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),nM,1.5,231887,DB00988,Dopamine
,17005916,oral bioavailability coefficient,"In mice, the oral bioavailability coefficient, i.e., the ratio of plasma areas under the curve after oral and i.v. administrations, respectively, was 84%.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),%,84,231888,DB00988,Dopamine
,17005916,ED50,"BF2.649 dose dependently enhanced tele-methylhistamine levels in mouse brain, an index of histaminergic neuron activity, with an ED50 value of 1.6 mg/kg p.o., a response that persisted after repeated administrations for 17 days.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),[mg] / [kg],1.6,231889,DB00988,Dopamine
,19192440,half-life,"Its unique pharmacokinetic profile as an oral drug with long half-life (2-7 weeks), low cost, and low induction of extrapyramidal symptoms warrants further investigation, particularly in psychiatric patients with low adherence to treatment.",Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192440/),weeks,2-7,233080,DB00988,Dopamine
,8181287,maximum dose,Timed infusion of dopexamine to a maximum dose of 6 micrograms/kg/min.,Protecting the gut and the liver in the critically ill: effects of dopexamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181287/),,6,234870,DB00988,Dopamine
,8181287,Cardiac index,"Cardiac index increased with dopexamine from a baseline median of 4.0 L/min/m2 (range 1.2 to 5.5) to 4.8 L/min/m2 (range 1.5 to 8.03) (p < .01), and returned to its previous level 1 hr after the infusion ended (median 4.0 L/min/m2 [range 1.4 to 5.8], p < .01).",Protecting the gut and the liver in the critically ill: effects of dopexamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181287/),[l] / [m2·min],4.0,234871,DB00988,Dopamine
,8181287,Cardiac index,"Cardiac index increased with dopexamine from a baseline median of 4.0 L/min/m2 (range 1.2 to 5.5) to 4.8 L/min/m2 (range 1.5 to 8.03) (p < .01), and returned to its previous level 1 hr after the infusion ended (median 4.0 L/min/m2 [range 1.4 to 5.8], p < .01).",Protecting the gut and the liver in the critically ill: effects of dopexamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181287/),[l] / [m2·min],4.8,234872,DB00988,Dopamine
,8181287,Cardiac index,"Cardiac index increased with dopexamine from a baseline median of 4.0 L/min/m2 (range 1.2 to 5.5) to 4.8 L/min/m2 (range 1.5 to 8.03) (p < .01), and returned to its previous level 1 hr after the infusion ended (median 4.0 L/min/m2 [range 1.4 to 5.8], p < .01).",Protecting the gut and the liver in the critically ill: effects of dopexamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181287/),[l] / [m2·min],4.0,234873,DB00988,Dopamine
,8181287,half-life,"Indocyanine green half-life decreased but not significantly with dopexamine (medians before and during the infusion were 6.6 and 6.3 mins, respectively).",Protecting the gut and the liver in the critically ill: effects of dopexamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181287/),min,6.6,234874,DB00988,Dopamine
,8181287,half-life,"Indocyanine green half-life decreased but not significantly with dopexamine (medians before and during the infusion were 6.6 and 6.3 mins, respectively).",Protecting the gut and the liver in the critically ill: effects of dopexamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181287/),min,6.3,234875,DB00988,Dopamine
,8181287,half-life,"Indocyanine green half-life increased significantly 1 hr after the infusion ended (median 7.4 mins [range 4.4 to 14.8], p < .05), and changes in cardiac index correlated with changes in indocyanine green half-life (Rs2 = 0.60, p < .001).",Protecting the gut and the liver in the critically ill: effects of dopexamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181287/),min,7.4,234876,DB00988,Dopamine
,17519385,plasma elimination half-life,"3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively.",Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519385/),h,1.9,235022,DB00988,Dopamine
,17519385,plasma elimination half-life,"3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively.",Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519385/),h,0.5,235023,DB00988,Dopamine
,17519385,plasma elimination half-life,"3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively.",Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519385/),h,21.1,235024,DB00988,Dopamine
,2117017,permeability,"The individual permeabilities were determined by linear regression analysis, according to which the average methyl-FDOPA permeability in the blood-brain barrier was twice that of FDOPA, which averaged 0.037 ml g-1 min-1.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),[ml] / [g·min],0.037,235129,DB00988,Dopamine
,2117017,perme,"The permeability ratio was used to determine the fractional clearance from the brain of FDOPA (and hence of methyl-FDOPA), which averaged 0.081 min-1.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),1/[min],0.081,235130,DB00988,Dopamine
,2117017,fractional clearance,"The permeability ratio was used to determine the fractional clearance from the brain of FDOPA (and hence of methyl-FDOPA), which averaged 0.081 min-1.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),1/[min],0.081,235131,DB00988,Dopamine
,2117017,de,"In the striatum, the measured average FDOPA decarboxylation rate constant (kD3) was 0.010 min-1, or no more than 1% of the rate of striatal decarboxylation of DOPA measured in vitro and in vivo.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),1/[min],0.010,235132,DB00988,Dopamine
,1904753,clearance,"2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[ml] / [kg·min],4.43,235664,DB00988,Dopamine
,1904753,clearance,"2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[ml] / [kg·min],4.92,235665,DB00988,Dopamine
,1904753,half-lives,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),min,29.2,235666,DB00988,Dopamine
,1904753,half-lives,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),min,32.5,235667,DB00988,Dopamine
,1904753,volumes of distribution,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[l] / [kg],0.183,235668,DB00988,Dopamine
,1904753,volumes of distribution,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),1/[kg·l],0.235,235669,DB00988,Dopamine
,7669486,refractory period,The refractory period for a second prolactin release similar to the first one after remoxipride was found to be 24 h for most of the subjects.,Influence of the dosing interval on prolactin release after remoxipride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669486/),h,24,236103,DB00988,Dopamine
,33599975,maximum/minimum ratio of plasma concentration,"The maximum/minimum ratio of plasma concentration was estimated as 1.10 at steady state, indicating minimal fluctuation.",Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D2 Receptor Occupancy in Clinical Settings. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33599975/),,1.10,236128,DB00988,Dopamine
≤,23739987,tmax,"Intranasally administered loxapine was efficiently absorbed into systemic circulation followed by entering brain, with tmax ≤15 min in all brain regions.",Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739987/),min,15,236624,DB00988,Dopamine
,31984737,maximum plasma concentrations,A new ultrahigh-performance liquid chromatography method coupled to electrospray ionization tandem mass spectrometry (UHPLC-ESI-MS/MS) method determined maximum plasma concentrations of 12.0-17.3 nM free hordenine after 0-60 min.,"Absorption, Biokinetics, and Metabolism of the Dopamine D2 Receptor Agonist Hordenine (N,N-Dimethyltyramine) after Beer Consumption in Humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31984737/),nM,12.0-17.3,236705,DB00988,Dopamine
,31984737,elimination half-lives,The elimination half-lives in plasma were 52.7-66.4 min for free hordenine and about 60/80 min longer for hordenine sulfate and hordenine glucuronide.,"Absorption, Biokinetics, and Metabolism of the Dopamine D2 Receptor Agonist Hordenine (N,N-Dimethyltyramine) after Beer Consumption in Humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31984737/),min,52.7-66.4,236706,DB00988,Dopamine
,31984737,elimination half-lives,The elimination half-lives in plasma were 52.7-66.4 min for free hordenine and about 60/80 min longer for hordenine sulfate and hordenine glucuronide.,"Absorption, Biokinetics, and Metabolism of the Dopamine D2 Receptor Agonist Hordenine (N,N-Dimethyltyramine) after Beer Consumption in Humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31984737/),min,60/80,236707,DB00988,Dopamine
,31984737,Urinary excretion,"Urinary excretion peaked 2-3.5 h after consumption and accumulated to 3.78 μmol within 24 h, corresponding to 9.9% of the ingested dose.","Absorption, Biokinetics, and Metabolism of the Dopamine D2 Receptor Agonist Hordenine (N,N-Dimethyltyramine) after Beer Consumption in Humans. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31984737/),μM,3.78,236708,DB00988,Dopamine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.1,237702,DB00988,Dopamine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,10.5,237703,DB00988,Dopamine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.5,237704,DB00988,Dopamine
,8008708,Kpapp,"The mean Kpapp values for (+)-MPD in the striatum at 120 and 240 min after administration of racemic MPD were 10.1 and 10.5, respectively, and these values at each time were significantly larger than the Kpapp values (7.5 and 7.0, respectively) for the (-)-isomer (P < 0.01).",Stereospecific distribution of methylphenidate enantiomers in rat brain: specific binding to dopamine reuptake sites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008708/),,7.0,237705,DB00988,Dopamine
,34018344,plasma half-life,"Pharmacokinetic analysis indicated rapid absorption and dose-linear pharmacokinetics of mesdopetam, with a plasma half-life of around 7 h, upon single and repeated dosing.","A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34018344/),h,7,237731,DB00988,Dopamine
<,10630885,C.V.,The precision of the method was satisfactory as indicated by an intra-day C.V. of < or = 4% and an inter-day C.V. of < or = 6%.,High-performance liquid chromatographic analysis of the D4 receptor antagonist SCH 66712 in rat plasma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630885/),%,4,237934,DB00988,Dopamine
<,10630885,C.V.,The precision of the method was satisfactory as indicated by an intra-day C.V. of < or = 4% and an inter-day C.V. of < or = 6%.,High-performance liquid chromatographic analysis of the D4 receptor antagonist SCH 66712 in rat plasma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630885/),%,6,237935,DB00988,Dopamine
,20836725,clearance,"In vivo, PF-592379 has low-moderate clearance relative to liver blood flow of 6.3 and 8.5 ml/min/kg in dog and 44.8 and 58.2 ml/min/kg in rat.","Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),[ml] / [kg·min],6.3,238432,DB00988,Dopamine
,20836725,clearance,"In vivo, PF-592379 has low-moderate clearance relative to liver blood flow of 6.3 and 8.5 ml/min/kg in dog and 44.8 and 58.2 ml/min/kg in rat.","Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),[ml] / [kg·min],8.5,238433,DB00988,Dopamine
,20836725,clearance,"In vivo, PF-592379 has low-moderate clearance relative to liver blood flow of 6.3 and 8.5 ml/min/kg in dog and 44.8 and 58.2 ml/min/kg in rat.","Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),[ml] / [kg·min],44.8,238434,DB00988,Dopamine
,20836725,clearance,"In vivo, PF-592379 has low-moderate clearance relative to liver blood flow of 6.3 and 8.5 ml/min/kg in dog and 44.8 and 58.2 ml/min/kg in rat.","Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),[ml] / [kg·min],58.2,238435,DB00988,Dopamine
,20836725,oral bioavailability,It has high permeability in Caco-2 cells and was completely absorbed in rat and dog pharmacokinetic studies with an oral bioavailability of 28% in both rats and 61 and 87% in the dogs.,"Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),%,28,238436,DB00988,Dopamine
,20836725,oral bioavailability,It has high permeability in Caco-2 cells and was completely absorbed in rat and dog pharmacokinetic studies with an oral bioavailability of 28% in both rats and 61 and 87% in the dogs.,"Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),%,61,238437,DB00988,Dopamine
,20836725,oral bioavailability,It has high permeability in Caco-2 cells and was completely absorbed in rat and dog pharmacokinetic studies with an oral bioavailability of 28% in both rats and 61 and 87% in the dogs.,"Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),%,87,238438,DB00988,Dopamine
>,20836725,oral bioavailability,PF-592379 was predicted to have complete absorption from the gastrointestinal tract and an oral bioavailability of >60% in the clinic.,"Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),%,60,238439,DB00988,Dopamine
,20836725,oral clearance,"Clinical data verified that PF-592379 is a low clearance compound in human, with a mean oral clearance of 6.5 ml/min/kg following a 200 mg oral dose.","Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20836725/),[ml] / [kg·min],6.5,238440,DB00988,Dopamine
,2573048,renal plasma clearance,"Fenoldopam-8-sulfate exhibited a mean (+/- SE) renal plasma clearance of 129 +/- 4 ml/min, which was independent of its AUC.",A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573048/),[ml] / [min],129,239145,DB00988,Dopamine
,2573048,renal plasma clearance,"In contrast, fenoldopam renal plasma clearance ranged from 2220 to 150 ml/min and decreased nonlinearily with increasing fenoldopam AUC.",A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573048/),[ml] / [min],2220 to 150,239146,DB00988,Dopamine
,2573048,initial maximal renal clearance,"The analysis predicted an initial maximal renal clearance of 2852 ml/min, which decreased to 78 ml/min at maximal inhibition.",A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573048/),[ml] / [min],2852,239147,DB00988,Dopamine
,2573048,initial maximal renal clearance,"The analysis predicted an initial maximal renal clearance of 2852 ml/min, which decreased to 78 ml/min at maximal inhibition.",A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573048/),[ml] / [min],78,239148,DB00988,Dopamine
,2573048,AUC,The fenoldopam AUC required to half-saturate fenoldopam renal clearance was 5.2 ng x hr/ml.,A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573048/),[h·ng] / [ml],5.2,239149,DB00988,Dopamine
,10755648,partition coefficients,"The partition coefficients in octanol and buffer were 2.12 and 2.19 at pH 7.0 and 7.4, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),,2.12,239616,DB00988,Dopamine
,10755648,partition coefficients,"The partition coefficients in octanol and buffer were 2.12 and 2.19 at pH 7.0 and 7.4, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),,2.19,239617,DB00988,Dopamine
,10755648,uptake,"Biodistribution displayed moderate uptake in rat brain (0.28 %ID/organ at 2 min) and the striatal uptake was 0.193, 0.142, and 0.136 %ID/g at 2, 60, and 120 min, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),[%id] / [g],0.193,239618,DB00988,Dopamine
,10755648,uptake,"Biodistribution displayed moderate uptake in rat brain (0.28 %ID/organ at 2 min) and the striatal uptake was 0.193, 0.142, and 0.136 %ID/g at 2, 60, and 120 min, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),[%id] / [g],0.142,239619,DB00988,Dopamine
,10755648,uptake,"Biodistribution displayed moderate uptake in rat brain (0.28 %ID/organ at 2 min) and the striatal uptake was 0.193, 0.142, and 0.136 %ID/g at 2, 60, and 120 min, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),[%id] / [g],0.136,239620,DB00988,Dopamine
,10755648,ratios,"The ratios of striatal/cerebellar (ST/CB) uptake were 2.4, 4.45, and 2.45 %ID/g at 60, 120, and 240 min, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),[%id] / [g],2.4,239621,DB00988,Dopamine
,10755648,ratios,"The ratios of striatal/cerebellar (ST/CB) uptake were 2.4, 4.45, and 2.45 %ID/g at 60, 120, and 240 min, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),[%id] / [g],4.45,239622,DB00988,Dopamine
,10755648,ratios,"The ratios of striatal/cerebellar (ST/CB) uptake were 2.4, 4.45, and 2.45 %ID/g at 60, 120, and 240 min, respectively.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),[%id] / [g],2.45,239623,DB00988,Dopamine
,10755648,initial half-life,"Blood clearance kinetics was performed in rabbits, and the initial half-life of 1.18 min and late half-life of 367.8 min were obtained.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),min,1.18,239624,DB00988,Dopamine
,10755648,late half-life,"Blood clearance kinetics was performed in rabbits, and the initial half-life of 1.18 min and late half-life of 367.8 min were obtained.",The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755648/),min,367.8,239625,DB00988,Dopamine
,1860323,half-lives of distribution,"The half-lives of distribution and elimination were 1.8 +/- 1.1 and 26 +/- 14 (SD) mins, respectively.",Pharmacokinetics of dopamine in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860323/),min,1.8,239917,DB00988,Dopamine
,1860323,elimination,"The half-lives of distribution and elimination were 1.8 +/- 1.1 and 26 +/- 14 (SD) mins, respectively.",Pharmacokinetics of dopamine in infants and children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860323/),min,26,239918,DB00988,Dopamine
,1860323,apparent volume of distribution,The apparent volume of distribution was 2952 +/- 2332 mL/kg.,Pharmacokinetics of dopamine in infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860323/),[ml] / [kg],2952,239919,DB00988,Dopamine
,1860323,clearance rate,The clearance rate was 454 +/- 900 mL/kg.min.,Pharmacokinetics of dopamine in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860323/),[ml] / [kg·min],454,239920,DB00988,Dopamine
,27436172,apparent oral clearance (CL/F),"Estimated armodafinil apparent oral clearance (CL/F), volume of distribution (Vc/F), and absorption t½ were 2.01 L/h, 45 L, and 0.226 hours, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),[l] / [h],2.01,240084,DB00988,Dopamine
,27436172,volume of distribution (Vc/F),"Estimated armodafinil apparent oral clearance (CL/F), volume of distribution (Vc/F), and absorption t½ were 2.01 L/h, 45 L, and 0.226 hours, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),l,45,240085,DB00988,Dopamine
,27436172,absorption t½,"Estimated armodafinil apparent oral clearance (CL/F), volume of distribution (Vc/F), and absorption t½ were 2.01 L/h, 45 L, and 0.226 hours, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),h,0.226,240086,DB00988,Dopamine
,27436172,CL/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),[l] / [h],16.7,240087,DB00988,Dopamine
,27436172,CL/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),[l] / [h],6.82,240088,DB00988,Dopamine
,27436172,Vc/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),l,8.95,240089,DB00988,Dopamine
,27436172,Vc/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),l,12.4,240090,DB00988,Dopamine
,24647883,Tmax,"The study data showed that YQA-14 is a basic lipophilic compound, with rapid absorption (Tmax ~ 1 h) in both rats and dogs.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),h,1,241017,DB00988,Dopamine
,24647883,clearance,"The PBPK model refined with human data predicted that YQA-14 would have a clearance of 8.0 ml/min/kg, a volume distribution of 1.7 l/kg and a bioavailability of 16.9%.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),[ml] / [kg·min],8.0,241018,DB00988,Dopamine
,24647883,volume distribution,"The PBPK model refined with human data predicted that YQA-14 would have a clearance of 8.0 ml/min/kg, a volume distribution of 1.7 l/kg and a bioavailability of 16.9%.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),[l] / [kg],1.7,241019,DB00988,Dopamine
,24647883,bioavailability,"The PBPK model refined with human data predicted that YQA-14 would have a clearance of 8.0 ml/min/kg, a volume distribution of 1.7 l/kg and a bioavailability of 16.9%.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),%,16.9,241020,DB00988,Dopamine
,21477416,Peak D₂ receptor occupancy,"Peak D₂ receptor occupancy was significantly higher with quetiapine IR than XR in all subjects (50 ± 4% and 32 ± 11%, respectively), consistent with lower peak plasma concentrations for the XR formulation.",Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477416/),%,50,243487,DB00988,Dopamine
,21477416,Peak D₂ receptor occupancy,"Peak D₂ receptor occupancy was significantly higher with quetiapine IR than XR in all subjects (50 ± 4% and 32 ± 11%, respectively), consistent with lower peak plasma concentrations for the XR formulation.",Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477416/),%,32,243488,DB00988,Dopamine
,22773165,D₂ occupancies,JNJ-37822681 plasma concentrations of 3.17 to 63.0 ng/mL resulted in D₂ occupancies of 0 % to 62 %.,"D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773165/),,0,244414,DB00988,Dopamine
,22773165,D₂ occupancies,JNJ-37822681 plasma concentrations of 3.17 to 63.0 ng/mL resulted in D₂ occupancies of 0 % to 62 %.,"D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773165/),,62,244415,DB00988,Dopamine
,22773165,concentration leading to 50 % occupancy,The concentration leading to 50 % occupancy was 18.5 ng/mL (coefficient of variation 3.9 %) after single dose and 26.0 ng/mL (8.2 %) at steady state.,"D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773165/),[ng] / [ml],18.5,244416,DB00988,Dopamine
,22773165,concentration leading to 50 % occupancy,The concentration leading to 50 % occupancy was 18.5 ng/mL (coefficient of variation 3.9 %) after single dose and 26.0 ng/mL (8.2 %) at steady state.,"D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773165/),[ng] / [ml],26.0,244417,DB00988,Dopamine
,16600452,peak plasma concentrations,"Before carbamazepine coadministration, the peak plasma concentrations+/-SD of perospirone and ID-15036 were 4.0+/-4.3 and 11.7+/-7.1 ng/ml, respectively.",Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600452/),[ng] / [ml],4.0,244893,DB00988,Dopamine
,16600452,peak plasma concentrations,"Before carbamazepine coadministration, the peak plasma concentrations+/-SD of perospirone and ID-15036 were 4.0+/-4.3 and 11.7+/-7.1 ng/ml, respectively.",Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16600452/),[ng] / [ml],11.7,244894,DB00988,Dopamine
,25817262,overall recoveries,"The overall recoveries of LE300 and its N-methyl metabolite from mouse sera were in the range 97.9-101.5% with %RSD ranging from 0.98% to 3.63%, which were in line with ICH guidelines.",Selective microemulsion liquid chromatography analysis of dopamine receptor antagonist LE300 and its N-methyl metabolite in mouse sera by using a monolithic silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25817262/),%,97.9-101.5,245849,DB00988,Dopamine
,3342635,clearance,"Dopamine clearance averaged 96.2 +/- 55.4 ml/kg.min in 13 patients in the neonatal ICU, and 58.8 +/- 51 ml/kg.min in 14 patients in the pediatric ICU.",Steady-state dopamine clearance in critically ill infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342635/),[ml] / [kg·min],96.2,245886,DB00988,Dopamine
,3342635,clearance,"Dopamine clearance averaged 96.2 +/- 55.4 ml/kg.min in 13 patients in the neonatal ICU, and 58.8 +/- 51 ml/kg.min in 14 patients in the pediatric ICU.",Steady-state dopamine clearance in critically ill infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342635/),[ml] / [kg·min],58.8,245887,DB00988,Dopamine
,3342635,clearance,Dopamine clearance in these patients (25.1 +/- 17.2 ml/kg.min) was substantially lower than in the other patients (p less than .01).,Steady-state dopamine clearance in critically ill infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342635/),[ml] / [kg·min],25.1,245888,DB00988,Dopamine
,16390347,H(1)R,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,16.7,246573,DB00988,Dopamine
,16390347,H(1)R,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,77.7,246574,DB00988,Dopamine
,16390347,H(1)R,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,14.7,246575,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,16.7,246576,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,77.7,246577,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,14.1,246578,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,85.9,246579,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,14.7,246580,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,76.1,246581,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,12.8,246582,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,69.7,246583,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,12.5,246584,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,66.5,246585,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,13.9,246586,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,65.8,246587,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,19.5,246588,DB00988,Dopamine
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,60.6,246589,DB00988,Dopamine
,16390347,occupancy,"Overall cortical mean H(1)R occupancy of olopatadine and ketotifen were 15% and 72%, respectively.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),%,15,246590,DB00988,Dopamine
,16390347,occupancy,"Overall cortical mean H(1)R occupancy of olopatadine and ketotifen were 15% and 72%, respectively.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),%,72,246591,DB00988,Dopamine
,27214664,tmax,Dipraglurant was rapidly absorbed (tmax = 1 hour).,A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214664/),h,1,246701,DB00988,Dopamine
,27214664,Cmax,The 100-mg dose led to a mean Cmax of 1844 ng/mL on day 28.,A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214664/),[ng] / [ml],1844,246702,DB00988,Dopamine
,7636721,peak plasma,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),μM,1.7,246902,DB00988,Dopamine
,7636721,peak plasma,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,36,246903,DB00988,Dopamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),μM,2.9,246904,DB00988,Dopamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,73,246905,DB00988,Dopamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,25,246906,DB00988,Dopamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,50,246907,DB00988,Dopamine
,21678422,distribution volume,"Accordingly, the distribution volume during the terminal phase of PETc (13.6 ± 10.8 L) was significantly lower than that during the terminal phase (82.2 ± 30.5 L) and at steady state (59.4 ± 20 L) for REFc, and the dilution of raclopride in body for PETc at 50 min was 38 L, whereas it was 1015 L for REFc at 30 h.",Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21678422/),l,13.6,247538,DB00988,Dopamine
,21678422,distribution volume,"Accordingly, the distribution volume during the terminal phase of PETc (13.6 ± 10.8 L) was significantly lower than that during the terminal phase (82.2 ± 30.5 L) and at steady state (59.4 ± 20 L) for REFc, and the dilution of raclopride in body for PETc at 50 min was 38 L, whereas it was 1015 L for REFc at 30 h.",Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21678422/),l,82.2,247539,DB00988,Dopamine
,21678422,distribution volume,"Accordingly, the distribution volume during the terminal phase of PETc (13.6 ± 10.8 L) was significantly lower than that during the terminal phase (82.2 ± 30.5 L) and at steady state (59.4 ± 20 L) for REFc, and the dilution of raclopride in body for PETc at 50 min was 38 L, whereas it was 1015 L for REFc at 30 h.",Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21678422/),l,59.4,247540,DB00988,Dopamine
,2774511,distribution half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,5,247981,DB00988,Dopamine
,2774511,elimination half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,33,247982,DB00988,Dopamine
,23138261,concentrations at half-maximal inhibition,"Plasma haloperidol concentrations at half-maximal inhibition were 0.791 and 0.650 ng/ml, in putamen and caudate nucleus.","Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138261/),[ng] / [ml],0.791,248007,DB00988,Dopamine
,23138261,concentrations at half-maximal inhibition,"Plasma haloperidol concentrations at half-maximal inhibition were 0.791 and 0.650 ng/ml, in putamen and caudate nucleus.","Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138261/),[ng] / [ml],0.650,248008,DB00988,Dopamine
,6190484,biological half-life,"The intracerebral level of morphine was found to depend on the dose injected, and the biological half-life of the drug was estimated to be about 1 hr.",Direct correlation between level of morphine and its biochemical effect on monoamine systems in mouse brain. Evidence for involvement of dopaminergic neurons in the pharmacological action of acute morphine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6190484/),h,1,248070,DB00988,Dopamine
,2139724,half-life,Myocardial accumulation of GBR 12909 showed monophasic exponential kinetics with a half-life of 93 min.,"Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,93,248645,DB00988,Dopamine
,2139724,half-lives,"The disposition followed a three-phasic exponential time-course with half-lives of 1.1, 17 and 98 min., respectively, which was interpreted as three-compartment kinetics.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,1.1,248646,DB00988,Dopamine
,2139724,half-lives,"The disposition followed a three-phasic exponential time-course with half-lives of 1.1, 17 and 98 min., respectively, which was interpreted as three-compartment kinetics.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,17,248647,DB00988,Dopamine
,2139724,half-lives,"The disposition followed a three-phasic exponential time-course with half-lives of 1.1, 17 and 98 min., respectively, which was interpreted as three-compartment kinetics.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,98,248648,DB00988,Dopamine
,2139724,EC50,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),nM,29,248649,DB00988,Dopamine
,2139724,EC50,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),nM,688,248650,DB00988,Dopamine
,2139724,Hill-exponents,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),,0.6,248651,DB00988,Dopamine
,2139724,Hill-exponents,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),,1.1,248652,DB00988,Dopamine
,9013291,pKb,"These findings may be due, at least in part, to the greater hydrophobicity of CE relative to COC and to the lower pKb of CE (8.23) than that of COC (8.60).",Cocaine- and cocaethylene-creatinine clearance ratios in humans. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013291/),,8.23,248689,DB00988,Dopamine
,9013291,pKb,"These findings may be due, at least in part, to the greater hydrophobicity of CE relative to COC and to the lower pKb of CE (8.23) than that of COC (8.60).",Cocaine- and cocaethylene-creatinine clearance ratios in humans. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013291/),,8.60,248690,DB00988,Dopamine
,26763106,volume of distribution,"This study showed that the geometric mean of the volume of distribution, clearance, and half-life (198 mL/kg, 46 mL/kg/min, and 3.0 mins) is similar to pharmacokinetic parameters for humans.","The pharmacokinetics of intravenous fenoldopam in healthy, awake cats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26763106/),[ml] / [kg],198,248830,DB00988,Dopamine
,26763106,clearance,"This study showed that the geometric mean of the volume of distribution, clearance, and half-life (198 mL/kg, 46 mL/kg/min, and 3.0 mins) is similar to pharmacokinetic parameters for humans.","The pharmacokinetics of intravenous fenoldopam in healthy, awake cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26763106/),[ml] / [kg·min],46,248831,DB00988,Dopamine
,26763106,half-life,"This study showed that the geometric mean of the volume of distribution, clearance, and half-life (198 mL/kg, 46 mL/kg/min, and 3.0 mins) is similar to pharmacokinetic parameters for humans.","The pharmacokinetics of intravenous fenoldopam in healthy, awake cats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26763106/),min,3.0,248832,DB00988,Dopamine
,20082577,inactivation constant (K(I)),"For human CYP3A, the inactivation constant (K(I)) is 12 microM, and the maximum inactivation rate (k(inact)) is 0.037 min(-1).",Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20082577/),μM,12,249994,DB00988,Dopamine
,20082577,maximum inactivation rate (k(inact)),"For human CYP3A, the inactivation constant (K(I)) is 12 microM, and the maximum inactivation rate (k(inact)) is 0.037 min(-1).",Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20082577/),1/[min],0.037,249995,DB00988,Dopamine
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.94,250000,DB00988,Dopamine
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.62,250001,DB00988,Dopamine
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.26,250002,DB00988,Dopamine
,23318470,Oral bioavailability,Oral bioavailability of each compound ranged from 6% (C-DIM8) to 42% (C-DIM12).,Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318470/),%,6,250570,DB00988,Dopamine
,23318470,Oral bioavailability,Oral bioavailability of each compound ranged from 6% (C-DIM8) to 42% (C-DIM12).,Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318470/),%,42,250571,DB00988,Dopamine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.35,251269,DB00988,Dopamine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.82,251270,DB00988,Dopamine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],2.14,251271,DB00988,Dopamine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],3.27,251272,DB00988,Dopamine
,11847938,time to Cmax,"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),h,4,251273,DB00988,Dopamine
,7884663,elimination half-lives,"Cabergoline elimination half-lives calculated from urinary data were 68 and 63 h after administration of the tablets and the solution, respectively.",Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884663/),h,68,251358,DB00988,Dopamine
,7884663,elimination half-lives,"Cabergoline elimination half-lives calculated from urinary data were 68 and 63 h after administration of the tablets and the solution, respectively.",Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884663/),h,63,251359,DB00988,Dopamine
,7884663,U,"Urinary excretion of unchanged cabergoline accounted, on average, for 1.92% (range, 0.14-3.26) and 1.80% (range, 0.67-3.09) of the dose after administration of the tablets and the aqueous solution, respectively.",Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884663/),,1,251360,DB00988,Dopamine
,7884663,Relative bioavailability,Relative bioavailability of tablets vs solution was 99% (geometric mean with the 90% confidence intervals of 68-144%).,Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884663/),%,99,251361,DB00988,Dopamine
,32279140,maximal concentration,"The maximal concentration of R-PhP in the brain tissues was 28 µg/g and 18 µg/g tissue after ip and po administration, respectively.",Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279140/),[μg] / [g],28,252921,DB00988,Dopamine
,32279140,maximal concentration,"The maximal concentration of R-PhP in the brain tissues was 28 µg/g and 18 µg/g tissue after ip and po administration, respectively.",Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279140/),[μg] / [g],18,252922,DB00988,Dopamine
,15689153,Ki,"Benzazepines 1 and 2 (SCH 23390 and SCH 39166, respectively) are two classical benzazepine D1/D5 antagonists, with Ki values 1.4 and 1.2 nM, respectively.","Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689153/),nM,1.4,253722,DB00988,Dopamine
,15689153,Ki,"Benzazepines 1 and 2 (SCH 23390 and SCH 39166, respectively) are two classical benzazepine D1/D5 antagonists, with Ki values 1.4 and 1.2 nM, respectively.","Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15689153/),nM,1.2,253723,DB00988,Dopamine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,78.87,254806,DB00988,Dopamine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,81.55,254807,DB00988,Dopamine
,18498913,recoveries,"The mean recoveries of the 0.4, 20.0, and 180.0 ng/mL levels were 78.87%, 81.55%, and 81.98%, respectively.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,81.98,254808,DB00988,Dopamine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],6.20,254809,DB00988,Dopamine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],11.60,254810,DB00988,Dopamine
,18498913,C(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],25.34,254811,DB00988,Dopamine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,5.70,254812,DB00988,Dopamine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.00,254813,DB00988,Dopamine
,18498913,T(max),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.89,254814,DB00988,Dopamine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],486.19,254815,DB00988,Dopamine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],889.32,254816,DB00988,Dopamine
,18498913,AUC(0-t),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],1772.91,254817,DB00988,Dopamine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],540.05,254818,DB00988,Dopamine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],932.07,254819,DB00988,Dopamine
,18498913,AUC(0-infinity),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],1853.29,254820,DB00988,Dopamine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,66.86,254821,DB00988,Dopamine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,63.57,254822,DB00988,Dopamine
,18498913,t(1/2),"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,62.06,254823,DB00988,Dopamine
,18498913,MRT,"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),,99.37,254824,DB00988,Dopamine
,18498913,MRT,"After single-dose oral administration, the main pharmacokinetic parameters found for memantine at doses of 5, 10, and 20 mg were as follows: C(max), 6.20 (0.75), 11.60 (1.95), and 25.34 (8.34) ng/mL, respectively; T(max), 5.70 (1.64), 6.00 (1.33), and 6.89 (1.41) h; AUC(0-t), 486.19 (80.00), 889.32 (239.49), and 1772.91 (784.07) ng x h/mL; AUC(0-infinity), 540.05 (89.68), 932.07 (230.82), and 1853.29 (776.85) ng x h/mL; t(1/2), 66.86 (11.75), 63.57 (12.58), and 62.06 (9.26) h; and MRT, 99.37 (16.96), 91.73 (18.16), and 89.56 (13.77) h.",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),,91.73,254825,DB00988,Dopamine
,18498913,T(max),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,6.80,254826,DB00988,Dopamine
,18498913,C(ssmax),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],19.69,254827,DB00988,Dopamine
,18498913,C(ssmin),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],12.76,254828,DB00988,Dopamine
,18498913,C(ssav),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[ng] / [ml],16.10,254829,DB00988,Dopamine
,18498913,t(1/2),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,64.57,254830,DB00988,Dopamine
,18498913,MRT,"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),h,93.17,254831,DB00988,Dopamine
,18498913,AUC(ss),"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),[h·ng] / [ml],386.37,254832,DB00988,Dopamine
,18498913,DF,"The main pharmacokinetic parameters found for memantine at doses of 5 mg once daily for 14 days were as follows: T(max), 6.80 (2.46) h; C(ssmax), 19.69 (2.00) ng/mL; C(ssmin), 12.76 (2.80) ng/mL; C(ssav), 16.10 (2.46) ng/mL; t(1/2), 64.57 (15.78) h; MRT, 93.17 (23.38) h; AUC(ss),386.37 (59.00) ng x h/mL; and DF, 44.47% (15.27%).",Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498913/),%,44.47,254833,DB00988,Dopamine
,9571226,cumulative excretion,"One week after administration of the dose, cumulative excretion amounted to 67.8 +/- 2.5% in the urine and 22.0 +/- 5.6% in the feces.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),%,67.8,255209,DB00988,Dopamine
,9571226,cumulative excretion,"One week after administration of the dose, cumulative excretion amounted to 67.8 +/- 2.5% in the urine and 22.0 +/- 5.6% in the feces.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),%,22.0,255210,DB00988,Dopamine
,9571226,maximum plasma concentration,"Mean maximum plasma concentration values for unchanged CP-93,393 were 10.92 and 1.02 ng/ml for poor metabolizers (PMs) and extensive metabolizers (EMs) of dextromethorphan, respectively.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),[ng] / [ml],10.92,255211,DB00988,Dopamine
,9571226,maximum plasma concentration,"Mean maximum plasma concentration values for unchanged CP-93,393 were 10.92 and 1.02 ng/ml for poor metabolizers (PMs) and extensive metabolizers (EMs) of dextromethorphan, respectively.","Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571226/),[ng] / [ml],1.02,255212,DB00988,Dopamine
,8748619,elimination half life,"Apomorphine is lipophilic; it has a large volume of distribution and is rapidly cleared from plasma, with an elimination half life of 33 minutes.",Pharmacokinetics of apomorphine in Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748619/),min,33,255582,DB00988,Dopamine
,7883840,maximal plasma concentrations (Cmax),"Mean CAB maximal plasma concentrations (Cmax) were 33.3 +/- 3.69, 40.3 +/- 2.49, and 67.0 +/- 9.79 ng/L after 0.5, 1.0, and 1.5 mg CAB, respectively; time to Cmax was 2 h (median) for all doses; CAB AUC(0-168 h) after 0.5 mg CAB was significantly lower (P < 0.01) than after 1.5 mg CAB.","Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883840/),[ng] / [l],33.3,256106,DB00988,Dopamine
,7883840,maximal plasma concentrations (Cmax),"Mean CAB maximal plasma concentrations (Cmax) were 33.3 +/- 3.69, 40.3 +/- 2.49, and 67.0 +/- 9.79 ng/L after 0.5, 1.0, and 1.5 mg CAB, respectively; time to Cmax was 2 h (median) for all doses; CAB AUC(0-168 h) after 0.5 mg CAB was significantly lower (P < 0.01) than after 1.5 mg CAB.","Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883840/),[ng] / [l],40.3,256107,DB00988,Dopamine
,7883840,maximal plasma concentrations (Cmax),"Mean CAB maximal plasma concentrations (Cmax) were 33.3 +/- 3.69, 40.3 +/- 2.49, and 67.0 +/- 9.79 ng/L after 0.5, 1.0, and 1.5 mg CAB, respectively; time to Cmax was 2 h (median) for all doses; CAB AUC(0-168 h) after 0.5 mg CAB was significantly lower (P < 0.01) than after 1.5 mg CAB.","Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883840/),[ng] / [l],67.0,256108,DB00988,Dopamine
,7883840,time to Cmax,"Mean CAB maximal plasma concentrations (Cmax) were 33.3 +/- 3.69, 40.3 +/- 2.49, and 67.0 +/- 9.79 ng/L after 0.5, 1.0, and 1.5 mg CAB, respectively; time to Cmax was 2 h (median) for all doses; CAB AUC(0-168 h) after 0.5 mg CAB was significantly lower (P < 0.01) than after 1.5 mg CAB.","Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883840/),h,2,256109,DB00988,Dopamine
,7315181,t 1/2 alpha,Elimination of dopamine from plasma after termination of infusion had a biphasic course with t 1/2 alpha around 1 min and t 1/2 beta about 9 min in both groups.,Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315181/),min,1,256330,DB00988,Dopamine
,7315181,t 1/2 beta,Elimination of dopamine from plasma after termination of infusion had a biphasic course with t 1/2 alpha around 1 min and t 1/2 beta about 9 min in both groups.,Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315181/),min,9,256331,DB00988,Dopamine
,28331050,Cmax,"Pharmacokinetic analysis revealed a Cmax of 1.5 to 7.5 μg/mL (∼3.9-19.4 μmol/L), mean half-life of 11.3 hours, and mean AUC of 37.7 h·μg/L.",First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28331050/),[μg] / [ml],1.5 to 7.5,256537,DB00988,Dopamine
,28331050,half-life,"Pharmacokinetic analysis revealed a Cmax of 1.5 to 7.5 μg/mL (∼3.9-19.4 μmol/L), mean half-life of 11.3 hours, and mean AUC of 37.7 h·μg/L.",First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28331050/),h,11.3,256538,DB00988,Dopamine
,28331050,AUC,"Pharmacokinetic analysis revealed a Cmax of 1.5 to 7.5 μg/mL (∼3.9-19.4 μmol/L), mean half-life of 11.3 hours, and mean AUC of 37.7 h·μg/L.",First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28331050/),[h·μg] / [l],37.7,256539,DB00988,Dopamine
,30811206,binding energy,"Molecular dynamics simulation of PU and Pluronic F68 demonstrated the interaction energy and binding energy of -88.1 kJ/mol and -40.201 ± 0.685 kJ/mol, respectively, indicating a spontaneous binding with van der Waals interactions.",Oral Delivery of Puerarin Nanocrystals To Improve Brain Accumulation and Anti-Parkinsonian Efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811206/),[kj] / [mol],88.1,257650,DB00988,Dopamine
,30811206,binding energy,"Molecular dynamics simulation of PU and Pluronic F68 demonstrated the interaction energy and binding energy of -88.1 kJ/mol and -40.201 ± 0.685 kJ/mol, respectively, indicating a spontaneous binding with van der Waals interactions.",Oral Delivery of Puerarin Nanocrystals To Improve Brain Accumulation and Anti-Parkinsonian Efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811206/),[kj] / [mol],-,257651,DB00988,Dopamine
,30811206,binding energy,"Molecular dynamics simulation of PU and Pluronic F68 demonstrated the interaction energy and binding energy of -88.1 kJ/mol and -40.201 ± 0.685 kJ/mol, respectively, indicating a spontaneous binding with van der Waals interactions.",Oral Delivery of Puerarin Nanocrystals To Improve Brain Accumulation and Anti-Parkinsonian Efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811206/),[kj] / [mol],40.201,257652,DB00988,Dopamine
,10980240,clearance half-life,Total extracellular [18F] radioactivity in rat striata was observed to rise and peak at 30 min post-injection (p.i.) and declined with clearance half-life of 2 h.,6-fluoroDOPA metabolism in rat striatum: time course of extracellular metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980240/),h,2,258340,DB00988,Dopamine
,30371791,maximum dosage,The maximum dosage of BIM23B065 administered in this study was 1.5 mg.,A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30371791/),mg,1,258706,DB00988,Dopamine
,8352818,urinary recovery,"The 24-h urinary recovery of the 3 metabolites considered together, expressed as a percentage of the dose of SIM2055 administered, was 78 +/- 6 with the 100 mg dose, 66 +/- 11 with the 200 mg dose and 55 +/- 6 with the 300 mg dose (mean +/- S. D.).",Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352818/),,78,258850,DB00988,Dopamine
,8352818,urinary recovery,"The 24-h urinary recovery of the 3 metabolites considered together, expressed as a percentage of the dose of SIM2055 administered, was 78 +/- 6 with the 100 mg dose, 66 +/- 11 with the 200 mg dose and 55 +/- 6 with the 300 mg dose (mean +/- S. D.).",Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352818/),,66,258851,DB00988,Dopamine
,8352818,urinary recovery,"The 24-h urinary recovery of the 3 metabolites considered together, expressed as a percentage of the dose of SIM2055 administered, was 78 +/- 6 with the 100 mg dose, 66 +/- 11 with the 200 mg dose and 55 +/- 6 with the 300 mg dose (mean +/- S. D.).",Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352818/),,55,258852,DB00988,Dopamine
,22399238,total plasma clearance,"The mean total plasma clearance of pridopidine was 541 and 138 mL/min in EM and PM, respectively (p = 0.003), and was slightly higher in PM than the mean renal plasma clearance (105 mL/min; p = 0.11).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[ml] / [min],541,259617,DB00988,Dopamine
,22399238,total plasma clearance,"The mean total plasma clearance of pridopidine was 541 and 138 mL/min in EM and PM, respectively (p = 0.003), and was slightly higher in PM than the mean renal plasma clearance (105 mL/min; p = 0.11).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[ml] / [min],138,259618,DB00988,Dopamine
,22399238,renal plasma clearance,"The mean total plasma clearance of pridopidine was 541 and 138 mL/min in EM and PM, respectively (p = 0.003), and was slightly higher in PM than the mean renal plasma clearance (105 mL/min; p = 0.11).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[ml] / [min],105,259619,DB00988,Dopamine
,22399238,plasma,"The mean plasma area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)) of the N-depropyl metabolite ACR30 was higher in EM than in PM (1,377 vs. 61 nmol h/mL, respectively; p < 0.001).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[h·nM] / [ml],"1,377",259620,DB00988,Dopamine
,22399238,area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)),"The mean plasma area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)) of the N-depropyl metabolite ACR30 was higher in EM than in PM (1,377 vs. 61 nmol h/mL, respectively; p < 0.001).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[h·nM] / [ml],"1,377",259621,DB00988,Dopamine
,22399238,area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)),"The mean plasma area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)) of the N-depropyl metabolite ACR30 was higher in EM than in PM (1,377 vs. 61 nmol h/mL, respectively; p < 0.001).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[h·nM] / [ml],61,259622,DB00988,Dopamine
,22399238,urinary excretion,The urinary excretion of pridopidine + ACR30 was high in both EM (85 %) and PM (78 %).,The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),%,85,259623,DB00988,Dopamine
,22399238,urinary excretion,The urinary excretion of pridopidine + ACR30 was high in both EM (85 %) and PM (78 %).,The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),%,78,259624,DB00988,Dopamine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,24.2,260824,DB00988,Dopamine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,10.3,260825,DB00988,Dopamine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,75.2,260826,DB00988,Dopamine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,66.6,260827,DB00988,Dopamine
,28844183,PDI,"Optimized formulation (A10) showed spherical droplets with mean diameter of 60.00 ± 15 nm, PDI of 0.121 ± 0.053, and zeta potential values of -24.40 ± 0.16 mV.",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),,0.121,260891,DB00988,Dopamine
,28844183,zeta potential,"Optimized formulation (A10) showed spherical droplets with mean diameter of 60.00 ± 15 nm, PDI of 0.121 ± 0.053, and zeta potential values of -24.40 ± 0.16 mV.",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),mv,-24.40,260892,DB00988,Dopamine
,28844183,transmittance,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),%,100.50,260893,DB00988,Dopamine
,28844183,refractive index,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),,1.41,260894,DB00988,Dopamine
,28844183,viscosity,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),cp,30.54,260895,DB00988,Dopamine
,17908924,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives were approximately 2 h in rats, approximately 4 h in monkeys, and approximately 24 h in humans.","Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),h,2,261299,DB00988,Dopamine
,17908924,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives were approximately 2 h in rats, approximately 4 h in monkeys, and approximately 24 h in humans.","Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),h,4,261300,DB00988,Dopamine
,17908924,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives were approximately 2 h in rats, approximately 4 h in monkeys, and approximately 24 h in humans.","Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),h,24,261301,DB00988,Dopamine
,17908924,Total body clearance,"Total body clearance and steady-state volume of distribution values were 199 ml/min/kg and 24 l/kg, respectively, in the rat and 32 ml/min/kg and 46 l/kg, respectively, in the monkey.","Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),[ml] / [kg·min],199,261302,DB00988,Dopamine
,17908924,Total body clearance,"Total body clearance and steady-state volume of distribution values were 199 ml/min/kg and 24 l/kg, respectively, in the rat and 32 ml/min/kg and 46 l/kg, respectively, in the monkey.","Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),[ml] / [kg·min],32,261303,DB00988,Dopamine
,17908924,steady-state volume of distribution,"Total body clearance and steady-state volume of distribution values were 199 ml/min/kg and 24 l/kg, respectively, in the rat and 32 ml/min/kg and 46 l/kg, respectively, in the monkey.","Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),[l] / [kg],24,261304,DB00988,Dopamine
,17908924,steady-state volume of distribution,"Total body clearance and steady-state volume of distribution values were 199 ml/min/kg and 24 l/kg, respectively, in the rat and 32 ml/min/kg and 46 l/kg, respectively, in the monkey.","Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),[l] / [kg],46,261305,DB00988,Dopamine
,17908924,Absolute bioavailability,Absolute bioavailability was 7% in rats and 0.8% in monkeys.,"Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),%,7,261306,DB00988,Dopamine
,17908924,Absolute bioavailability,Absolute bioavailability was 7% in rats and 0.8% in monkeys.,"Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17908924/),%,0.8,261307,DB00988,Dopamine
,26681081,Volume of distribution,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [kg],0.48,261685,DB00988,Dopamine
,26681081,clearance,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [h·kg],0.0034,261686,DB00988,Dopamine
,26681081,half-life,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),h,93.7,261687,DB00988,Dopamine
,21732952,steady-state plasma fenoldopam concentrations,"Mean ± SD, steady-state plasma fenoldopam concentrations of 20 ± 17 ng/mL were achieved within 10 min of starting the infusion.",Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21732952/),[ng] / [ml],20,264381,DB00988,Dopamine
,21732952,Area under the plasma concentration-time curve,"Area under the plasma concentration-time curve was 3678 ± 3030 ng/mL · min, and plasma clearance was 66 ± 43 mL/min per kg.",Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21732952/),[ng] / [min·ml],3678,264382,DB00988,Dopamine
,21732952,plasma clearance,"Area under the plasma concentration-time curve was 3678 ± 3030 ng/mL · min, and plasma clearance was 66 ± 43 mL/min per kg.",Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21732952/),[ml] / [kg·min],66,264383,DB00988,Dopamine
,16326078,window occupancy,"For conventional antipsychotics, the window occupancy is approximately 70-80%.","Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326078/),%,70-80,265444,DB00988,Dopamine
,8370571,Tmax,"After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min).",Pharmacokinetics of apomorphine in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8370571/),min,16,266247,DB00988,Dopamine
,8370571,plasma half-life,"After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min).",Pharmacokinetics of apomorphine in parkinsonian patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8370571/),min,69.7,266248,DB00988,Dopamine
,25116481,elimination half-life,Median maximum concentrations of BMS-820836 were observed at 4.0-5.5 h post-dose; estimated elimination half-life was 44-74 h.,"Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116481/),h,44-74,266329,DB00988,Dopamine
,25116481,occupancy,Striatal DAT occupancy ranged between 14 % and 35 % at 8 h post-dose with a slight decline at 24 h post-dose.,"Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116481/),%,14,266330,DB00988,Dopamine
,25116481,occupancy,Striatal DAT occupancy ranged between 14 % and 35 % at 8 h post-dose with a slight decline at 24 h post-dose.,"Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116481/),%,35,266331,DB00988,Dopamine
,18058087,receptor,"The dopamine D2 receptor occupancies in the striatum measured with [11C]raclopride and the temporal cortex measured with [11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),%,54.2-85.5,266897,DB00988,Dopamine
,18058087,occupancies,"The dopamine D2 receptor occupancies in the striatum measured with [11C]raclopride and the temporal cortex measured with [11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),%,54.2-85.5,266898,DB00988,Dopamine
,18058087,occupancies,"The dopamine D2 receptor occupancies in the striatum measured with [11C]raclopride and the temporal cortex measured with [11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),%,34.5-87.3,266899,DB00988,Dopamine
,18058087,ED50,"ED50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),[mg] / [d],2.38,266900,DB00988,Dopamine
,18058087,ED50,"ED50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively.",Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058087/),[mg] / [d],2.84,266901,DB00988,Dopamine
>,23484785,extraction recovery,"The extraction recovery was >84%, while the internal standard-normalized matrix factors ranged from 0.97-1.03 for all three analytes.","Stable-isotope dilution LC-MS/MS assay for determination of iloperidone and its two major metabolites, P 88 and P 95, in human plasma: application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23484785/),%,84,267179,DB00988,Dopamine
,18425847,R(i),"In vivo, GA2-50 showed high brain uptake (R(i) approximately 10), large volume of distribution (V(ss) = 37 L/kg), and long elimination half-life (t((1/2)) = 19 h).",The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18425847/),,10,267420,DB00988,Dopamine
,18425847,volume of distribution (V(ss),"In vivo, GA2-50 showed high brain uptake (R(i) approximately 10), large volume of distribution (V(ss) = 37 L/kg), and long elimination half-life (t((1/2)) = 19 h).",The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18425847/),[l] / [kg],37,267421,DB00988,Dopamine
,18425847,elimination half-life (t((1/2)),"In vivo, GA2-50 showed high brain uptake (R(i) approximately 10), large volume of distribution (V(ss) = 37 L/kg), and long elimination half-life (t((1/2)) = 19 h).",The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18425847/),h,19,267422,DB00988,Dopamine
,15588905,bioavailability,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),%,10.6,267590,DB00988,Dopamine
,15588905,bioavailability,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),%,13.2,267591,DB00988,Dopamine
,15588905,steady state input rate,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),[nM] / [cm2·h],75.3,267592,DB00988,Dopamine
,15588905,steady state input rate,The patients treated with the surfactant formulations showed a statistically significant increase of bioavailability (from 10.6+/-0.8% to 13.2+/-1.4%) and of the steady state input rate (from 75.3+/-6.6 to 98.3+/-12.1 nmol/cm2 h) compared to the control patients (iontophoresis without absorption enhancers).,Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15588905/),[nM] / [cm2·h],98.3,267593,DB00988,Dopamine
,17149874,oral bioavailability,"Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a.","Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149874/),%,68,267817,DB00988,Dopamine
,17149874,oral bioavailability,"Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a.","Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149874/),%,85,267818,DB00988,Dopamine
,17149874,oral bioavailability,"Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a.","Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149874/),%,91,267819,DB00988,Dopamine
,2379385,clearance,Dopamine clearance was 60.7 +/- 28.1 ml/kg/min.,Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379385/),[ml] / [kg·min],60.7,268044,DB00988,Dopamine
,2379385,clearance,"The age of the patient exerted an effect on clearance of dopamine (r = -0.63; p less than 0.05), and dopamine clearance was nearly twice as rapid in children younger than 2 years as it was in older children (82.3 +/- 27.7 ml/kg/min versus 45.9 +/- 17.0 mg/kg/min).",Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379385/),[ml] / [kg·min],82.3,268045,DB00988,Dopamine
,2379385,clearance,"The age of the patient exerted an effect on clearance of dopamine (r = -0.63; p less than 0.05), and dopamine clearance was nearly twice as rapid in children younger than 2 years as it was in older children (82.3 +/- 27.7 ml/kg/min versus 45.9 +/- 17.0 mg/kg/min).",Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379385/),[mg] / [kg·min],45.9,268046,DB00988,Dopamine
,2379385,clearance,Conjugated bilirubin exerted an age-independent effect on clearance of dopamine; clearance was 44.8 +/- 28.6 ml/kg/min in children with abnormal conjugated bilirubin (greater than or equal to 0.9 mg/dl) and 70.1 +/- 2.56 ml/kg/min in children with normal conjugated bilirubin (less than 0.9 mg/dl).,Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379385/),[ml] / [kg·min],44.8,268047,DB00988,Dopamine
,2379385,clearance,Conjugated bilirubin exerted an age-independent effect on clearance of dopamine; clearance was 44.8 +/- 28.6 ml/kg/min in children with abnormal conjugated bilirubin (greater than or equal to 0.9 mg/dl) and 70.1 +/- 2.56 ml/kg/min in children with normal conjugated bilirubin (less than 0.9 mg/dl).,Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379385/),[ml] / [kg·min],70.1,268048,DB00988,Dopamine
,2379385,Clearance,Clearance was lowest (29.8 +/- 5.7 ml/kg/min) in the four children who had both hepatic and renal dysfunction.,Dopamine clearance in critically ill infants and children: effect of age and organ system dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379385/),[ml] / [kg·min],29.8,268049,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,66,268126,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,39,268127,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,2,268128,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,62,268129,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,35,268130,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,-,268131,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,6,268132,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,68,268133,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,47,268134,DB00988,Dopamine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,11,268135,DB00988,Dopamine
,23417515,occupancy half-life,The time-course of receptor occupancy across the regions indicated an occupancy half-life of 8.3 h.,Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),h,8.3,268136,DB00988,Dopamine
,9951426,QTcmax,Mean QTcmax observed within 20 hours of pimozide administration was significantly greater in the clarithromycin-treated group (23.8 +/- 12.2 ms; P = .0397) than in the placebo-treated group (16.8 +/- 6 ms).,Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951426/),ms,23.8,268231,DB00988,Dopamine
,9951426,QTcmax,Mean QTcmax observed within 20 hours of pimozide administration was significantly greater in the clarithromycin-treated group (23.8 +/- 12.2 ms; P = .0397) than in the placebo-treated group (16.8 +/- 6 ms).,Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951426/),ms,16.8,268232,DB00988,Dopamine
>,20496886,oral bioavailability,"Pramipexole is a hydrophilic, weakly basic drug, but exhibits high oral bioavailability in humans (>90%).",Uptake of pramipexole by human organic cation transporters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20496886/),%,90,268244,DB00988,Dopamine
,20496886,K(t),"hOCT2 transported pramipexole in a high affinity manner (K(t) = 15.4 +/- 4.1 microM, J(max) = 0.476 +/- 0.028 pmol/s/cm(2)).",Uptake of pramipexole by human organic cation transporters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20496886/),μM,15.4,268245,DB00988,Dopamine
,20496886,J(max),"hOCT2 transported pramipexole in a high affinity manner (K(t) = 15.4 +/- 4.1 microM, J(max) = 0.476 +/- 0.028 pmol/s/cm(2)).",Uptake of pramipexole by human organic cation transporters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20496886/),[pM·s] / [cm(2],0.476,268246,DB00988,Dopamine
,20496886,K(t),"hOCT3 transported pramipexole in a low affinity manner (K(t) = 138 +/- 31 microM, J(max) = 1.10 +/- 0.08 pmol/s/cm(2)).",Uptake of pramipexole by human organic cation transporters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20496886/),μM,138,268247,DB00988,Dopamine
,20496886,J(max),"hOCT3 transported pramipexole in a low affinity manner (K(t) = 138 +/- 31 microM, J(max) = 1.10 +/- 0.08 pmol/s/cm(2)).",Uptake of pramipexole by human organic cation transporters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20496886/),[pM·s] / [cm(2],1.10,268248,DB00988,Dopamine
,8382588,sodium clearance,"2. Baseline sodium clearance with placebo was 0.65 +/- 0.35 ml/min, but with lithium it increased to 1.25 +/- 0.44 (P < 0.001) and 1.17 +/- 0.46 ml/min (P < 0.01) after 450 and 600mg, respectively.","Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382588/),[ml] / [min],0.65,268518,DB00988,Dopamine
,8382588,sodium clearance,"2. Baseline sodium clearance with placebo was 0.65 +/- 0.35 ml/min, but with lithium it increased to 1.25 +/- 0.44 (P < 0.001) and 1.17 +/- 0.46 ml/min (P < 0.01) after 450 and 600mg, respectively.","Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382588/),[ml] / [min],1.25,268519,DB00988,Dopamine
,8382588,sodium clearance,"2. Baseline sodium clearance with placebo was 0.65 +/- 0.35 ml/min, but with lithium it increased to 1.25 +/- 0.44 (P < 0.001) and 1.17 +/- 0.46 ml/min (P < 0.01) after 450 and 600mg, respectively.","Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382588/),[ml] / [min],1.17,268520,DB00988,Dopamine
,2906159,Tmax,"5. Pharmacokinetic study From the pharmacokinetic parameters measured, two features were recognized: one was the slowness of Tmax (4-6 hours) and the other was the length of its biological half-life (56-88 hours).","Phase 1 study of a new antipsychotic drug, OPC-4392. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906159/),h,4-6,268579,DB00988,Dopamine
,2906159,biological half-life,"5. Pharmacokinetic study From the pharmacokinetic parameters measured, two features were recognized: one was the slowness of Tmax (4-6 hours) and the other was the length of its biological half-life (56-88 hours).","Phase 1 study of a new antipsychotic drug, OPC-4392. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906159/),h,56-88,268580,DB00988,Dopamine
,19480558,Oral bioavailability,Oral bioavailability was 0.7% in dog and less than 5% in rat.,"Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480558/),%,0.7,269144,DB00988,Dopamine
less,19480558,Oral bioavailability,Oral bioavailability was 0.7% in dog and less than 5% in rat.,"Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480558/),%,5,269145,DB00988,Dopamine
,19480558,bioavailabilities,Pre-clinical assessments in rat and dog demonstrated intranasal bioavailabilities of 16-38% in rat and 54-61% in dog with very rapid absorption.,"Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480558/),%,16-38,269146,DB00988,Dopamine
,19480558,bioavailabilities,Pre-clinical assessments in rat and dog demonstrated intranasal bioavailabilities of 16-38% in rat and 54-61% in dog with very rapid absorption.,"Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480558/),%,54-61,269147,DB00988,Dopamine
,19480558,bioavailability,It was predicted that an intranasal dose in man would give approximately 25-50% bioavailability.,"Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480558/),%,25-50,269148,DB00988,Dopamine
,19480558,bioavailability,The intranasal bioavailability in man was estimated to be 26-38%.,"Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480558/),%,26-38,269149,DB00988,Dopamine
,9575250,volume of distribution,The volume of distribution in the striatum was 94+/-24 ml/ml.,"Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9575250/),[ml] / [ml],94,269496,DB00988,Dopamine
,9575250,effective dose,Radiation exposure to the study subject is 0.022+/-0.004 mSv/MBq (effective dose).,"Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9575250/),[msv] / [Mbq],0.022,269497,DB00988,Dopamine
,15849845,t(+15),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.4,269747,DB00988,Dopamine
,15849845,t(+15),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,3.3,269748,DB00988,Dopamine
,15849845,t(+30),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,6.7,269749,DB00988,Dopamine
,15849845,t(+30),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,3.7,269750,DB00988,Dopamine
,15849845,t(+60),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,7.7,269751,DB00988,Dopamine
,15849845,t(+60),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.1,269752,DB00988,Dopamine
,15849845,t(+120),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,8.5,269753,DB00988,Dopamine
,15849845,t(+120),"The plasma paracetamol concentrations 15, 30, 60, and 120 minutes after the administration of paracetamol were significantly higher in metoclopramide group than in control group: (t(+15)) 5.4-/+2.7 vs 3.3-/+2.5 (Mann-Whitney U test; P=0.017); (t(+30)) 6.7-/+2.4 vs 3.7-/+2.0 (P=0.006); (t(+60)) 7.7-/+2.5 vs 5.1-/+3.2 (P=0.008); (t(+120)) 8.5-/+2.2 vs 5.2-/+2.8 (P=0.005).",Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,5.2,269754,DB00988,Dopamine
,15849845,AUC,The AUC value was 34% larger in the metoclopramide group vs control group (574-/+296 vs 429-/+309; P=0.027).,Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,574,269755,DB00988,Dopamine
,15849845,AUC,The AUC value was 34% larger in the metoclopramide group vs control group (574-/+296 vs 429-/+309; P=0.027).,Metoclopramide improves gastric but not gallbladder emptying in cardiac surgery patients with early intragastric enteral feeding: randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15849845/),,429,269756,DB00988,Dopamine
,11149673,receptor,"In humans, the striatal D2/D3 receptor occupancy was 0.27+/-0.085 and the in vivo Kd for haloperidol was 0.25+/-0.1 nmol/L, which is comparable to Kd values as obtained from in vitro studies.",In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149673/),,0.27,270562,DB00988,Dopamine
,11149673,occupancy,"In humans, the striatal D2/D3 receptor occupancy was 0.27+/-0.085 and the in vivo Kd for haloperidol was 0.25+/-0.1 nmol/L, which is comparable to Kd values as obtained from in vitro studies.",In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149673/),,0.27,270563,DB00988,Dopamine
,11149673,Kd,"In humans, the striatal D2/D3 receptor occupancy was 0.27+/-0.085 and the in vivo Kd for haloperidol was 0.25+/-0.1 nmol/L, which is comparable to Kd values as obtained from in vitro studies.",In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149673/),[nM] / [l],0.25,270564,DB00988,Dopamine
,7915310,elimination half-lives,"Mean elimination half-lives of 36.8, 39.6, and 52.4 min and mean clearance values of 229 +/- 35, 202 +/- 85, and 191 +/- 36 mL/min/kg were obtained for doses of 0.1, 0.5, and 1.0 mg/kg/h, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),min,36.8,270811,DB00988,Dopamine
,7915310,elimination half-lives,"Mean elimination half-lives of 36.8, 39.6, and 52.4 min and mean clearance values of 229 +/- 35, 202 +/- 85, and 191 +/- 36 mL/min/kg were obtained for doses of 0.1, 0.5, and 1.0 mg/kg/h, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),min,39.6,270812,DB00988,Dopamine
,7915310,elimination half-lives,"Mean elimination half-lives of 36.8, 39.6, and 52.4 min and mean clearance values of 229 +/- 35, 202 +/- 85, and 191 +/- 36 mL/min/kg were obtained for doses of 0.1, 0.5, and 1.0 mg/kg/h, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),min,52.4,270813,DB00988,Dopamine
,7915310,clearance,"Mean elimination half-lives of 36.8, 39.6, and 52.4 min and mean clearance values of 229 +/- 35, 202 +/- 85, and 191 +/- 36 mL/min/kg were obtained for doses of 0.1, 0.5, and 1.0 mg/kg/h, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),[ml] / [kg·min],229,270814,DB00988,Dopamine
,7915310,clearance,"Mean elimination half-lives of 36.8, 39.6, and 52.4 min and mean clearance values of 229 +/- 35, 202 +/- 85, and 191 +/- 36 mL/min/kg were obtained for doses of 0.1, 0.5, and 1.0 mg/kg/h, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),[ml] / [kg·min],202,270815,DB00988,Dopamine
,7915310,clearance,"Mean elimination half-lives of 36.8, 39.6, and 52.4 min and mean clearance values of 229 +/- 35, 202 +/- 85, and 191 +/- 36 mL/min/kg were obtained for doses of 0.1, 0.5, and 1.0 mg/kg/h, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),[ml] / [kg·min],191,270816,DB00988,Dopamine
,7915310,steady-state volumes of distribution,"The steady-state volumes of distribution were estimated as 3.89 +/- 0.816, 3.53 +/- 1.62, and 4.70 +/- 3.67 L/kg for the same doses, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),[l] / [kg],3.89,270817,DB00988,Dopamine
,7915310,steady-state volumes of distribution,"The steady-state volumes of distribution were estimated as 3.89 +/- 0.816, 3.53 +/- 1.62, and 4.70 +/- 3.67 L/kg for the same doses, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),[l] / [kg],3.53,270818,DB00988,Dopamine
,7915310,steady-state volumes of distribution,"The steady-state volumes of distribution were estimated as 3.89 +/- 0.816, 3.53 +/- 1.62, and 4.70 +/- 3.67 L/kg for the same doses, respectively.",Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915310/),[l] / [kg],4.70,270819,DB00988,Dopamine
,12607628,elimination half-life,BP is rapidly absorbed after oral administration and demonstrates biphasic elimination with an elimination half-life of 11 - 14 hours.,Bupropion: pharmacological and clinical profile in smoking cessation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12607628/),h,11 - 14,271070,DB00988,Dopamine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,136,271167,DB00988,Dopamine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,144,271168,DB00988,Dopamine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,90,271169,DB00988,Dopamine
,29477356,Passive permeation,"Passive permeation of PRAM and RAS (20 mM each) across porcine skin after 6 h was 15.7 ± 1.9 and 16.0 ± 2.9 µg/cm2, respectively.",Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29477356/),[μg] / [cm2],15.7,271232,DB00988,Dopamine
,29477356,Passive permeation,"Passive permeation of PRAM and RAS (20 mM each) across porcine skin after 6 h was 15.7 ± 1.9 and 16.0 ± 2.9 µg/cm2, respectively.",Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29477356/),[μg] / [cm2],16.0,271233,DB00988,Dopamine
,29477356,cumulative permeation,"Co-iontophoresis at 0.15, 0.3 and 0.5 mA/cm2 resulted in statistically significant increases in delivery of PRAM and RAS; at 0.5 mA/cm2, cumulative permeation of PRAM and RAS was 613.5 ± 114.6 and 441.1 ± 169.2 µg/cm2, respectively - corresponding to 38- and 27-fold increases over passive diffusion.",Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29477356/),[μg] / [cm2],613.5,271234,DB00988,Dopamine
,29477356,cumulative permeation,"Co-iontophoresis at 0.15, 0.3 and 0.5 mA/cm2 resulted in statistically significant increases in delivery of PRAM and RAS; at 0.5 mA/cm2, cumulative permeation of PRAM and RAS was 613.5 ± 114.6 and 441.1 ± 169.2 µg/cm2, respectively - corresponding to 38- and 27-fold increases over passive diffusion.",Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29477356/),[μg] / [cm2],441.1,271235,DB00988,Dopamine
,2162278,tubular segmental reabsorption rates,"Using the renal clearance of lithium (CLi) as an index of proximal tubular outflow of sodium and water, together with simultaneous measurements of effective renal plasma flow, glomerular filtration rate (GFR) and sodium clearance (CNa), renal function and the tubular segmental reabsorption rates of sodium and water during dopamine infusion (3 micrograms min-1 kg-1) were estimated in 12 normal volunteers.",Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2162278/),[μg] / [kg·min],3,271580,DB00988,Dopamine
,9164577,K1-,"GTS-21 bound to human alpha 4 beta 2 nAChR (K1-20 nM) 100-fold more potently than to human alpha 7 nAChR, and was 18- and 2-fold less potent than (-)-nicotine at human alpha 4 beta 2 and alpha 7 nAChR, respectively.",Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164577/),nM,20,272379,DB00988,Dopamine
,9164577,EC50,"GTS-21 stimulated [5H]dopamine release from rat striatal slices with an EC50 of 10 +/- 2 microM (250-fold less potent and 70% as efficacious as (-)-nicotine), an effect blocked by the nAChR antagonist dihydro-beta-erythroidine.",Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164577/),μM,10,272380,DB00988,Dopamine
,9098876,Cmax,"After pharmacologically active CI-1007 doses, mean plasma CI-1007 Cmax increased from 19 to 200 ng/ml in Sprague-Dawley rats at doses of 3-30 mg/ kg, and from 8.1 to 34 ng/ml in squirrel monkeys at doses of 0.6-1.2 mg/kg, but corresponding plasma M1 Cmax values were near or below the limit of quantitation (5 ng/ml).","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),[ng] / [ml],19 to 200,273039,DB00988,Dopamine
,9098876,Cmax,"After pharmacologically active CI-1007 doses, mean plasma CI-1007 Cmax increased from 19 to 200 ng/ml in Sprague-Dawley rats at doses of 3-30 mg/ kg, and from 8.1 to 34 ng/ml in squirrel monkeys at doses of 0.6-1.2 mg/kg, but corresponding plasma M1 Cmax values were near or below the limit of quantitation (5 ng/ml).","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),[ng] / [ml],8.1 to 34,273040,DB00988,Dopamine
,9098876,Cmax,"After pharmacologically active CI-1007 doses, mean plasma CI-1007 Cmax increased from 19 to 200 ng/ml in Sprague-Dawley rats at doses of 3-30 mg/ kg, and from 8.1 to 34 ng/ml in squirrel monkeys at doses of 0.6-1.2 mg/kg, but corresponding plasma M1 Cmax values were near or below the limit of quantitation (5 ng/ml).","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),[ng] / [ml],5,273041,DB00988,Dopamine
,9098876,EC50,"CI-1007 EC50 was 31.1 ng/ml in rats, calculated from a long-linear regression.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),[ng] / [ml],31.1,273042,DB00988,Dopamine
,9098876,ECe50,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),[ng] / [ml],4.8,273043,DB00988,Dopamine
,9098876,ECe50,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),[ng] / [ml],4.5,273044,DB00988,Dopamine
,9098876,gamma,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),[ng] / [ml],4.5,273045,DB00988,Dopamine
,9098876,gamma,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),1/[h],1.9,273046,DB00988,Dopamine
,9098876,gamma,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),1/[h],2.0,273047,DB00988,Dopamine
,9098876,gamma,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),1/[h],0.47,273048,DB00988,Dopamine
,9098876,Keo,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),1/[h],2.0,273049,DB00988,Dopamine
,9098876,Keo,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),1/[h],0.47,273050,DB00988,Dopamine
,9098876,Keo,"In monkeys, CI-1007 ECe50, gamma, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr-1, respectively, calculated by the link model.","Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098876/),1/[h],0.48,273051,DB00988,Dopamine
,23523781,half-life,"Approximately 0.3% of the administered dose was taken up by the brain and was slowly eliminated, with a half-life of approximately 3 weeks.","Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523781/),weeks,3,273413,DB00988,Dopamine
,32030559,cumulative urinary excretion,The mean cumulative urinary excretion over 24 h was just 2.96 ± 0.96%ID.,Phase I clinical study with different doses of 99mTc-TRODAT-1 in healthy adults. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030559/),%id,2.96,273719,DB00988,Dopamine
,32030559,absorbed dose,"The highest absorbed dose was in the dose-limiting organ, liver (20.88 ± 4.45 × 10-3 mSv/MBq).",Phase I clinical study with different doses of 99mTc-TRODAT-1 in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030559/),[msv] / [Mbq],20.88,273720,DB00988,Dopamine
,32030559,effective dose,The average effective dose was 5.22 ± 1.05 × 10-3 mSv/MBq.,Phase I clinical study with different doses of 99mTc-TRODAT-1 in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030559/),[msv] / [Mbq],5.22,273721,DB00988,Dopamine
,20571519,Plasma EC(50),Plasma EC(50) estimates ranged from 150 to 550 ng/mL according to the constraints on the model.,Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20571519/),[ng] / [ml],150 to 550,273893,DB00988,Dopamine
